irinotecan has been researched along with Neoplasms in 507 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 77 (15.19) | 18.2507 |
| 2000's | 199 (39.25) | 29.6817 |
| 2010's | 176 (34.71) | 24.3611 |
| 2020's | 55 (10.85) | 2.80 |
| Authors | Studies |
|---|---|
| Cheng, L; Feng, W; LaVoie, EJ; Liu, AA; Liu, LF; Satyanarayana, M; Tsai, YC | 1 |
| Akiyama, Y; Ando, Y; Fujita, K; Hirose, T; Ichikawa, W; Ishida, H; Kawara, K; Miwa, K; Miya, T; Mizuno, K; Nagashima, F; Narabayashi, M; Saji, S; Sasaki, Y; Sugiyama, M; Sunakawa, Y; Yamamoto, W; Yamashita, K | 1 |
| Chen, YL; Cheng, CM; Chung, KY; Hsu, CY; Huang, KS; Kao, CL; Tseng, CH; Tzeng, CC | 1 |
| Dong, G; Guo, Z; Miao, Z; Sheng, C; Wang, S; Wu, Y; Yao, J; Zhang, W; Zhang, Y; Zhu, L; Zhuang, C | 1 |
| Dannhardt, G; Ganser, C; Kindler, T; Kramb, JP; Lauermann, E; Maderer, A; Moehler, M; Plutizki, S; Stauder, T | 1 |
| Duh, TH; Lin, YT; Liu, YP; Lo, YH; Lu, PJ; Wu, MJ | 1 |
| Fu, ZD; Huang, JT; Ji, TF; Li, DZ; Li, XY; Lin, JP; Liu, HY; Pan, XD; Song, HX; Wang, CY; Zhang, QZ; Zhang, YL | 1 |
| Benetti, E; Centamore, A; Collina, S; Della Volpe, S; Martino, E; Sakaj, M; Sala, A; Terribile, E | 1 |
| Chen, HL; Cheng, PL; Goto, M; Hsieh, KY; Lee, KH; Liu, YQ; Morris-Natschke, SL; Yang, GZ; Yang, QR; Zhang, N; Zhang, XS; Zhu, GX | 1 |
| Dong, G; Fang, Y; Liu, N; Liu, Y; Sheng, C; Wu, S; Zhang, W | 1 |
| Jiang, J; Muhammad, Y; Rashid, HU; Wang, L; Xu, Y | 1 |
| Gao, F; Wang, T; Xiao, J; Zhang, X | 1 |
| Dou, X; Huang, H; Jiang, L; Jiao, N; Jin, H; Jin, Z; Li, Z; Liu, Y; Liu, Z; Sun, X; Zhang, L; Zhu, G; Zou, Y | 1 |
| Guo, K; Li, J; Ma, X; Wu, L; Zhang, C | 1 |
| Kurjata, J; Piorecka, K; Stanczyk, WA | 1 |
| Chen, Y; Cheng, Z; Huang, Y; Lu, W; Wang, L; Yang, B; Yu, J | 1 |
| Bies, RR; Cecchin, E; Cox, NJ; Etheridge, AS; Forrest, A; Innocenti, F; Karas, S; Mathijssen, RHJ; Mohlke, KL; Nickerson, DA; Toffoli, G | 1 |
| Glish, GL; Larson, TS; Lockett, MR | 1 |
| Bilić, I; Božina, N; Ganoci, L; Lešnjaković, L; Pleština, S; Šimičević, L; Trkulja, V | 1 |
| Ambudkar, SV; Aoki, J; Doi, T; Funayama, S; Kajiwara, T; Kano, K; Karasawa, H; Kikuchi, H; Kokubo, S; Murakami, M; Naitoh, T; Ohnuma, S; Ohsawa, K; Sugisawa, N; Suzuki, H; Unno, M; Yamamura, A | 1 |
| Asher, GN; Dumond, J; Fallon, JK; Gbolahan, OB; Ivanova, A; McRee, AJ; Moore, DT; O'Neil, BH; Sanoff, HK; Smith, PC | 1 |
| Chen, X; Sun, M; Yang, Z | 1 |
| Alonso, C; Martín-Encinas, E; Palacios, F; Selas, A | 1 |
| Bies, RR; Forrest, A; Innocenti, F; Karas, S; Mathijssen, RHJ; van Schaik, RHN; Wiltshire, T | 1 |
| Atasilp, C; Biswas, M; Hongkaew, Y; Jinda, P; Nuntharadthanaphong, N; Rachanakul, J; Saokaew, S; Sukasem, C; Vanwong, N | 1 |
| Beharry, AA; Kailass, K; Sadovski, O; Zipfel, WR | 1 |
| Antunes, MV; Basso, J; Hahn, RZ; Ibaldi, MR; Linden, R; Pavei, CC; Schaefer, VD; Schwartsmann, G | 1 |
| Addisu, KD; Birhan, YS; Darge, HF; Gebrie, HT; Thankachan, D; Tsai, HC; Wu, SY | 1 |
| Bojko, A; Czarnecka-Herok, J; Herok, M; Mosieniak, G; Sikora, E; Sliwinska, MA; Strzeszewska-Potyrala, A; Targonska, A; Wolny, A | 1 |
| Alexander, M; Campbell, I; Campbell, R; Fagery, M; Georgiou, C; Glewis, S; Harris, S; IJzerman, M; Krishnasamy, M; Lee, B; Lingaratnam, S; Martin, J; Michael, M; Tie, J; Underhill, C; Warren, M | 1 |
| Brennan, M; Chmielowski, B; Finn, RS; Glaspy, JA; Goldman, J; Hecht, JR; Konecny, GE; Martinez, D; McCann, KE; O'Brien, N; Price, MM; Singh, AS; Slamon, DJ; Von Euw, E; Wainberg, ZA; Yonemoto, L | 1 |
| Badgett, T; Crimella, J; Fridley, BL; Gill, J; Gorlick, R; Llosa, N; Metts, JL; Reed, D; Sandler, E; Sansil, S; Smith, T; Thapa, R; Thompson, P; Trucco, M; Weiser, DA | 1 |
| Borrelli, MJ; Chhetri, BP; Fologea, D; Gandy, J; Griffin, RJ; Jamshidi-Parsian, A; Jenkins, SV; Phillips, JH; Stolarz, AJ | 1 |
| Kan, ANC; Ku, DTL; Lam, YL; Liu, APY; To, KF; Yan, CLS; Yu, SH | 1 |
| Dong, F; He, Z; Huang, Y; Kamei, KI; Li, L; Liu, T; Song, J; Sun, B; Sun, J; Wang, X; Zhu, Z; Zuo, S | 1 |
| Abu, YF; Chen, C; Meng, J; Ramakrishnan, S; Roy, S; Tao, J; Xie, Y; Yan, Y; Zhang, Y; Zhou, Y | 1 |
| Choy, YB; Han, JH; Ji, HB; Kim, CR; Kim, MJ; Kim, SN; Lee, C; Min, CH | 1 |
| Dunichand-Hoedl, AR; Isesele, P; Mazurak, VC; Monirujjaman, M; Renani, LB | 1 |
| Aguiar, S; Aires-da-Silva, F; André, AS; António, JPM; Braz, BS; Bule, P; Carrapiço, B; Carvalho, JI; Castanho, M; Cavaco, M; Correia, JDG; Dias, JNR; Gano, L; Gil, S; Gois, PMP; Goncalves, J; Neves, V; Nogueira, S; Oliveira, S; Rütgen, B; Tavares, L; Vicente, G | 1 |
| Bates, SE; Connolly, RM; Gano, K; LaRose, M; O'Sullivan, CC; Pommier, Y; Thomas, A; Velcheti, V; Vilimas, R | 1 |
| Broudin, C; Gallois, C; Jenvrin, A; Palmieri, LJ; Perret, A; Rance, B; Soularue, E; Taieb, J | 1 |
| Dai, QL; Jia, HJ; Rui Bai, S; Wang, XB; Xia, J; Yue He, S; Zhou, M | 1 |
| Li, J; Qin, J; Sun, M; Wang, D; Zhen, Y | 1 |
| Alexandrov, IA; Gahramanov, V; Gerlitz, G; Kaczmarczyk, L; Kumar, S; Patel, S; Salmon-Divon, M; Sherman, MY; Yaglom, J | 1 |
| Hummon, AB; Wang, Y | 1 |
| Chen, L; Chen, Y; Deng, D; Guo, Y; He, W; Liu, K; Peng, B; Si, W; Tang, M; Xiang, M; Xu, D; Xu, Q; Yang, T; Yang, Y; Yuan, X; Zhang, C; Zhang, S; Zou, Y | 1 |
| Dai, Y; Li, Y; Qian, M | 1 |
| Deenen, MJ; Gelderblom, H; Guchelaar, HJ; Hulshof, EC; Mathijssen, RH; Peeters, SL; Swen, JJ; Thijs, AM | 1 |
| Chen, L; Chen, X; Feng, M; He, H; Lan, S; Wang, K; Zhu, Y; Zuo, D | 1 |
| Gou, S; Huang, X; Wang, H; Zhang, B | 1 |
| Bailly, C | 1 |
| Chi, D; He, Z; Lin, X; Liu, H; Sun, J; Wang, Y; Wang, Z; Wu, X; Xu, Z | 1 |
| Chen, J; Esfandyarpour, R; Joshi, K; Velasco, V | 1 |
| Bojko, A; Charzynska, A; Czarnecka-Herok, J; Dabrowski, M; Sikora, E | 1 |
| Baglo, Y; Hasan, T; Huang, HC; Liang, BJ; Najafali, D; Pigula, M | 1 |
| Fontaine, SD; Ghilu, S; Houghton, PJ; Kurmasheva, RT; Li, Q; Santi, DV; Zheng, S | 1 |
| Liu, J; Tang, X; Wu, C; Xu, K; Yang, L; Zhai, Z; Zhao, L; Zhong, W | 1 |
| Azcarate-Peril, MA; Bailey, ST; Bhatt, AP; Biernat, KA; Bultman, SJ; Creekmore, BC; Darr, DB; Gharaibeh, RZ; Letertre, MM; Montgomery, SA; Pellock, SJ; Redinbo, MR; Roach, JM; Roques, JR; Sartor, RB; Swann, JR; Wallace, BD; Walton, WG; Wilson, ID | 1 |
| Kciuk, M; Kontek, R; Marciniak, B | 1 |
| Chi, D; He, Z; Lin, G; Lin, X; Liu, H; Sun, J; Wang, Y; Wang, Z; Xu, Z | 1 |
| Bahrami, A; Bishop, MW; Brennan, RC; Campagne, O; Clay, MR; Federico, SM; Furman, WL; Gartrell, J; Godwin, K; Hawkins, D; Helmig, S; Kaste, SC; McCarville, MB; Pappo, AS; Sahr, N; Santana, VM; Shelat, A; Stewart, CF; Stewart, E; Sykes, A | 1 |
| Cohen, R; de Gramont, A; Fuchs, C; Goldberg, RM; Hurwitz, H; Kempf, E; Lopes, GS; Olswold, CL; Saltz, L; Shi, Q; Tournigand, C | 1 |
| Dai, X; Jiang, T; Li, J; Qi, X; Wu, G; Yin, R; Zhang, X; Zhang, Y | 1 |
| Chen, X; Huang, Z; Ma, S; Si, X; Song, W; Tang, Z; Xu, Y; Yao, H; Yu, H; Zhang, Y; Zhao, J | 1 |
| Chen, BF; He, Y; He, ZD; Huang, YZ; Tu, B; Wang, HR; Wang, YH; Zhang, M; Zhu, SQ | 1 |
| Bishop, MW; Borinstein, SC; DuBois, SG; Hingorani, P; Krystal, J; Laetsch, TW; Levy, DE; Mascarenhas, L; Mo, G; Muscal, JA; Ogawa, C; Shahir, A; Slotkin, EK; Weigel, BJ; Wright, J | 1 |
| Guo, L; Guo, Y; Liu, F; Liu, H; Liu, Y; Xiao, H; Yuan, M | 1 |
| Arora, M; Christensen, S; Gandara, DR; Gong, IY; Kelly, K; Kim, EJ; Li, T; Riess, JW; Semrad, TJ | 1 |
| Ariizumi, H; Fujita, KI; Hirasawa, Y; Ishida, H; Ishiguro, T; Kondo, Y; Kubota, Y; Kusuhara, H; Matsumoto, N; Ohkuma, R; Sasaki, Y; Tomoda, Y; Tsuboya, A; Tsunoda, T | 1 |
| Jang, HJ; Kang, RH; Kim, D; Kim, JH; Kim, JS; Kim, NH; Kim, Y; Ko, HM; Lee, SH; Shim, I | 1 |
| Ghaedi, K; Majd, A; Miralaei, N; Peymani, M; Safaei, M | 1 |
| Fioretzaki, R; Kosmas, C; Papageorgiou, G; Tsakatikas, S | 1 |
| Sahota, S; Vahdat, LT | 1 |
| Bardia, A; Goldenberg, DM; Govindan, SV; Guarino, M; Isakoff, SJ; Maliakal, P; Mayer, IA; Messersmith, WA; Ocean, AJ; Picozzi, VJ; Sharkey, RM; Starodub, AN; Vahdat, LT; Wegener, WA | 1 |
| Blaydorn, L; Coats, J; Farley, JH; Khemka, V; Lynch, CA; McGahey, K; Niu, J; Sangal, A; Waypa, J; Weiss, GJ | 1 |
| Bahrami, A; Blankenship, K; Bradley, C; Chen, X; Clay, MR; Dapper, J; Downing, J; Dyer, MA; Easton, J; Federico, SM; Freeman, BB; Gordon, B; Honnell, V; Karlstrom, A; Mardis, ER; Ocarz, M; Pappo, A; Shelat, AA; Stewart, E; Twarog, NR; Wilson, RK; Wu, J; Xu, B; Zhang, J; Zhou, X | 1 |
| Duan, Z; Pan, D; Peng, H; Wei, X; Wen, J | 1 |
| Hawkins, CJ; Miles, MA | 1 |
| Alsina, M; Braña, I; Britten, CD; Del Conte, G; Ezeh, P; Houk, B; Kern, KA; Leong, S; Pathan, N; Pierce, KJ; Siu, LL; Soares, HP; Tabernero, J; Vermette, J; Wainberg, ZA | 1 |
| Bao, WG; Li, YQ; Shi, WG; Tu, ZK; Wu, D; Yin, QL; Yu, H; Yu, YY; Zhao, DW; Zhong, BH | 1 |
| Chia, YL; Eldon, MA; Gordi, T; Hoch, U; Sy, SKB | 1 |
| Fukushima, K; Fukushima, S; Hata, A; Irie, K; Kaji, R; Katakami, N; Masuda, Y; Okada, A; Okada, Y; Okuda, C; Sugioka, N | 1 |
| Aldaz Pastor, A; Garcia-Del-Barrio, MA; Martin-Algarra, S | 1 |
| Hosokawa, T; Ishikawa, T; Kanazawa, M; Kanbayashi, Y; Kawano, R; Nakajima, Y; Tabuchi, Y; Taguchi, T; Takayama, K; Yoshida, N; Yoshioka, T | 1 |
| Ahmad, N; Ahmad, R; Alam, MA; Jalees Ahmad, F; Umar, S | 1 |
| Antunes, MV; Hahn, RZ; Linden, R; Perassolo, MS; Schwartsmann, G; Suyenaga, ES; Verza, SG | 1 |
| Cui, Y; Hu, M; Huang, F; Liang, L; Yang, Y; Zhong, Q; Zhou, M | 1 |
| Deng, B; Jia, L; Li, X; Li, Y; Lou, Y; Tan, H; Yu, L | 1 |
| Ishikura, K; Mizukami, Y; Okuyama, H; Tamura, K | 1 |
| Bao, X; Kim, S; Li, J; LoRusso, P; Wu, J | 1 |
| Bhuniya, S; Bobba, KN; Han, J; Kim, JS; Maiti, M; Miao, LX; Podder, A; Sharma, A; Shin, J; Won, M; Yu, L; Zhou, Y | 1 |
| Ding, HF; Huang, YQ; Ji, M; Qian, G; Song, YS; Wang, JL; Yuan, JD; Zhang, Y | 1 |
| Fujita, KI; Ishida, H; Iwai, S; Kamei, D; Kubota, Y; Sasaki, Y; Taki-Takemoto, I; Tsuboya, A | 1 |
| Akahori, D; Amano, T; Hasegawa, H; Kakutani, T; Koda, K; Kunimoto, Y; Matsui, T; Niwa, H; Ozawa, Y; Suda, T; Tanahashi, M; Yamada, K; Yokomura, K | 1 |
| Bi, Y; Lee, RJ; Li, C; Li, L; Sun, Y; Teng, L; Wang, M; Wang, X; Xie, J | 1 |
| Barbolosi, D; Deyme, L; Gattacceca, F | 1 |
| Fujii, H; Iihara, H; Kobayashi, R; Matsuhashi, N; Suzuki, A; Takahashi, T; Yoshida, K; Yoshimi, C | 1 |
| Chen, J; Cheng, D; Deng, L; Ma, J; Wu, C; Yang, D; Zhang, J; Zhang, Y | 1 |
| Chi, D; Liu, J; Pan, S; Wang, D; Wang, X; Wang, Y; Zhao, L | 1 |
| Ahmad, T; Ahmed, M; Chen, ZS; Czejka, M; Fan, Y; Khan, RA; Mansoor, N; Sharib, S; Wu, ZX; Yang, DH | 1 |
| Gholami, L; Jaafari, MR; Mahmoudi, A; Malaekeh-Nikouei, B; Ramezanian, N | 1 |
| Páez, D | 1 |
| Pommier, Y; Thomas, A | 1 |
| Gao, S; Huang, D; Si, J; Sui, M; Zhao, X | 1 |
| Alonso, J; Bertran, J; Bigas, A; Borràs, E; Boulton, SJ; Colomer, C; Espinosa, L; González-Farré, M; Iglesias, M; Margalef, P; Martinez-Iniesta, M; Montagut, C; Pecharroman, I; Sabidó, E; Solé, L; Vert, A; Villanueva, A | 1 |
| Bozzato, E; Lopes, A; Papavasileiou, M; Préat, V; Tsakiris, N; Vigneron, AM | 1 |
| Cardillo, TM; Gold, DV; Goldenberg, DM; Govindan, SV; Sharkey, RM; Tat, F | 1 |
| Boku, N; Fujiki, T; Fujino, K; Gemma, A; Kakihata, K; Masatani, S; Morita, S; Shiozawa, T; Tadokoro, J | 1 |
| Beeram, M; Bekaii-Saab, T; Buchbinder, A; Lokiec, FM; Papadopoulos, KP; Patnaik, A; Rezaï, K; Schaaf, LJ; Tahiri, S; Tolcher, AW; Urien, S | 1 |
| Matsuzaki, T; Nagaoka, M; Shishido, Y; Ueno, S; Yamazaki, R | 1 |
| Boxberger, F; Dörje, F; Harich, HD; Hohenberger, W; Koch, S; Neurath, MF; Siebler, J; Wein, A | 1 |
| Gu, Z; Mao, W; Shen, Y; Sui, M; Sun, W; Sun, X; Tang, J; Wang, J | 1 |
| Brown, GW; Giaever, G; Lee, AY; Nislow, C; Torres, NP | 1 |
| Fujiwara, K; Katakami, N; Kitao, A; Matsumoto, K; Minami, H; Morita, S; Negoro, S; Shibata, N; Tanioka, M; Yamaguchi, S | 1 |
| Davidson, TB; Malogolowkin, M; Mascarenhas, L; May, W; Sposto, R; Venkatramani, R | 1 |
| Bala, V; Boyd, BJ; Prestidge, CA; Rao, S | 1 |
| Lopes, Gde L | 1 |
| Bendell, JC; Burris, HA; Chan, E; Ikeda, S; Infante, JR; Jones, SF; Keedy, VL; Kodaira, H; Lee, W; Rothenberg, ML; Wu, H; Zamboni, BA; Zamboni, WC | 1 |
| Fujisaki, H; Hara, J; Okada, K; Osugi, Y; Tanaka, C; Yamasaki, K | 1 |
| Blackwood, E; Del Nagro, C; Evangelista, M; Jackson, PK; Kowanetz, K; Malek, S; O'Brien, T; Ramiscal, J; Xiao, Y | 1 |
| Ames, MM; Erlichman, C; Goetz, MP; Goldberg, RM; Grothey, AA; Kuffel, MA; Mandrekar, SJ; McGovern, RM; McKean, HA; McWilliams, R; Reid, JM; Safgren, SL; Tan, AD | 1 |
| Bekaii-Saab, T; Clinton, SK; Grever, MR; Kraut, EH; Martin, LK; Monk, P; Serna, D | 1 |
| Adamson, PC; Ahern, C; Bagatell, R; Blaney, S; Fox, E; Ingle, AM; Little, AR; Norris, R; Voss, S; Weigel, BJ | 1 |
| Fujita, K; Sasaki, Y | 1 |
| Bloomfield, A; Dorton, R; Guan, J; Leamon, CP; Nelson, M; Reddy, JA; Vetzel, M | 1 |
| Cheng, L; Dong, XL; Hu, J; Li, M; Liu, BR; Qian, XP; Ren, W; Sun, ZP; Xie, L; Xu, GX | 1 |
| Chen, X; Gan, Y; Guo, S; Li, F; Li, J; Wang, X; Zhang, X | 1 |
| Beau, J; Innominato, PF; Iurisci, I; Karaboue, A; Lévi, F; Madrid, JA; Moreau, T; Ortiz-Tudela, E; Rol, MA | 1 |
| An, GY; Gong, LL; Guo, CL; Han, FF; Li, GR; Liu, H; Liu, LH; Lv, YL; Yu, D; Zhu, J | 1 |
| Cao, S; Durrani, FA; Rustum, YM; Tóth, K | 1 |
| Boige, V; Dias, MM; Glimelius, B; Karapetis, CS; Kweekel, DM; Lara, PN; Laurent-Puig, P; Martinez-Balibrea, E; McKinnon, RA; Páez, D; Pignon, JP; Punt, CJ; Redman, MW; Sorich, MJ; Toffoli, G; Wadelius, M | 1 |
| Ahmad, S; Kong, R; Liu, T; Phan, AT; Scott, JE; Williams, AL; Wong, ST; Yeh, LA; Zhao, H; Zhu, X | 1 |
| Cao, J; Huang, XE; Liu, J; Lu, YY; Wang, L; Wu, XY; Xiang, J | 1 |
| Amini, M; Dinarvand, R; Ghahremani, MH; Ghanbarpour, AR; Gharghabi, M; Ostad, SN; Rouhani, H; Sepehri, N; Tavassolian, F | 1 |
| Cho, AR; Heo, JH; Hwhang, TH; Kim, WM; Lee, DH; Park, DJ; Won, JH; Yun, HJ | 1 |
| Phelps, MA; Sparreboom, A | 1 |
| Das, S; House, LK; Innocenti, F; Janisch, L; Karrison, T; Maitland, ML; Marsh, R; Ramírez, J; Ratain, MJ; Salgia, R; Schilsky, RL; Turcich, M; Undevia, S; Wu, K | 1 |
| Tadje, M | 1 |
| Cabral, H; Kataoka, K | 1 |
| Cai, P; Gao, F; Gao, L; Gao, X; Huang, G; Liang, J; Liu, R; Wang, Y; Wei, Y; Yuan, Q; Zhu, H | 1 |
| Doi, A; Doi, T; Hamaguchi, T; Ichinohe, R; Kaniwa, N; Matsumura, Y; Odaka, Y; Ohtsu, A; Okuda, H; Okuyama, M; Sai, K; Saijo, N; Saito, Y; Sakamoto, H; Sawada, J; Shimada, Y; Takahashi, A; Takahashi, H; Yoshida, T; Yoshino, T | 1 |
| Brennan, RC; Furman, W; Mao, S; McGregor, LM; Santana, V; Stewart, CF; Turner, DC; Wu, J | 1 |
| Azuma, S; Kawato, N; Makihara, K; Nakata, I; Ueno, H | 1 |
| Cho, HJ; Choi, HG; Choi, JY; Kim, JO; Ramasamy, T; Shin, BS; Umadevi, SK; Yong, CS | 1 |
| Chang, JY; Chang, TC; Chen, LT; Cheng, AL; Chiang, NJ; Shen, BN; Shiah, HS; Wang, YW; Yang, CH; Yeh, CG; Yeh, KH | 1 |
| Bendell, JC; Burris, HA; Chan, E; Ikeda, S; Infante, JR; Jones, SF; Keedy, VL; Kirschbrown, WP; Kodaira, H; Lee, W; Rothenberg, ML; Wu, H; Zamboni, BA; Zamboni, WC | 1 |
| Arakawa, Y | 1 |
| Kaku, Y; Kanno, T; Nishizaki, T; Tsuchiya, A | 1 |
| Crona, DJ; de Graan, AJ; Innocenti, F; Mathijssen, RH; Qiao, W; Ramirez, J; Ratain, MJ; Rosner, GL; van Schaik, RH | 1 |
| Eto, K; Fukushima, H; Furuhata, T; Isobe, H; Iwanaga, I; Kawamoto, Y; Komatsu, Y; Kudo, M; Masuko, H; Minami, S; Miyagishima, T; Nakajima, J; Nakamura, M; Oba, K; Ohsaki, Y; Okita, K; Sasaki, K; Shibuya, H; Takahashi, Y; Tateyama, M; Yokoyama, R; Yuki, S | 1 |
| Amzerin, M; Errihani, H; Mokrim, M; Piccart, MJ | 1 |
| Ballesta, A; Dulong, S; Lévi, F; Okyar, A | 1 |
| Cirkel, GA; Daenen, LG; Gerrits, J; Houthuijzen, JM; Huitema, AD; Ishihara, K; Oosterom, I; Roodhart, JM; van Tinteren, H; Verhoeven-Duif, NM; Voest, EE | 1 |
| Palakurthi, S | 1 |
| Gjerset, RA; Zhao, M | 1 |
| Acquaviva, J; Astsaturov, I; Bates, RC; Chimmanamada, D; He, S; Inoue, T; Jimenez, JP; Khazak, V; Ogawa, LS; Osman, S; Proia, DA; Sang, J; Sequeira, M; Smith, DL; Tatsuta, N; Ying, W; Zhang, C; Zhang, J | 1 |
| Akiyama, Y; Fujita, K; Kato, Y; Kawara, K; Kitamura, M; Kunishima, M; Masuo, Y; Okumura, H; Sasaki, Y; Shimada, K; Sunakawa, Y; Suzuki, H; Watanabe, Y | 1 |
| Arzt, J; Busman, TA; Holen, KD; Lian, G; LoRusso, P; Rosen, LS; Rudersdorf, NS; Tolcher, AW; Vanderwal, CA; Waring, JF; Yang, J | 1 |
| Bawa, O; Bosq, J; Daudigeos-Dubus, E; Geoerger, B; Lanvers-Kaminsky, C; Le Dret, L; Opolon, P; Pagès, M; Vassal, G; Vievard, A; Villa, I; Zopf, D | 1 |
| Baryawno, N; Calero, R; Darabi, A; Dyberg, C; Einvik, C; Johnsen, JI; Kogner, P; Kool, M; Milosevic, J; Sandén, E; Siesjö, P; Sveinbjörnsson, B; Wickström, M | 1 |
| Cheng, Y; Wang, C; Wang, X; Wang, Y; Xiao, J; Zhang, J; Zhang, Q | 1 |
| Li, J; Lin, G; Wang, L; Xie, J; Yi, L; Zhang, K; Zhang, R | 1 |
| Bell, T; Boerner, JL; Boerner, SA; Bowditch, A; Burger, A; Cai, D; Chen, AP; Cleary, JM; Ferry-Galow, K; Heilbrun, LK; Ji, J; Kinders, RJ; Li, J; LoRusso, PM; Marrero, AM; Parchment, RE; Pilat, MJ; Rubinstein, L; Sausville, EA; Shapiro, GI; Smith, D; Tolaney, SM; Wolanski, A; Zhang, J; Zhang, Y | 1 |
| Liu, JY; Nie, YL; Wang, XF; Wei, LM; Yan, L; Zhang, LR | 1 |
| Anthony Greco, F; Barton, JH; Bendell, JC; Burris, HA; Infante, JR; Jones, SF; Nambu, Y; Thompson, DS; Watanabe, N | 1 |
| Alzghari, SK; Chee, W; La-Beck, NM; Petersen, GH; Sankari, SS | 1 |
| Lee, RJ; Teng, L; Teng, M; Xie, J; Yang, S; Yu, B; Zhang, X | 1 |
| Spindler, A; Stefan, K; Wiese, M | 1 |
| Durmus, S; Schinkel, AH; van Hoppe, S | 1 |
| Guo, B; Qian, SY; Sun, M; Yang, X; Zhang, Q | 1 |
| Asakiewicz, C; Braiteh, F; Chaudhary, A; Denlinger, CS; Gao, L; Lee, JJ; Lin, Y; LoRusso, P; Nasroulah, F; Shepard, DR; Wang, D | 1 |
| Byrne, A; Dean, A; Hayden, I; Marinova, M | 1 |
| Chen, S; Chowbay, B; Khor, CC; Lam, S; Sutiman, N; Yu, Y; Zhang, CZ | 1 |
| Cheung, YK; Mao, X | 1 |
| Balasubramanian, P; Chen, AP; Evrard, YA; Kinders, RJ; Kummar, S; Wang, L | 1 |
| Terada, T | 1 |
| Gelderblom, H; Guchelaar, HJ; Kweekel, D | 1 |
| Inui, K; Onoue, M | 1 |
| Eberhardt, S; Lee, F; Lee, SJ; Lu, H; Maestas, A; Rabinowitz, I; Royce, M; Sayar, H; Shen, Z; Smith, H; Verschraegen, C | 1 |
| Drengler, R; Duan, W; Kolesar, JM; Kuhn, J; Otterson, G; Schaaf, LJ; Shapiro, C; Villalona-Calero, MA; Xu, Y | 1 |
| Berlin, JD; Chan, E; Goff, LW; Lockhart, AC; Roth, BJ; Rothenberg, ML; VerMeulen, WL | 1 |
| Brown, K; Carvajal, R; Chung, K; Egorin, MJ; Gonen, M; Kelsen, D; Klimstra, DS; Lefkowitz, R; Maki, R; Manova-Todorova, K; Mui, J; O'Reilly, E; Schwartz, GK; Shah, M; Sheikh, T; Sikorski, R; Tipian, C; Tse, AN; Wu, N | 1 |
| Akiyama, Y; Ando, Y; Araki, K; Endo, H; Fujita, K; Hirose, T; Ichikawa, W; Ishida, H; Kawara, K; Miya, T; Mizuno, K; Nagashima, F; Narabayashi, M; Sasaki, Y; Sugiyama, M; Sunakawa, Y; Yamamoto, W; Yamashita, K | 1 |
| Fujimitsu, Y; Kojima, H; Kojima, T; Kure, N; Matsui, T; Mochizuki, Y; Uemura, T | 1 |
| Angiolillo, A; Cohen, MB; Gorlick, R; Jakacki, R; Levy, AS; Meyers, PA; Ringuette, SN; Wexler, LH | 1 |
| Batist, G; Chi, KN; Chia, SK; Gelmon, KA; Janoff, AS; Louie, AC; Mayer, LD; Miller, WH; Swenson, CE | 1 |
| Adamson, PC; Blaney, SM; Furman, WL; Ivy, P; Krailo, MD; McGregor, LM; Schaiquevich, P; Speights, R; Spunt, SL; Stewart, CF | 1 |
| Aoun, N; Baz, W; Burton, J; El-Soueidi, R; Forte, F; Lowry, J; Nakhl, F | 1 |
| Fukushima, M; Inui, K; Kanai, M; Katsura, T; Kobayashi, M; Matsumoto, S; Nishimura, T; Onoue, M; Shimizu, A; Terada, T; Teramukai, S; Yanagihara, K | 1 |
| Berg, DJ; Bernaards, C; Blanchard, R; Denlinger, CS; Dorr, A; Hambleton, J; Holden, S; Kearns, A; Kenkare-Mitra, S; Litwin, S; Lum, B; McLaughlin, S; Meropol, NJ; O'Dwyer, PJ; Redlinger, M; Spittle, C; Xu, L | 1 |
| Hoskins, JM; Innocenti, F; McLeod, HL; Ratain, MJ; Rosner, GL | 1 |
| Axelrod, F; Basi, J; Clarke, MF; Donigian, L; Dylla, S; Fitch-Bruhns, M; Gurney, A; Hoey, T; Lazetic, S; Lewicki, J; Park, IK; Sato, A; Satyal, S; Wang, X; Yen, WC | 1 |
| Fram, RJ; Yurkovetskiy, AV | 1 |
| Crews, KR; Daw, NC; Furman, WL; Gajjar, AJ; Houghton, PJ; McCarville, MB; McGregor, LM; Navid, F; Panetta, JC; Rodriguez-Galindo, C; Santana, VM; Spunt, SL; Stewart, CF; Wu, J | 1 |
| Cha, PC; Furuhata, T; Harada, H; Hirata, K; Kawamoto, S; Mushiroda, T; Nakamura, Y; Nishidate, T; Sasaki, K; Shimoyama, R; Shinoda, N; Zembutsu, H | 1 |
| Ehrnrooth, E; Frederiksen, KS; Skak, K; Søndergaard, H | 1 |
| Bhonde, MR; Fechner, H; Hanski, C; Hanski, ML; Jebautzke, B; Lin, WC; Peiró-Jordán, R; Stehr, J; Yokoyama, KK; Zeitz, M | 1 |
| Arceci, RJ; Bagatell, R; Boklan, J; Gore, L; Harbison, C; Herzog, C; Hunger, SP; Katzenstein, HM; Kuttesch, J; Langer, C; Lu, H; Smith, AA; Trippett, TM; Weber, M; Whitlock, JA; Wolff, J; Zhou, X | 1 |
| Hamaguchi, T; Kaniwa, N; Kim, SR; Kunitoh, H; Maekawa, K; Matsumura, Y; Minami, H; Nishimaki-Mogami, T; Ohe, Y; Ohtsu, A; Sai, K; Saijo, N; Saito, Y; Sawada, J; Shirao, K; Tamura, T; Yamada, Y; Yamamoto, N; Yoshida, T | 1 |
| Baggstrom, MQ; Fracasso, P; Govindan, R; Morgensztern, D; Pillot, G; Suresh, R; Tan, B; Wildi, J | 1 |
| Blobe, GC; Dugan, E; Fernando, NH; Gockerman, JP; Hurwitz, HI; Meadows, KL; Morse, MA; Petros, WP; Truax, R | 1 |
| Adamson, PC; Ames, MM; Blaney, SM; Ingle, AM; Nelson, MD; Perentesis, JP; Reid, JM; Safgren, SL; Wagner, LM | 1 |
| Innocenti, F; Ratain, MJ | 2 |
| Alberti, DB; Choi, BS; Eickhoff, JC; Holen, KD; Ivy, SP; Kolesar, JM; Marnocha, R; Schelman, WR; Thomas, JP; Wilding, G | 1 |
| Furuya, K; Goto, T; Kato, M; Kikuchi, Y; Takano, M; Yoshikawa, T | 1 |
| Brendel, E; Laferriere, N; Langenberg, MH; Mergui-Roelvink, M; Roodhart, JM; Schellens, JH; van der Sar, J; Verheul, HM; Voest, EE; Witteveen, PO | 1 |
| Hu, ZY; Yu, Q; Zhao, YS | 1 |
| Heideman, RL; McNall-Knapp, RY; Meyer, WH; Reeves, EN; Williams, CN | 1 |
| Barrett, JS; Ida, K; Ishida, Y; Kaneko, M; Kashiwase, S; Kimura, T; Kumagai, M; Makimoto, A; Mugishima, H; Nagatoshi, Y; Taga, T | 1 |
| Matsumura, Y | 1 |
| Briasoulis, E; Fountzilas, G; Golfinopoulos, V; Karina, M; Papakostas, P; Pavlidis, N | 1 |
| Hamaguchi, T; Hosokawa, M; Kaniwa, N; Kunitoh, H; Matsumura, Y; Minami, H; Naito, M; Nishimaki-Mogami, T; Ohe, Y; Ohtsu, A; Okuda, H; Sai, K; Saijo, N; Saito, Y; Sawada, J; Shirao, K; Tamura, T; Tatewaki, N; Yamada, Y; Yamamoto, N; Yoshida, T | 1 |
| Belcastro, V; Bosotti, R; Brunetti-Pierri, N; di Bernardo, D; Ferriero, R; Iorio, F; Isacchi, A; Mithbaokar, P; Murino, L; Scacheri, E; Tagliaferri, R | 1 |
| Adkins, DR; Arquette, MA; Cai, SR; Chen, RC; Creekmore, AN; Dancey, J; Ellis, MJ; Fleshman, JW; Fracasso, PM; Goodner, SA; Guo, Z; Lin, L; Ma, CX; McLeod, HL; Naughton, MJ; Picus, J; Piwnica-Worms, H; Pluard, TJ; Rader, JS; Rudek, MA; Ryan, CE; Soares, EM; Tan, BR; Tao, Y; Williams, KJ; Wright, LP | 1 |
| Armand, JP; Boven, E; Brega, NM; Countouriotis, AM; Hartog, V; Massard, C; Ruiz-Garcia, A; Soria, JC; Tillier, C | 1 |
| Eng, C | 1 |
| Lee, SY; McLeod, HL | 1 |
| Jaitner, S; Jung, A; Kirchner, T; Schäffauer, AJ | 1 |
| Benner, RJ; Benson, AB; Berlin, JD; Denis, LJ; Goff, LW; LoRusso, PM; Rothenberg, ML; Tan, AR; Yin, D | 1 |
| de Jong, FA; Mathijssen, RH; Sleijfer, S; Sparreboom, A; van Daele, PL; van de Geijn, FE; van der Bol, JM; van Fessem, MA; van Schaik, RH; Verweij, J | 1 |
| Doi, T; Eguchi-Nakajima, T; Fuse, N; Hamaguchi, T; Kato, K; Matsumoto, S; Matsumura, Y; Ohtsu, A; Shimada, Y; Takanashi, M; Yamada, Y | 1 |
| Cane, LM; Carvajal, RD; Dials, HJ; Dickson, MA; Gonen, M; Lefkowitz, RA; Rathkopf, D; Schwartz, GK; Shah, MA; Tse, A; Wu, N | 1 |
| Strassburg, CP | 1 |
| Huang, XE; Jiang, Y; Li, Y; Xiang, J; Yan, PW | 1 |
| de Bruijn, P; de Jong, FA; Konings, IR; Lam, MH; Loos, WJ; Mathijssen, RH; van der Bol, JM; van Meerten, E; Verweij, J; Wiemer, EA | 1 |
| Chen, KC; Cheng, TL; Huang, PT; Leu, YL; Prijovich, ZM; Roffler, SR | 1 |
| Farndon, P; Li-Wan-Po, A | 1 |
| Crews, KR; Furman, WL; Houghton, PJ; McCarville, MB; McGregor, LM; Navid, F; Rodriguez-Galindo, C; Santana, VM; Stewart, CF; Tagen, M; Wozniak, A; Wu, J | 1 |
| Dzurenkova, A; Kadasi, L; Minarik, G; Mladosievicova, B; Soltysova, A; Sufliarska, S; Turna, J | 1 |
| Gemma, A; Kakihata, K; Kon, A; Nagashima, M; Suzuki, T; Yoshii, N | 1 |
| Aiyama, R; Asakawa, N; Furuta, T; Hatano, H; Igarashi, Y; Kodaira, H; Matsuzaki, T; Nishiyama, Y; Sugimoto, Y; Takahashi, H; Yagi, N; Yamazaki, R | 1 |
| Anderson, K; Burris, HA; Jones, S; Marier, JF; Pheng, L; Porubek, D; Trinh, MM; Warner, S | 1 |
| Adjei, AA; Garmey, E; Schwartz, B | 1 |
| Manabe, S; Matsumura, Y; Tarin, D; Yasunaga, M | 1 |
| Hashimoto, M; Hiraike, M; Honda, S; Misumi, N; Nabeshima, A; Nawata, F; Takase, I; Tanigawa, K | 1 |
| Ariyoshi, Y; Fukuoka, M; Kakihata, K; Masatani, S; Sakata, Y; Shimazaki, M; Shiozawa, T; Tadokoro, J; Yamaguchi, F | 1 |
| Cohen, EE; House, LK; Innocenti, F; Janisch, L; Karrison, T; Ramírez, J; Ratain, MJ; Wu, K | 1 |
| Assenat, E; Bleuse, JP; Mazard, T; Pinguet, F; Portales, F; Poujol, S; Samalin, E; Thezenas, S; Thirion, A; Ychou, M | 1 |
| Anantha, M; Bally, MB; Sutherland, B; Verreault, M; Waterhouse, DN; Yapp, D | 1 |
| Akama, TO; Bobkov, AA; Fukuda, M; Fukuda, MN; Hatakeyama, S; Nakayama, J; Ohyama, C; Shibata, TK; Sugihara, K; Takano, Y; Tamura, N; Wong, SM | 1 |
| Murayama, J; Okazaki, K; Saito, I; Watanabe, T | 1 |
| Awada, A; Azim, HA | 1 |
| Fujita, K; Ishida, H; Kato, Y; Miwa, K; Saji, S; Sasaki, T; Sasaki, Y; Sunakawa, Y; Yamashita, K | 1 |
| Dias, MM; McKinnon, RA; Sorich, MJ | 1 |
| Bach, PB; Conti, RM; Polite, BN; Rosenthal, MB; Shih, YC | 1 |
| Baracos, VE; Bibova, I; Dieleman, LA; Field, CJ; Gänzle, MG; Ketabi, A; Lin, XB; Sawyer, MB; Xue, H | 1 |
| Gilbert, KS; Secrist, JA; Waud, WR | 1 |
| Assadourian, S; Billemont, B; Cartot-Cotton, S; Khayat, D; Meric, JB; Rixe, O; Soussan-Lazard, K; Tejpar, S; Van Cutsem, E; Verslype, C | 1 |
| Bendell, JC; Burris, HA; Chan, E; Ikeda, S; Infante, JR; Jones, SF; Keedy, VL; Kodaira, H; Lee, W; Rothenberg, ML; Wu, H; Zamboni, WC | 1 |
| Larsen, AK; Petitprez, A | 1 |
| Aiba, K; Arakawa, Y | 1 |
| Al-Kasspooles, MF; Decedue, CJ; Henry, D; Howell, J; Niu, F; Roby, KF; Williamson, SK | 1 |
| Etoh, T; Hayashi, H; Inoue, K; Itoh, K; Kawamura, Y; Kikuyama, M; Kimura, M; Matsumura, T; Minami, S; Sonobe, M; Suzuki, T; Takagi, M; Tsuji, D; Utsuki, H; Yamazaki, T | 1 |
| Assadourian, S; Bloch, J; Cartot-Coton, S; Khayat, D; Soussan-Lazard, K; Spano, JP; Tejpar, S; Van Cutsem, E; Vandecaveye, V; Verslype, C | 1 |
| Arce Abaitua, B; Blumenfeld Olivares, JA; Cormenzana Carpio, M; Hernández-Marqués, C; Lassaletta-Atienza, A; Madero Lopez, L; Ruiz Hernández, A | 1 |
| Green, MR; Leong, SS; Perkel, JA; Putman, T; Rocha Lima, CM; Safa, AR; Sherman, CA | 1 |
| Karlsson, MO; Mathijssen, RH; Sparreboom, A; Verweij, J; Xie, R | 1 |
| Ma, MK; McLeod, HL; Xu, G; Zhang, W | 1 |
| Loos, WJ; Mathijssen, RH; Sparreboom, A; Verweij, J | 1 |
| Mansky, PJ; Straus, SE | 1 |
| Baidas, S; Marshall, JL; Rizvi, N | 1 |
| Kolesar, JM; Villalona-Calero, MA | 1 |
| Hara, N; Harada, T; Inoue, K; Izumi, M; Kimotsuki, K; Minami, T; Nakanishi, Y; Osaki, S; Takano, K; Takayama, K; Wataya, H | 1 |
| Adams, AL; Brady, D; Engstrom, PF; Gallo, JM; Kilpatrick, D; Lewis, NL; Litwin, S; Meropol, NJ; Scher, R; Szarka, CE; Weiner, LM | 1 |
| Adjei, AA; Alberts, SR; Atherton, P; Erlichman, C; Goldberg, RM; Kaufmann, SH; Miller, LL; Pitot, HC; Rubin, J; Sloan, JA | 1 |
| Villalona-Calero, MA; Xu, Y | 1 |
| Siderov, J | 1 |
| Albanell, J; Baselga, J | 1 |
| Bernstein, ML; Blaney, SM; Dubowy, RL; Hershon, L; McLeod, WD; Souid, AK; Sullivan, J | 1 |
| Conroy, T; Gourgou, S; Hua, A; Kramar, A; Mery-Mignard, D; Seitz, JF; Ychou, M | 1 |
| McLeod, HL; Watters, JW | 1 |
| Blackburn, A; Cunningham, C; Freeman, S; Gibson, B; Nemunaitis, J; Netto, G; Paulson, AS; Post, L; Randlev, B; Rich, D; Sands, B; Tong, A | 1 |
| Ando, M; Hanioka, N; Jinno, H; Kaniwa, N; Minami, H; Ohtsu, A; Ozawa, S; Saeki, M; Sai, K; Saijo, N; Saito, Y; Sawada, J; Shirao, K; Tanaka-Kagawa, T; Yoshida, T | 1 |
| Aisner, J; Beers, S; Gounder, M; Licitra, EJ; Lin, Y; Musanti, R; Nelson, K; Poplin, E; Rajendra, R; Rubin, EH; Saleem, A; Schaaf, LJ; Smith, S; Thomas, C; Toppmeyer, D; Vyas, V | 1 |
| Boiocchi, M; Cecchin, E; Corona, G; Toffoli, G | 1 |
| Crane, CH; Liao, Z; Masferrer, J; Mason, KA; Milas, L | 1 |
| Burris, HA; Greco, FA; Hainsworth, JD; Jones, SF; Kuzur, ME; Miranda, FT; Raefsky, EA; White, MB; Willcutt, NT; Yardley, DA | 1 |
| Burris, HA; Gian, VG; Greco, FA; Hainsworth, JD; Jones, SF; Miranda, FT; Shipley, DL; Thompson, DS; Toomey, MA; Willcutt, NT | 1 |
| Hwang, JJ; Marshall, JL; Rizvi, N | 1 |
| Bailly, C; Lansiaux, A | 1 |
| Kobayashi, K | 1 |
| Gandara, DR; Houston, J; Lara, PN; Lau, DH; Lauder, J; Meyers, FJ; Tanaka, M; Wang, SE; Wild, CA | 1 |
| Chen, X; Davis, AJ; Kochman, D; Kusenda, Z; Moore, MJ; Oza, AM; Siu, LL; Yi, QL | 1 |
| Adjei, AA; Ames, MM; Atherton, P; Erlichman, C; Galanis, E; Goetz, MP; Goldberg, RM; Pitot, H; Reid, JM; Rubin, J; Sloan, JA; Windebank, AJ | 1 |
| Desai, AA; Innocenti, F; Ratain, MJ | 1 |
| Doz, F; Frappaz, D; Germa, C; Imadalou, K; Mignard, D; O'Quigley, J; Pein, F; Risse, ML; Santos, A; Sicard, E; Vassal, G | 1 |
| Evans, SS; Harper, SM; Nagourney, RA; Radecki, S; Sommers, BL | 1 |
| Budman, D; Byrd, J; Enders Klein, C; Fleming, G; Hohl, R; Hollis, D; Kastrissios, H; Leichman, CG; Marshall, J; Ramirez, J; Ratain, MJ; Rosner, GL; Venook, AP; Villalona, M | 1 |
| Danks, MK; Potter, PM | 1 |
| Baas, F; Brendel, E; Buss, P; Mersmann, S; Mross, K; Reil, M; Schwartz, B; Steinbild, S; Voliotis, D | 1 |
| Viele, CS | 1 |
| Davis, ID; Green, M; Jefford, M; McClure, B; Michael, M; Rosenthal, MA; Smith, J; Waite, B; Zalcberg, J | 1 |
| Alpaugh, RK; Cohen, SJ; Gallo, J; Gentner, L; Lewis, NL; Meropol, NJ; Palmer, PA; Rogatko, A; Schol, J; Verhaeghe, T; Weiner, LM; Yeslow, G; Zannikos, P | 1 |
| Albritton, K; Crews, KR; Fuller, CE; Goldsby, RE; Houghton, PJ; Iacono, LC; McCarville, MB; Santana, VM; Stewart, CF; Wagner, LM | 1 |
| Algazy, K; Giantonio, B; Hahn, S; Haller, DG; O'Dwyer, PJ; Redlinger, M; Stevenson, JP; Sun, W; Thorn, C; Vaughn, D; Veronese, ML; Whitehead, AS | 1 |
| Baker, SD; Brahmer, JR; Carducci, MA; Lee, CK; Sparreboom, A; Verweij, J; Wolff, AC; Zabelina, Y; Zhao, M | 1 |
| Liang, H; Sha, N | 1 |
| Cao, S; Durrani, FA; Rustum, YM | 1 |
| de Bruijn, P; de Heus, G; de Jonge, MJ; Eskens, FA; Kehrer, DF; Klaren, A; Mathijssen, RH; Palmer, PA; Planting, AS; Sparreboom, A; Verhaeghe, T; Verheij, C; Verweij, J; Xie, R; Zhang, S | 1 |
| Hasegawa, R; Jinno, H; Kamakura, S; Kamatani, N; Kaniwa, N; Katori, N; Kitakaze, M; Kitamura, Y; Komamura, K; Minami, H; Ohtsu, A; Ozawa, S; Saeki, M; Sai, K; Saijo, N; Saito, Y; Sawada, J; Shirao, K; Ueno, K; Yoshida, T | 1 |
| Kullmann, F; Schölmerich, J; Schultz, M | 1 |
| de Jong, FA; Mathijssen, RH; Sparreboom, A; Verweij, J; Xie, R | 1 |
| Danesi, R; Figg, WD; Mathijssen, RH; Paoluzzi, L; Price, DK; Singh, AS; Sparreboom, A; Verweij, J | 1 |
| Kiribayashi, Y; Maeda, Y; Murakami, T; Nakamura, M; Ohune, T; Yamasaki, M | 1 |
| de Jong, FA; King, C; Marsh, S; Mathijssen, RH; McLeod, HL; Sparreboom, A; Verweij, J | 1 |
| Jung, SH; Kirsh, KL; Loehrer, P; Nagy, C; Navari, RM; Passik, SD; Vinson, J | 1 |
| Innocenti, F; Mani, S; Prado, M; Ramírez, J; Ratain, MJ; Schilsky, RL; Undevia, SD; Vogelzang, NJ | 1 |
| Harrington, KJ; Marshall, CJ; Mavria, G; Porter, CD | 1 |
| Cunningham, D; Ng, M | 1 |
| Assadourian, S; Beijnen, JH; Huinink, WW; Kuppens, IE; Lefebvre, P; Sanderink, GJ; Schellens, JH; Schoemaker, NE | 1 |
| Paukstadt, W | 1 |
| Assadourian, S; deJonge, MJ; Dumez, H; Eskens, FA; Sanderink, GJ; Selleslach, J; Semiond, D; Soepenberg, O; Sparreboom, A; ter Steeg, J; van Oosterom, AT; Verweij, J | 1 |
| Cecchin, E; Toffoli, G | 1 |
| Assadourian, S; de Jong, FA; de Jonge, MJ; Dumez, H; Eskens, FA; Lefebvre, P; Sanderink, GJ; Selleslach, J; Soepenberg, O; Sparreboom, A; Ter Steeg, J; Thomas, J; van Oosterom, AT; van Schaik, RH; Verweij, J | 1 |
| Berg, S; Blaney, SM; Bomgaars, L; Kerr, J; Klenke, R; Kuttesch, J | 1 |
| Beringer, P; Garcia, AA; Iqbal, S; Jeffers, S; Lenz, HJ; Louie, S; Pujari, M | 1 |
| Alfonso, R; Carcas, A; Cortés-Funes, H; Díaz-Rubio, E; Frías, J; Grávalos, C; Guerra, P; Paz-Ares, L; Pronk, L; Sastre, J | 1 |
| Brenner, B; Cordon-Cardo, C; Drobnjak, M; Gonen, M; Kelsen, DP; Kortmansky, J; Lefkowitz, R; Motwani, M; O'Reilly, E; Saltz, L; Schwartz, GK; Shah, MA; Tong, W; Weyerbacher, A; Yi, S | 1 |
| Fioravanti, S; Grem, JL; Guo, X; Harold, N; Hopkins, JL; Leguizamo, JP; Leonard, GD; Lin, P; Monahan, BP; Morrison, G; Nguyen, D; Pang, J; Quinn, MG; Saif, MW; Schuler, B; Szabo, E; Wright, MA | 1 |
| Adjei, AA; Croghan, GC; Dy, GK; Furth, A; Hanson, LJ; Mandrekar, S; Okuno, SH; Peethambaram, PP | 1 |
| Cain, A; Crews, KR; Daw, NC; Furman, W; Houghton, PH; Panetta, JC; Rodriguez-Galindo, C; Santana, VM; Stewart, CF; Tan, M | 1 |
| Cree, IA; Di Nicolantonio, F; Di Palma, S; Fernando, A; Gabriel, FG; Glaysher, S; Gulliford, T; Higgins, B; Hurren, J; Johnson, P; Knight, LA; Lamont, A; Mercer, SJ; Sharma, S; Somers, SS; Toh, S; Whitehouse, PA; Yiangou, C | 1 |
| Cao, S; Durrani, FA; Fakih, M; Rustum, YM | 1 |
| Goetz, MP; Grothey, A; Mandrekar, SJ; Sargent, DJ | 1 |
| Baker, SD; Gelderblom, H; Guchelaar, HJ; Nortier, JW; Rudek, MA; Sparreboom, A; van Erp, NP; Zhao, M | 1 |
| Isomura, M; Miki, Y | 1 |
| Lokiec, F; Rezaí, K; Urien, S | 1 |
| Adjei, AA; Alberts, SR; Atherton, PJ; Denis, L; Duncan, BA; Erlichman, C; McGovren, P; Miller, LL; Pitot, HC; Reid, JM; Rubin, J; Schaaf, LJ; Sharma, A; Sloan, JA; Yin, D | 1 |
| de Jong, FA; de Jonge, MJ; Mathijssen, RH; Verweij, J | 1 |
| Kandabashi, K; Sasaki, T | 1 |
| Billups, C; Crews, KR; Daw, NC; Dome, JS; Furman, WL; Gajjar, AJ; Houghton, PJ; Panetta, JC; Patrick, CC; Rodriguez-Galindo, C; Santana, VM; Stewart, CF; Wu, J | 1 |
| Azrak, RG; Badmaev, V; Creaven, PJ; Fakih, MG; Lawrence, D; Pendyala, L; Prey, JD; Reid, ME; Rustum, YM; Smith, PF | 1 |
| Innocenti, F | 1 |
| Duncan, J; McLeod, HL; Scheffer, GL; Scheper, RJ; Shannon, WD; Zhang, W | 1 |
| Ando, Y; Araki, K; Endo, H; Fujita, K; Kodama, K; Miya, T; Nagashima, F; Narabayashi, M; Sasaki, Y; Yamamoto, W | 3 |
| Assadourian, S; Awada, A; de Boeck, G; de Bruijn, EA; Dumez, H; Guetens, G; Maes, RA; Piccart, M; Semiond, D; van Oosterom, A | 1 |
| Khoukaz, T | 1 |
| Innocenti, F; Ratain, MJ; Vokes, EE | 1 |
| Hanada, R; Kawa, K; Manabe, A; Matsunaga, T; Mimaya, J; Mugishima, H; Shimada, A; Shitara, T; Sugimoto, T; Tsuchida, Y; Tsurusawa, M | 1 |
| Duan, W; Kleiber, B; Kuhn, J; Otterson, G; Panico, K; Phillips, G; Schaaf, L; Shah, M; Villalona-Calero, M; Wu, WH; Young, D | 1 |
| McLeod, HL | 1 |
| Middleton, MR; Sabharwal, A | 1 |
| Assadourian, S; Beijnen, JH; Bonneterre, J; Bonneterre, ME; Boot, H; Dansin, E; Feger, C; Kuppens, IE; Schellens, JH | 1 |
| Cisar, LA; Compton, LD; Duncan, BA; Elfring, GL; Goel, R; Goldberg, RM; Gruia, G; Hammond, LA; Kuhn, JG; McGovren, JP; Miller, LL; Pirotta, N; Rothenberg, ML; Schaaf, LJ; Sharma, A; Tipping, SJ; Yin, D | 1 |
| Maitland, ML; Ratain, MJ; Vasisht, K | 1 |
| Ando, Y; Hasegawa, Y; Shimokata, K | 1 |
| Brunetto, AL; Castro, CG; Cruz, LB; Rech, A; Ribeiro, AS; Rosa, LG | 1 |
| Blanchard, RL; Nagar, S | 1 |
| Bally, MB; Harasym, NL; Harasym, TO; Janoff, AS; Johnstone, SA; Mayer, LD; Ramsay, EC; Shew, CR; Tardi, PG | 1 |
| Chowbay, B; Fan, L; Goh, BC; Jada, SR; Lee, SC; Li, HH; Lim, R; Tan, EH; Tham, LS; Wong, CI; Xiang, X; Zhou, QY | 1 |
| Appleman, LJ; Clark, J; Cusack, JC; Dees, EC; Eder, JP; Fidias, P; Kashala, O; O'Neil, BH; Orlowski, RZ; Rocha Lima, CM; Ryan, DP; Supko, JG | 1 |
| Baas, F; Brendel, E; Christensen, O; Gmehling, D; Mross, K; Radtke, M; Steinbild, S; Unger, C; Voliotis, D | 1 |
| Sekine, N; Terada, K | 1 |
| Baetz, T; Brail, LH; de Alwis, DP; Doppler, K; Eisenhauer, E; Fisher, B; Khan, AZ; MacLean, M; Moore, M; Siu, L; Walsh, W; Weitzman, A | 1 |
| Ando, M; Ando, Y; Hasegawa, Y; Hashimoto, N; Imaizumi, K; Shimokata, K | 1 |
| Baker, S; Bulgaru, A; Camacho, F; Chaudhary, I; Desai, K; Einstein, M; Goel, S; Goldberg, G; Gollamudi, R; Karri, S; Kaubisch, A; Mani, S | 1 |
| Azrak, RG; Cao, S; Combs, GF; Durrani, FA; Fakih, M; Pendyala, L; Prey, J; Rustum, YM; Smith, PF | 1 |
| Beeram, M; Chu, Q; De Bono, J; Forouzesh, B; Hammond, LA; Hong, S; John, W; Latz, JE; Nguyen, B; Rowinsky, EK; Schwartz, G | 1 |
| Antonia, S; Chiappori, A; de Lima Lopes, G; Haura, E; Langevin, M; Lush, R; Rocha-Lima, CM; Simon, G; Sullivan, D | 1 |
| Cusimano, L; Li, M; Saif, MW; Sellers, S; Wang, H; Wang, W; Zhang, R | 1 |
| Cowen, RL; Flint, PJ; Matzow, T; Saunders, MP; Southgate, TD; Telfer, BA; Williams, KJ | 1 |
| de Bruijn, P; de Jong, FA; Engels, FK; Kitzen, JJ; Loos, WJ; Mathijssen, RH; Mathot, RA; Sparreboom, A; Verweij, J | 1 |
| Ando, Y; Araki, K; Eodo, H; Fujita, K; Kodama, K; Miya, T; Nagashima, F; Narabayashi, M; Sasaki, Y; Yamamoto, W | 1 |
| Baker, SD; Carducci, MA; Dancey, J; Donehower, RC; Hidalgo, M; Jimeno, A; Laheru, DA; Messersmith, WA; Purcell, T; Rudek, MA | 1 |
| Innocenti, F; Kim, TW | 1 |
| Hamaguchi, T; Kaniwa, N; Kubota, K; Minami, H; Ohmatsu, H; Ohtsu, A; Ozawa, S; Saeki, M; Sai, K; Saijo, N; Saito, Y; Sawada, J; Shirao, K; Suzuki, K; Yamada, Y; Yamamoto, N; Yoshida, T | 1 |
| Billups, C; Fraga, CH; Furman, WL; Gajjar, A; Liu, T; McGregor, LM; O'Shaughnessy, MA; Owens, T; Panetta, JC; Rodriguez-Galindo, C; Stewart, CF; Throm, SL | 1 |
| Ando, Y; Fujita, K; Hasegawa, Y; Sasaki, Y | 1 |
| Akasawa, A; Jinno, H; Kamatani, N; Kaniwa, N; Kim, SR; Matsumoto, K; Minami, H; Ohtsu, A; Ozawa, S; Sai, K; Saijo, N; Saito, H; Saito, Y; Sawada, J; Shirao, K; Tanaka-Kagawa, T; Yamamoto, N; Yoshida, T | 1 |
| Chowbay, B; Goh, BC; Jada, SR; Lee, SC; Lim, R; Sandanaraj, E; Shu, X; Zhou, Q; Zhou, S | 1 |
| Janoff, AS; Mayer, LD | 1 |
| Flaherty, KT; Fleming, RA; Kerr, DJ; Koch, KM; Middleton, MR; Midgley, RS; O'Dwyer, PJ; Pratap, SE; Smith, DA; Stevenson, JP; Versola, M; Ward, C | 1 |
| Harasym, NL; Harasym, TO; Harvie, P; Johnstone, SA; Mayer, LD; Tardi, PG | 1 |
| Adamson, PC; Bernstein, M; Blaney, SM; Bomgaars, LR; Chen, Z; Das, S; Kadota, R; Krailo, M | 1 |
| Badmaev, V; Brady, W; Creaven, PJ; Fakih, MG; Pendyala, L; Prey, JD; Ross, ME; Rustum, YM; Smith, PF | 1 |
| Fukushima-Uesaka, H; Hamaguchi, T; Kamatani, N; Kaniwa, N; Kunitoh, H; Kurose, K; Minami, H; Ohe, Y; Ohtsu, A; Sai, K; Saijo, N; Saito, Y; Sawada, J; Shirao, K; Tamura, T; Yamada, Y; Yamamoto, N; Yoshida, T | 1 |
| Searle, B | 1 |
| Hirohashi, S; Kaniwa, N; Kurose, K; Ozawa, S; Saeki, M; Sai, K; Saijo, N; Saito, Y; Sakamoto, H; Sawada, J; Shirao, K; Yoshida, T | 1 |
| Félix, GM; Luis, JV; Sergio, GC | 1 |
| Barrett, J; Bernstein, ML; Blaney, SM; Bomgaars, L; Gupta, M; Mondick, J; Rosner, GL; Thompson, PA; Yu, A | 1 |
| Eastman, A; Fanous, AA; Levesque, AA; Poh, A | 1 |
| Hazama, S; Oka, M | 1 |
| Boige, V; Cohen, M; Delbaldo, C; Faivre, S; Namouni, F; Pautier, P; Peck, R; Raymond, E; Soria, JC | 1 |
| Greenberger, LM; Horak, ID; Kraft, P; Longley, C; Malaby, J; Mehlig, M; Sapra, P; Zhao, H | 1 |
| Brell, JM; Cooney, MM; Dowlati, A; Egorin, MJ; Gibbons, J; Hoppel, CL; Ingalls, ST; Ivy, SP; Krishnamurthi, SS; Li, X; Overmoyer, BA; Remick, SC; Schluchter, MD; Weaver, KC; Zuhowski, EG | 1 |
| Innocenti, F; Panetta, JC; Ratain, MJ; Rosner, GL | 1 |
| Biason, P; Masier, S; Toffoli, G | 1 |
| Ehmer, U; Lankisch, TO; Manns, MP; Strassburg, CP | 1 |
| Bonneterre, J | 1 |
| Donehower, RC; Grochow, LB; Kaufmann, SH; Rowinsky, EK; Slichenmyer, WJ | 1 |
| Chabot, GG | 2 |
| Arioka, H; Eguchi, K; Karato, A; Lieberman, R; Nakashima, H; Nomura, N; Ohmatsu, H; Shinkai, T; Shiraishi, J; Tamura, T | 1 |
| Arioka, H; Eguchi, K; Karato, A; Kunikane, H; Nishio, M; Ohe, Y; Oshita, F; Sasaki, Y; Shinkai, T; Tamura, T | 1 |
| Sinha, BK | 1 |
| Eguchi, K; Hakusui, H; Miya, T; Mizuno, S; Morita, M; Ohe, Y; Saijo, N; Sasaki, Y; Shinkai, T; Tamura, T | 1 |
| Fujii, H; Hakusui, H; Igarashi, T; Itoh, K; Ohtsu, T; Sasaki, Y; Sudoh, K; Wakita, H; Yoshida, Y | 1 |
| Schellens, JH; Verweij, J | 1 |
| Catimel, G; Chabot, GG; Clavel, M; Cote, C; Dumortier, A; Engel, C; Gouyette, A; Guastalla, JP; Mahjoubi, M; Mathieu-Boué, A | 1 |
| Abigerges, D; Armand, JP; Bugat, R; Catimel, G; Chabot, GG; Culine, S; de Forni, M; Extra, JM; Hérait, P; Mahjoubi, M | 1 |
| Abigerges, D; Armand, JP; Chabot, GG; Gandia, D; Gouyette, A; Hérait, P | 1 |
| Masuda, N | 1 |
| Saijo, N | 2 |
| Bugat, R; Chabot, GG; Culine, S; de Forni, M; Extra, JM; Gouyette, A; Madelaine, I; Marty, ME; Mathieu-Boué, A | 1 |
| Eguchi, K; Kanzawa, F; Karato, A; Kubota, N; Nishio, K; Ohe, Y; Saijo, N; Sasaki, Y; Shinkai, T; Tamura, T | 1 |
| Burris, HA; Chen, SF; Eckardt, J; Fields, SM; Kuhn, JG; Rothenberg, M; Von Hoff, DD | 1 |
| Abigerges, D; Armand, JP; Chabot, GG; Cote, C; Da Costa, L; Fadel, E; Gandia, D; Hérait, P | 1 |
| Cassidy, J; Graham, MA; Jodrell, D; Kaye, SB; Workman, P | 1 |
| Burris, HA; Eckardt, JR; Hilsenbeck, SG; Kuhn, JG; Nelson, J; Rodriguez, GI; Rothenberg, ML; Smith, LS; Tristan-Morales, M; Weiss, GR | 1 |
| Chen, TL; Donehower, RC; Ettinger, DS; Grochow, LB; Lubejko, BG; Rock, MK; Rowinsky, EK; Sartorius, SE | 1 |
| Creemers, GJ; Lund, B; Verweij, J | 1 |
| Kohno, K; Kuwano, M; Matsuo, K; Sato, S; Tanimura, H; Uchiumi, T; Yamada, Y | 1 |
| Furue, H | 1 |
| Kojima, A; Saijo, N; Shinkai, T | 1 |
| Donehower, RC; Slichenmyer, WJ | 1 |
| Fukuoka, M | 1 |
| Rothenberg, ML | 3 |
| Armand, JP | 1 |
| Armand, JP; Couteau, C; Goncalves, E; Terret, C; Yakendji, K | 1 |
| Gupta, E; Mick, R; Ratain, MJ; Vokes, EE | 1 |
| Ogawa, M | 2 |
| Dancey, J; Eisenhauer, EA | 1 |
| Hanauske, AR | 1 |
| Fukuoka, M; Kudoh, S; Masuda, N | 1 |
| O'Reilly, S; Rowinsky, EK | 1 |
| Berkery, R; Dietz, A; Eng, M; Kanowitz, J; Kelsen, DP; Kemeny, NE; Locker, P; Saltz, LB; Schaaf, L; Spriggs, D; Staton, BA; Steger, C | 1 |
| Abigerges, D; Armand, JP; Catimel, G; Clavel, M; Extra, YM; Marty, M | 1 |
| Mani, S; Ratain, MJ | 1 |
| Armand, JP; Couteau, C; Rixe, O; Terret, C | 1 |
| Arioka, H; Nishio, K; Saijo, N | 1 |
| Abigerges, D; Armand, JP; Bugat, R; Catimel, G; Extra, JM; Hérait, P; Mahjoubi, M; Marty, M; Merrouche, Y; Suc, E | 1 |
| Furukawa, M; Harada, T; Kuwano, M; Tanaka, T | 1 |
| Gupta, E; Lestingi, TM; Mick, R; Ramirez, J; Ratain, MJ; Vokes, EE; Wang, X | 1 |
| de Jonge, MJ; Gerrits, CJ; Schellens, JH; Stoter, G; Verweij, J | 1 |
| Kaye, SB; Vasey, PA | 1 |
| Crystal, RG; Hackett, NR; Kojima, A; Ohwada, A | 1 |
| Arbuck, SG; Kieffer, LV; Takimoto, CH | 1 |
| Boland, I; Cappelli, C; Gouyette, A; Imadalou, K; Lucchi, E; Morizet, J; Pein, F; Pondarré, C; Santos, A; Thomas, C; Vassal, G | 1 |
| Rowinsky, EK; Siu, LL | 1 |
| Jimbo, T; Kumazawa, E; Ochi, Y; Tohgo, A | 1 |
| Rosen, LS | 1 |
| Arbuck, SG; Takimoto, CH | 1 |
| Armand, JP; Canal, P; Haaz, MC; Lokiec, F; Rivory, LP; Robert, J | 1 |
| Albanese, P; Elfring, GL; Eng, M; Hanover, CK; Ilson, D; Kanowitz, J; Kelsen, D; Kemeny, N; Miller, LL; Saltz, LB; Schaaf, LJ; Schwartz, GK; Semple, D; Spriggs, D; Steger, C | 1 |
| Muggia, FM; O'Leary, J | 1 |
| Canal, P; Chabot, GG; Lokiec, F; Robert, J | 1 |
| Cottu, PH; Espie, M; Extra, JM; Lerebours, F; Marty, M | 1 |
| Armand, JP; Boige, V; Raymond, E | 1 |
| Armand, JP; Couteau, C | 1 |
| Drengler, RL; Elfring, GL; Hammond, LA; Hodges, S; Kraynak, MA; Kuhn, JG; Locker, PK; Miller, LL; Rodriguez, GI; Rothenberg, ML; Schaaf, LJ; Staton, BA; Stephenson, JA; Villalona-Calero, MA; Von Hoff, DD | 1 |
| de Bruijn, P; de Jonge, MJ; Loos, WJ; Mathijssen, RH; Nooter, K; Sparreboom, A; Stoter, G; van Alphen, RJ; Vernillet, L; Verweij, J | 1 |
| Candalh, E; Kramar, A; Lebecq, A | 1 |
| Chen, AY; Choy, H; Rothenberg, ML | 1 |
| Bowman, LC; Furman, WL; Hoffer, FA; Houghton, PJ; Ma, MK; Meyer, WH; Pappo, AS; Poquette, CA; Pratt, CB; Santana, VM; Stewart, CF; Walter, AW; Zamboni, WC | 1 |
| Beijnen, JH; Gruia, G; Herben, VM; Schellens, JH; Swart, M; ten Bokkel Huinink, WW; Vernillet, L | 1 |
| Fukuda, M; Kawabata, S; Kinoshita, A; Kohno, S; Nakatomi, K; Noguchi, Y; Oka, M; Soda, H; Takatani, H; Terashi, K; Tsukamoto, K; Tsurutani, J | 1 |
| Allegra, CJ; Arbuck, SG; Band, RA; Berger, NA; Berger, SJ; Chen, AP; Cottrell, J; Flemming, D; Gosky, DM; Grem, JL; Guemei, A; Hamilton, JM; Harold, N; Hehman, H; Hirota, H; Ismail, AS; Llorens, V; Monahan, BP; Morrison, G; Quinn, M; Shapiro, JD; Takimoto, CH; Wright, J | 1 |
| Dupuy, JL; Gaulier, JM; Lacassie, E; Lachâtre, F; Lachâtre, G; Marquet, P; Ragot, S; Rousseau, A | 1 |
| Adjei, AA; Alberts, SR; Atherton, P; Erlichman, C; Goldberg, RM; Hanson, LJ; Kastrissios, H; Klein, CE; Pitot, HC; Reid, JM; Rubin, J; Sloan, JA | 1 |
| Abad, T; Balcells, M; Dominguez, MS; Dorado, JF; García López, JL; Moyano, AJ; Nogué, M; Seguí, MA; Urruticoechea, L | 1 |
| Baker, DS; Bombardt, PA; Cathcart, KS; Compton, LD; Feenstra, KL; Johnson, MG; Lord, RS; Miller, LL; Pearson, LK; Pesheck, CV; Sams, JP; Schaaf, LJ; Slatter, JG; Verburg, MT | 1 |
| Furman, WL; Hanna, SK; Houghton, PJ; Ma, MK; Radomski, KM; Santana, VM; Smith, AK; Stewart, CF; Zamboni, WC | 1 |
| Boige, V; Cresteil, T; Deroussent, A; Gouyette, A; Pein, F; Raymond, E; Risse, ML; Santos, A; Vassal, G; Vernillet, L; Zanetta, S | 1 |
| Fukuoka, M; Nakagawa, K | 1 |
| Burtness, BA; Cheng, Y; DiStasio, SA; Leffert, JJ; Li, X; McKeon, A; Murren, JR; Peccerillo, K; Pizzorno, G | 1 |
| Ishikawa, N; Isobe, T; Oguri, T | 1 |
| Boven, E; Hausheer, FH; Pinedo, HM; Schlüper, HM; Van Hattum, AH | 1 |
| Furman, W; Houghton, PJ; Radomski, K; Rodriguez-Galindo, C; Santana, VM; Stewart, CF | 1 |
| Armand, JP; Bruno, R; Couteau, C; Ducreux, M; Lebecq, A; Lefresne-Soulas, F; Lokiec, F; Risse, ML; Riva, A; Rougier, P; Ruffié, P | 1 |
| Dhar, S; Graf, W; Jonsson, B; Jonsson, E; Larsson, R; Nygren, P | 1 |
| Haller, D; O'Dwyer, PJ; Redlinger, M; Stevenson, JP; Sun, W | 1 |
| Hoff, PM; Pazdur, R; Royce, ME | 1 |
| Ajani, JA | 1 |
| Berg, SL; Bernstein, M; Blaney, S; Luchtman-Jones, L; Pratt, C; Sullivan, J; Weitman, S | 1 |
| Boushey, RP; Drucker, DJ; Yusta, B | 1 |
| Brescia, FJ; Green, MR; Rocha Lima, CM; Sherman, CA; Urbanic, JJ | 1 |
| Fujii, H; Goya, T; Igarashi, T; Itoh, K; Minami, H; Miya, T; Ohtsu, T; Sasaki, Y | 1 |
| Agrawal, S; Alford, TL; Bailey, KS; Bono, CP; Chen, SF; Dexter, DL; Hill, B; Hollister, BA; Kandimalla, ER; Knoerzer, DL; Morton, PA; Yu, D | 1 |
| de Bruijn, P; de Jonge, MJ; Kehrer, DF; Nierop, CA; Ruijgrok, EJ; Sparreboom, A; van de Schraaf, J; Verweij, J | 1 |
| Prescott, LM | 1 |
| Aiba, K; Akaza, H; Hoctin-Boes, G; Isonishi, S; Kawai, K; Konishi, T; Mikami, O; Miki, T; Noguchi, S; Ohashi, Y; Saeki, T; Saijo, N; Smith, M; Sone, S; Stribling, D; Tsukagoshi, S; Tsuruo, T | 1 |
| Adjei, AA; Alberts, SR; Atherton, PJ; Burch, PA; Erlichman, C; Goldberg, RM; Kaufmann, SH; Okuno, SH; Pitot, HC; Rubin, J; Sloan, J | 1 |
| Lokich, J | 1 |
| Choy, H; MacRae, R | 1 |
| Atherton, P; Erlichman, C; Pitot, HC; Reid, J; Schaaf, L; Sloan, JA | 1 |
| Algazy, K; Giantonio, B; Haller, DG; Hardy, C; Kluijtmans, LA; O'Dwyer, PJ; Redlinger, M; Stevenson, JP; Sun, W; Whitehead, AS | 1 |
| Boyer, J; Ferguson, PR; Harkin, DP; Johnston, PG; Latif, T; Longley, DB; Lynch, M; Maxwell, P | 1 |
| Berg, SL; Blaney, SM; Bomgaars, L | 1 |
| Nishiyama, M; Okamoto, R; Okamura, T; Park, JS; Sekikawa, T; Sparreboom, A; Takano, H; Tanimoto, K; Verweij, J; Yamamoto, W | 1 |
| Eckhardt, SG; Elfring, GL; Hammond, LA; Hodges, S; Kuhn, JG; Locker, PK; Miller, LL; Petit, RG; Rinaldi, DA; Rodriguez, GI; Rothenberg, ML; Schaaf, LJ; Sharma, A; Villalona-Calero, MA; von Hoff, DD | 1 |
| Wilke, H | 1 |
| Aiba, K; Akaza, H; Blackledge, G; Boku, N; Ikeda, T; Isonishi, S; Kato, M; Kawai, K; Mikami, O; Ohashi, Y; Saeki, T; Saijo, N; Sone, S; Stribling, D; Tsukagoshi, S; Tsuruo, T | 1 |
| Freund, M; Köhne, CH; Schuff-Werner, P; Steiner, M | 1 |
| Calleja, E; Cosetti, M; Gerald, W; Gorlick, R; Healey, JH; Huvos, AG; LaQuaglia, M; Meyers, PA; Trippett, T; Wexler, LH | 1 |
| Aikawa, M; Dupree, K; Escandón, E; Fox, JA; Lowe, J; Sinicropi, D; Totpal, K; Xiang, H | 1 |
| Ando, M; Ando, Y; Hasegawa, Y; Sekido, Y; Shimokata, K | 1 |
| Burris, HA; Kuhn, JG; Rothenberg, ML; Von Hoff, DD | 1 |
| Diasio, RB; Stagg, MP | 1 |
| Furue, H; Hasegawa, K; Hattori, T; Niitani, H; Ohta, K; Taguchi, T; Wakui, A | 1 |
115 review(s) available for irinotecan and Neoplasms
| Article | Year |
|---|---|
The long story of camptothecin: From traditional medicine to drugs.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Camptotheca; Camptothecin; DNA Topoisomerases, Type I; Humans; Medicine, Traditional; Neoplasms; Structure-Activity Relationship | 2017 |
Research advances on anticancer activities of matrine and its derivatives: An updated overview.
Topics: Alkaloids; Antineoplastic Agents; Biomedical Research; Cell Proliferation; Dose-Response Relationship, Drug; Humans; Matrines; Molecular Conformation; Neoplasms; Quinolizines; Sophora; Structure-Activity Relationship | 2019 |
Quinolone hybrids and their anti-cancer activities: An overview.
Topics: Animals; Antineoplastic Agents; Humans; Neoplasms; Quinolones; Structure-Activity Relationship | 2019 |
Recent advances in combretastatin A-4 codrugs for cancer therapy.
Topics: Antineoplastic Agents, Phytogenic; Drug Design; Humans; Neoplasms; Organophosphates; Stilbenes; Water | 2022 |
Acriflavine, an Acridine Derivative for Biomedical Application: Current State of the Art.
Topics: Acridines; Acriflavine; Anti-Bacterial Agents; COVID-19 Drug Treatment; Humans; Intercalating Agents; Neoplasms; SARS-CoV-2 | 2022 |
The design and discovery of topoisomerase I inhibitors as anticancer therapies.
Topics: Antineoplastic Agents; DNA Topoisomerases, Type I; Enzyme Inhibitors; Humans; Irinotecan; Neoplasms; Topoisomerase I Inhibitors; Topotecan | 2022 |
Association of UGT1A1*6, UGT1A1*28, or ABCC2 c.3972C>T genetic polymorphisms with irinotecan-induced toxicity in Asian cancer patients: Meta-analysis.
Topics: Antineoplastic Agents, Phytogenic; Diarrhea; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Neoplasms; Neutropenia; Polymorphism, Genetic; Topoisomerase I Inhibitors | 2022 |
Structural Modification Endows Small-Molecular SN38 Derivatives with Multifaceted Functions.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Humans; Irinotecan; Neoplasms; Solubility | 2023 |
Irinotecan: 25 years of cancer treatment.
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Humans; Irinotecan; Neoplasms | 2019 |
Irinotecan-Still an Important Player in Cancer Chemotherapy: A Comprehensive Overview.
Topics: Activation, Metabolic; Antineoplastic Combined Chemotherapy Protocols; DNA, Neoplasm; Dosage Forms; Drug Compounding; Drug Resistance, Neoplasm; Drug Synergism; Female; Humans; Irinotecan; Male; Models, Molecular; Molecular Structure; Neoplasm Proteins; Neoplasms; Nucleic Acid Conformation; Polymorphism, Single Nucleotide; Prodrugs; Protein Conformation; Topoisomerase I Inhibitors | 2020 |
An overview of current results with the vincristine-irinotecan-temozolomide combination with or without bevacizumab in pediatric, adolescence and adult solid tumors.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Child; Dacarbazine; Humans; Irinotecan; Neoplasms; Temozolomide; Vincristine | 2021 |
Sacituzumab govitecan: an antibody-drug conjugate.
Topics: Antibodies, Monoclonal, Humanized; Breast Neoplasms; Camptothecin; Clinical Trials as Topic; Diarrhea; Female; Humans; Immunoconjugates; Irinotecan; Neoplasms; Neutropenia; Urologic Neoplasms | 2017 |
Pharmacokinetic and Pharmacogenetic Markers of Irinotecan Toxicity.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Neoplasms; Pharmacogenetics | 2019 |
UGT1A1*6 and UGT1A1*28 polymorphisms are correlated with irinotecan-induced toxicity: A meta-analysis.
Topics: Antineoplastic Agents; Diarrhea; Female; Genetic Predisposition to Disease; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Neoplasms; Neutropenia; Polymorphism, Single Nucleotide | 2018 |
Population pharmacokinetics of FOLFIRINOX: a review of studies and parameters.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasms; Oxaliplatin; Tissue Distribution | 2019 |
Targeting Topoisomerase I in the Era of Precision Medicine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; DNA Topoisomerases, Type I; Humans; Irinotecan; Molecular Targeted Therapy; Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Precision Medicine; Topoisomerase I Inhibitors; Topotecan | 2019 |
Advances in delivery of Irinotecan (CPT-11) active metabolite 7-ethyl-10-hydroxycamptothecin.
Topics: Animals; Drug Delivery Systems; Humans; Irinotecan; Nanostructures; Neoplasms; Topoisomerase I Inhibitors | 2019 |
Prodrug and nanomedicine approaches for the delivery of the camptothecin analogue SN38.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Drug Delivery Systems; Humans; Irinotecan; Nanomedicine; Neoplasms; Prodrugs | 2013 |
Optimization of cancer chemotherapy on the basis of pharmacokinetics and pharmacodynamics: from patients enrolled in clinical trials to those in the 'real world'.
Topics: Age Factors; Antineoplastic Agents; Camptothecin; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Drug Monitoring; Humans; Irinotecan; Neoplasms; Obesity; Oxonic Acid; Patient Selection; Polypharmacy; Renal Insufficiency; Tegafur | 2014 |
UGT1A1*6 polymorphisms are correlated with irinotecan-induced toxicity: a system review and meta-analysis in Asians.
Topics: Antineoplastic Agents, Phytogenic; Asian People; Camptothecin; Glucuronosyltransferase; Humans; Irinotecan; Neoplasms; Polymorphism, Genetic | 2014 |
Associations between UGT1A1*6 or UGT1A1*6/*28 polymorphisms and irinotecan-induced neutropenia in Asian cancer patients.
Topics: Alleles; Amino Acid Sequence; Asian People; Camptothecin; Glucuronosyltransferase; Humans; Irinotecan; Molecular Sequence Data; Neoplasms; Neutropenia; Polymorphism, Single Nucleotide; Topoisomerase I Inhibitors | 2014 |
The effect of the UGT1A1*28 allele on survival after irinotecan-based chemotherapy: a collaborative meta-analysis.
Topics: Alleles; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease Progression; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Neoplasms; Survival Analysis | 2014 |
Progress of drug-loaded polymeric micelles into clinical studies.
Topics: Antineoplastic Agents; Camptothecin; Delayed-Action Preparations; Drug Carriers; Epirubicin; Humans; Irinotecan; Micelles; Neoplasms; Paclitaxel; Platinum Compounds; Polymers | 2014 |
Challenges in SN38 drug delivery: current success and future directions.
Topics: Animals; Camptothecin; Chemistry, Pharmaceutical; Drug Delivery Systems; Humans; Immunoconjugates; Irinotecan; Nanoparticles; Neoplasms; Prodrugs; Solubility | 2015 |
Meta-analysis of clinical and preclinical studies comparing the anticancer efficacy of liposomal versus conventional non-liposomal doxorubicin.
Topics: Animals; Antibiotics, Antineoplastic; Camptothecin; Cisplatin; Doxorubicin; Humans; Irinotecan; Neoplasms; Paclitaxel; Polyethylene Glycols; Treatment Outcome | 2016 |
The impact of Organic Anion-Transporting Polypeptides (OATPs) on disposition and toxicity of antitumor drugs: Insights from knockout and humanized mice.
Topics: Animals; Antineoplastic Agents; Camptothecin; Doxorubicin; Drug Interactions; Gene Expression; Hepatocytes; Humans; Inactivation, Metabolic; Irinotecan; Liver; Liver-Specific Organic Anion Transporter 1; Methotrexate; Mice; Mice, Transgenic; Neoplasms; Niacinamide; Organic Cation Transport Proteins; Phenylurea Compounds; Platinum Compounds; Sorafenib; Taxoids | 2016 |
Pharmacogenetics of irinotecan, doxorubicin and docetaxel transporters in Asian and Caucasian cancer patients: a comparative review.
Topics: Antineoplastic Agents; Asian People; ATP-Binding Cassette Transporters; Camptothecin; Docetaxel; Doxorubicin; Humans; Irinotecan; Neoplasms; Polymorphism, Genetic; Solute Carrier Proteins; Taxoids; Treatment Outcome; White People | 2016 |
Promise and limits of the CellSearch platform for evaluating pharmacodynamics in circulating tumor cells.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Biomarkers, Tumor; Camptothecin; Clinical Trials as Topic; Cyclophosphamide; Epithelial Cell Adhesion Molecule; Humans; Irinotecan; Neoplasms; Neoplastic Cells, Circulating; Reproducibility of Results; Software; Specimen Handling; Treatment Outcome | 2016 |
Pharmaceutical Investigation for Individualized and Optimal Cancer Pharmacotherapy.
Topics: Antineoplastic Agents; Camptothecin; Drug Monitoring; Glucuronosyltransferase; Humans; Irinotecan; Neoplasms; Outpatients; Pharmacy Service, Hospital; Polymorphism, Genetic; Precision Medicine | 2016 |
Clinical and pharmacogenetic factors associated with irinotecan toxicity.
Topics: Adult; Age Distribution; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Incidence; Irinotecan; Male; Middle Aged; Neoplasms; Neutropenia; Pharmacogenetics; Pharmacology, Clinical; Risk Assessment; Sex Distribution; Survival Analysis; Treatment Outcome | 2008 |
XMT-1001, a novel polymeric camptothecin pro-drug in clinical development for patients with advanced cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials, Phase I as Topic; Delayed-Action Preparations; Humans; Irinotecan; Neoplasms; Polymers; Prodrugs; Topoisomerase I Inhibitors | 2009 |
Dose-dependent association between UGT1A1*28 polymorphism and irinotecan-induced diarrhoea: a meta-analysis.
Topics: Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as Topic; Diarrhea; Female; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Neoplasms; Polymorphism, Genetic | 2010 |
Preclinical and clinical studies of NK012, an SN-38-incorporating polymeric micelles, which is designed based on EPR effect.
Topics: Animals; Camptothecin; Capillary Permeability; Clinical Trials as Topic; Drug Evaluation, Preclinical; Extravasation of Diagnostic and Therapeutic Materials; Humans; Irinotecan; Micelles; Neoplasms | 2011 |
Pharmacogenetic tests in cancer chemotherapy: what physicians should know for clinical application.
Topics: Antineoplastic Agents; Camptothecin; Cytochrome P-450 CYP2D6; ErbB Receptors; Fluorouracil; Glucuronosyltransferase; Humans; Irinotecan; Neoplasms; Pharmacogenetics; Tamoxifen | 2011 |
Hyperbilirubinemia syndromes (Gilbert-Meulengracht, Crigler-Najjar, Dubin-Johnson, and Rotor syndrome).
Topics: Animals; Antineoplastic Agents, Phytogenic; Bilirubin; Camptothecin; Crigler-Najjar Syndrome; Diagnosis, Differential; Genetic Predisposition to Disease; Genetic Variation; Gilbert Disease; Glucuronosyltransferase; Humans; Hyperbilirubinemia, Hereditary; Irinotecan; Jaundice, Chronic Idiopathic; Neoplasms | 2010 |
Clinical development of new formulations of cytotoxics in solid tumors.
Topics: Aminopterin; Anthracyclines; Antineoplastic Agents; Camptothecin; Chemistry, Pharmaceutical; Folic Acid Antagonists; Humans; Irinotecan; Neoplasms; Paclitaxel; Topoisomerase I Inhibitors | 2012 |
Impact of the UGT1A1*28 allele on response to irinotecan: a systematic review and meta-analysis.
Topics: Alleles; Antineoplastic Agents, Phytogenic; Biomarkers, Pharmacological; Camptothecin; Diarrhea; Genetic Association Studies; Glucuronosyltransferase; Homozygote; Humans; Irinotecan; Neoplasms; Neutropenia | 2012 |
Irinotecan resistance is accompanied by upregulation of EGFR and Src signaling in human cancer models.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Drug Design; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Irinotecan; Molecular Targeted Therapy; Neoplasms; Signal Transduction; src-Family Kinases; Topoisomerase I Inhibitors; Up-Regulation | 2013 |
[Predictive biomarkers for response to irinotecan, platinum drugs, and taxanes].
Topics: Antineoplastic Agents; Biomarkers, Tumor; Camptothecin; Humans; Irinotecan; Neoplasms; Platinum Compounds; Taxoids | 2012 |
Pharmacology of topoisomerase I inhibitors irinotecan (CPT-11) and topotecan.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Chemical Phenomena; Chemistry, Physical; Clinical Trials as Topic; Enzyme Inhibitors; Humans; Irinotecan; Neoplasms; Topoisomerase I Inhibitors; Topotecan | 2002 |
Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity.
Topics: Animals; Apoptosis; Camptothecin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Neoplasms; NF-kappa B; Risk Assessment; Sensitivity and Specificity; Topoisomerase I Inhibitors | 2002 |
Epithelial growth factor receptor interacting agents.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Camptothecin; Cetuximab; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Drug Design; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Immunization, Passive; Irinotecan; MAP Kinase Signaling System; Mice; Mice, Nude; Neoplasm Proteins; Neoplasms; Quinazolines; Recombinant Fusion Proteins; Xenograft Model Antitumor Assays | 2002 |
Cancer pharmacogenomics: current and future applications.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Dihydrouracil Dehydrogenase (NADP); Disease Models, Animal; DNA Adducts; DNA Repair; Fluorouracil; Glucuronosyltransferase; Glutathione Transferase; Humans; Irinotecan; Mercaptopurine; Methyltransferases; Neoplasms; Organoplatinum Compounds; Oxidoreductases; Pharmacogenetics; Polymorphism, Genetic; Thymidylate Synthase | 2003 |
Pharmacogenetics of irinotecan.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Carboxylic Ester Hydrolases; Cytochrome P-450 Enzyme System; Glucuronosyltransferase; Humans; Inactivation, Metabolic; Irinotecan; Neoplasms; Polymorphism, Genetic; Topoisomerase I Inhibitors | 2003 |
Improvement of radiotherapy or chemoradiotherapy by targeting COX-2 enzyme.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Combined Modality Therapy; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Humans; Irinotecan; Isoenzymes; Membrane Proteins; Neoplasms; Prostaglandin-Endoperoxide Synthases; Radiotherapy | 2003 |
Phase I. Trial of irinotecan plus carboplatin in two dose schedules.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Randomized Controlled Trials as Topic; Treatment Outcome | 2003 |
Combined inhibition of topoisomerases: a phase I. Study of irinotecan and epirubicin.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Drug Evaluation; Drug Therapy, Combination; Enzyme Inhibitors; Epirubicin; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Topoisomerase Inhibitors | 2003 |
Irinotecan treatment in cancer patients with UGT1A1 polymorphisms.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Glucuronosyltransferase; Humans; Irinotecan; Neoplasms; Polymorphism, Genetic; Syndrome | 2003 |
[Chemotherapy-induced diarrhea].
Topics: Antidiarrheals; Antineoplastic Agents; Camptothecin; Diarrhea; Humans; Irinotecan; Neoplasms; Treatment Outcome | 2003 |
Overview of chemotherapy-induced diarrhea.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; Fluorouracil; Humans; Irinotecan; Neoplasms; Nurse-Patient Relations; Nursing Assessment; Nursing Methodology Research; Octreotide; Oncology Nursing; Quality of Life | 2003 |
Cetuximab (Erbitux)--an emerging targeted therapy for epidermal growth factor receptor-expressing tumours.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Camptothecin; Cetuximab; Combined Modality Therapy; ErbB Receptors; Humans; Irinotecan; Neoplasms; Treatment Outcome | 2004 |
Uridine diphosphoglucuronosyl transferase and methylenetetrahydrofolate reductase polymorphisms as genomic predictors of toxicity and response to irinotecan-, antifolate- and fluoropyrimidine-based chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Fluorouracil; Glucuronosyltransferase; Humans; Irinotecan; Male; Methotrexate; Methylenetetrahydrofolate Reductase (NADPH2); Neoplasms; Pharmacogenetics; Polymorphism, Genetic; Sensitivity and Specificity; Toxicogenetics | 2004 |
Selenium protects against toxicity induced by anticancer drugs and augments antitumor activity: a highly selective, new, and novel approach for the treatment of solid tumors.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cysteine; Drug Synergism; Humans; Irinotecan; Mice; Neoplasms; Organoselenium Compounds; Rats; Selenocysteine; Selenomethionine | 2005 |
[SNPs associated with adverse effects].
Topics: Antineoplastic Agents; Camptothecin; Fluorouracil; Glucuronosyltransferase; Humans; Irinotecan; Methotrexate; Methylenetetrahydrofolate Reductase (NADPH2); Neoplasms; Pharmacogenetics; Polymorphism, Genetic; Polymorphism, Single Nucleotide | 2005 |
Role of pharmacogenetics in irinotecan therapy.
Topics: Animals; Antineoplastic Agents, Phytogenic; ATP-Binding Cassette Transporters; Camptothecin; Forecasting; Humans; Irinotecan; Multidrug Resistance-Associated Protein 2; Neoplasms; Pharmacogenetics; Polymorphism, Genetic | 2006 |
Administration of anti-EGFR therapy: a practical review.
Topics: Algorithms; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Camptothecin; Cetuximab; Clinical Protocols; Decision Trees; Drug Monitoring; ErbB Receptors; Female; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neoplasms; Nursing Assessment; Oncology Nursing; Risk Assessment; Risk Factors | 2006 |
Individualizing cancer chemotherapy.
Topics: Camptothecin; Enzyme Inhibitors; Genetic Testing; Glucuronosyltransferase; Humans; Irinotecan; Neoplasms; Neutropenia; Toxicogenetics | 2006 |
Exploiting the role of O6-methylguanine-DNA-methyltransferase (MGMT) in cancer therapy.
Topics: Animals; Antineoplastic Agents; Camptothecin; Clinical Trials as Topic; Dacarbazine; DNA Adducts; DNA Methylation; DNA Topoisomerases, Type I; Drug Administration Schedule; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Guanine; Humans; Irinotecan; Neoplasms; O(6)-Methylguanine-DNA Methyltransferase; Organoplatinum Compounds; Prognosis; Promoter Regions, Genetic; Temozolomide; Topoisomerase I Inhibitors | 2006 |
TPMT, UGT1A1 and DPYD: genotyping to ensure safer cancer therapy?
Topics: Camptothecin; Dihydrouracil Dehydrogenase (NADP); Genotype; Glucuronosyltransferase; Humans; Irinotecan; Mercaptopurine; Methyltransferases; Neoplasms; Pharmacogenetics; Treatment Outcome | 2006 |
Screening for adverse reactions to irinotecan treatment using the Invader UGT1A1 Molecular Assay.
Topics: Alleles; Antineoplastic Agents, Phytogenic; Biological Assay; Camptothecin; Gene Frequency; Genotype; Glucuronosyltransferase; Homozygote; Humans; Irinotecan; Models, Genetic; Neoplasms; Polymorphism, Genetic; Promoter Regions, Genetic; Technology, Pharmaceutical | 2006 |
Pharmacogenetics of uridine diphosphoglucuronosyltransferase (UGT) 1A family members and its role in patient response to irinotecan.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Glucuronosyltransferase; Humans; Irinotecan; Isoenzymes; Models, Biological; Neoplasms; Pharmacogenetics; Polymorphism, Genetic | 2006 |
Pharmacogenetic approach for cancer treatment-tailored medicine in practice.
Topics: Alleles; Antineoplastic Agents, Phytogenic; Camptothecin; Glucuronosyltransferase; Homozygote; Humans; Irinotecan; Neoplasms; Pharmacogenetics; Polymorphism, Genetic | 2006 |
Insights, challenges, and future directions in irinogenetics.
Topics: Antineoplastic Agents, Phytogenic; Area Under Curve; Asian People; Camptothecin; Glucuronosyltransferase; Humans; Irinotecan; Liver; Neoplasms; Pharmacogenetics; Phenotype; Polymorphism, Genetic | 2007 |
UGT1AI*6 and UGT1A1*27 for individualized irinotecan chemotherapy.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Glucuronosyltransferase; Humans; Irinotecan; Neoplasms; Polymorphism, Genetic | 2007 |
Optimizing combination chemotherapy by controlling drug ratios.
Topics: Animals; Antineoplastic Agents; Camptothecin; Dose-Response Relationship, Drug; Drug Delivery Systems; Drug Synergism; Drug Therapy, Combination; Humans; Irinotecan; Liposomes; Neoplasms | 2007 |
UGT1A1*28 and other UGT1A polymorphisms as determinants of irinotecan toxicity.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Gene Frequency; Glucuronosyltransferase; Haplotypes; Humans; Irinotecan; Neoplasm Metastasis; Neoplasms; Neutropenia; Polymorphism, Genetic | 2008 |
Family 1 uridine-5'-diphosphate glucuronosyltransferases (UGT1A): from Gilbert's syndrome to genetic organization and variability.
Topics: Antineoplastic Agents, Phytogenic; Atazanavir Sulfate; Bilirubin; Camptothecin; Genetic Variation; Gilbert Disease; Glucuronosyltransferase; HIV Protease Inhibitors; Humans; Irinotecan; Isoenzymes; Jaundice; Neoplasms; Oligopeptides; Pharmacogenetics; Pyridines; Risk Factors; Terminology as Topic | 2008 |
[Topoisomerase I inhibitors. Review of phase II trials with irinotecan (CPT-11) and topotecan].
Topics: Antineoplastic Agents; Camptothecin; Clinical Trials, Phase II as Topic; Diarrhea; Drug Administration Schedule; Humans; Irinotecan; Neoplasms; Neutropenia; Topoisomerase I Inhibitors; Topotecan; Vomiting | 1995 |
Topoisomerase inhibitors. A review of their therapeutic potential in cancer.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Camptothecin; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Humans; Irinotecan; Neoplasms; Podophyllotoxin; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan | 1995 |
[Phase III trial of new anticancer agents from a medical oncologists viewpoint].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Protocols; Clinical Trials, Phase III as Topic; Humans; Irinotecan; Neoplasms; Randomized Controlled Trials as Topic; Vinblastine; Vinorelbine | 1995 |
[Strategies for the overcoming of drug resistance].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Dose-Response Relationship, Drug; Drug Resistance; Humans; Irinotecan; Neoplasms; Tumor Cells, Cultured | 1995 |
7-Ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxy camptothecin: mechanism of resistance and clinical trials.
Topics: Amino Acid Sequence; Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Line; Cell Survival; CHO Cells; Clinical Trials, Phase I as Topic; Cricetinae; DNA Topoisomerases, Type I; Drug Resistance; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Molecular Sequence Data; Neoplasms; Ovarian Neoplasms; Point Mutation; Topoisomerase I Inhibitors; Tumor Cells, Cultured | 1994 |
Pharmacokinetics and early clinical studies of selected new drugs.
Topics: Animals; Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Agents; Aziridines; Camptothecin; Clinical Trials, Phase I as Topic; Humans; Indolequinones; Indoles; Irinotecan; Lactones; Macrolides; Neoplasms; Suramin; Topotecan | 1993 |
Topoisomerase I inhibitors: topotecan and irenotecan.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Drug Resistance; Humans; Irinotecan; Neoplasms; Topoisomerase I Inhibitors; Topotecan | 1994 |
[Topoisomerase inhibitors developing in Japan].
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Benzopyrans; Camptothecin; Diketopiperazines; Glycosides; Humans; Irinotecan; Neoplasms; Phenazines; Piperazines; Razoxane; Topotecan | 1993 |
Recent clinical advances with camptothecin analogues.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Humans; Irinotecan; Neoplasms; Topotecan | 1995 |
[Current status and problems in clinical trial for new anticancer drug in Japan].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as Topic; Humans; Informed Consent; Irinotecan; Japan; Neoplasms | 1996 |
CPT-11: an original spectrum of clinical activity.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Enzyme Inhibitors; Female; Genital Neoplasms, Female; Humans; Irinotecan; Lung Neoplasms; Neoplasms; Topoisomerase I Inhibitors | 1996 |
CPT-11: clinical experience in phase I studies.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials, Phase I as Topic; Drug Administration Schedule; Enzyme Inhibitors; Humans; Irinotecan; Neoplasms; Topoisomerase I Inhibitors | 1996 |
[Taxotere (docetaxel) and CPT 11 (irinotecan): phase I trials].
Topics: Antidiarrheals; Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Tolerance; Female; Humans; Irinotecan; Loperamide; Male; Neoplasms; Neutropenia; Paclitaxel; Remission Induction; Taxoids; Topoisomerase I Inhibitors | 1996 |
[Chemotherapy of solid tumor].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Humans; Irinotecan; Neoplasms; Paclitaxel; Survival Rate | 1996 |
Current perspectives on camptothecins in cancer treatment.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Resistance; Humans; Irinotecan; Neoplasms; Topoisomerase I Inhibitors; Topotecan | 1996 |
The development of new chemotherapeutic agents.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Deoxycytidine; Gemcitabine; Glutamates; Guanine; Humans; Irinotecan; Neoplasms; Pemetrexed; Quinazolines; Thiophenes; Trimetrexate | 1996 |
Irinotecan (CPT-11): pharmacology and clinical applications.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as Topic; Humans; Irinotecan; Neoplasms; Neoplasms, Experimental | 1996 |
The clinical status of irinotecan (CPT-11), a novel water soluble camptothecin analogue: 1996.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as Topic; Humans; Irinotecan; Neoplasms | 1996 |
Promising new agents in oncologic treatment.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials, Phase II as Topic; Deoxycytidine; Drug Design; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Gemcitabine; Humans; Irinotecan; Mice; Microtubules; Neoplasm Proteins; Neoplasms; Paclitaxel; Thymidylate Synthase; Topoisomerase I Inhibitors; Topotecan | 1996 |
The current status of irinotecan (CPT-11) in the United States.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Approval; Female; Humans; Irinotecan; Neoplasms; United States; United States Food and Drug Administration | 1996 |
CPT-11. The European experience.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Europe; Humans; Irinotecan; Neoplasms | 1996 |
Clinical trials of irinotecan hydrochloride (CPT, campto injection, topotecin injection) in Japan.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Humans; Irinotecan; Japan; Neoplasms | 1996 |
[Apoptosis and chemosensitivity].
Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Cisplatin; Drug Screening Assays, Antitumor; Genes, bcl-2; Humans; Irinotecan; Neoplasms; Tumor Cells, Cultured | 1997 |
[DNA topoisomerases targeting anticancer agents and mechanism for acquirement of drug resistance].
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Drug Resistance, Neoplasm; Etoposide; Humans; Irinotecan; Mutation; Neoplasms; Teniposide; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 1997 |
Topoisomerase I inhibitors: the relevance of prolonged exposure for present clinical development.
Topics: Animals; Antineoplastic Agents; Camptothecin; Clinical Trials, Phase I as Topic; Drug Screening Assays, Antitumor; Humans; Irinotecan; Mice; Mice, Nude; Neoplasms; Topoisomerase I Inhibitors; Topotecan | 1997 |
Clinical pharmacokinetics of irinotecan.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Enzyme Inhibitors; Humans; Irinotecan; Neoplasms; Topoisomerase I Inhibitors | 1997 |
DNA topoisomerase I inhibitors.
Topics: Animals; Antineoplastic Agents; Antiviral Agents; Camptothecin; DNA Damage; DNA Topoisomerases, Type I; Enzyme Inhibitors; Humans; Irinotecan; Neoplasms; Topoisomerase I Inhibitors; Topotecan | 1997 |
Preclinical development of camptothecin derivatives and clinical trials in pediatric oncology.
Topics: Animals; Camptothecin; Child; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Enzyme Inhibitors; Humans; Irinotecan; Neoplasms; Topoisomerase I Inhibitors; Topotecan | 1998 |
Irinotecan in lymphoma, leukemia, and breast, pancreatic, ovarian, and small-cell lung cancers.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Irinotecan; Leukemia; Lung Neoplasms; Lymphoma; Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms | 1998 |
An overview of topoisomerase I-targeting agents.
Topics: Antineoplastic Agents; Camptothecin; DNA Topoisomerases, Type I; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Irinotecan; Neoplasms; Topoisomerase I Inhibitors; Topotecan | 1998 |
Camptothecins: a review of their development and schedules of administration.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; DNA Topoisomerases, Type I; Drug Administration Schedule; Humans; Irinotecan; Neoplasms; Topotecan | 1998 |
[Irinotecan pharmacokinetics].
Topics: Animals; Antineoplastic Agents, Phytogenic; Area Under Curve; Biotransformation; Blood Proteins; Body Fluid Compartments; Camptothecin; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Half-Life; Humans; Inactivation, Metabolic; Irinotecan; Liver; Mice; Models, Biological; Neoplasm Proteins; Neoplasms; Neoplasms, Experimental; Prodrugs; Rats; Tissue Distribution; Topoisomerase I Inhibitors | 1998 |
[Clinical activity spectrum of irinotecan].
Topics: Adenocarcinoma; Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bronchial Neoplasms; Camptothecin; Carcinoma, Small Cell; Child; Clinical Trials as Topic; Digestive System Neoplasms; Disease-Free Survival; Drug Administration Schedule; Enzyme Inhibitors; Female; Genital Neoplasms, Female; Hematologic Neoplasms; Humans; Irinotecan; Male; Neoplasm Proteins; Neoplasms; Remission Induction; Survival Rate; Topoisomerase I Inhibitors; Treatment Outcome | 1998 |
[Irinotecan: various administration schedules, study of drug combinations, phase I experience].
Topics: Administration, Oral; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase I as Topic; Colorectal Neoplasms; Diarrhea; Drug Administration Schedule; Drug Synergism; Enzyme Inhibitors; Fluorouracil; Hepatic Artery; Humans; Inactivation, Metabolic; Injections, Intra-Arterial; Injections, Intravenous; Irinotecan; Neoplasm Proteins; Neoplasms; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Topoisomerase I Inhibitors | 1998 |
[Irinotecan-containing combinations in solid tumors, except colonic carcinomas].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Diarrhea; Docetaxel; Enzyme Inhibitors; Etoposide; Female; Genital Neoplasms, Female; Humans; Irinotecan; Lung Neoplasms; Lymphoma, Non-Hodgkin; Male; Neoplasm Proteins; Neoplasms; Neutropenia; Paclitaxel; Stomach Neoplasms; Taxoids; Topoisomerase I Inhibitors; Treatment Outcome | 1998 |
Novel anticancer drugs in Japan.
Topics: Animals; Anthracyclines; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Fluorouracil; Humans; Irinotecan; Japan; Neoplasms | 1999 |
DNA topoisomerase I-targeting drugs as radiation sensitizers.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Cycle; Colonic Neoplasms; Combined Modality Therapy; DNA Damage; DNA Repair; DNA Topoisomerases, Type I; Enzyme Inhibitors; Female; Head and Neck Neoplasms; Humans; Irinotecan; Lung Neoplasms; Neoplasms; Ovarian Neoplasms; Radiation-Sensitizing Agents; Topotecan | 1999 |
[CPT-11 (irinotecan)--evidence from molecular and pharmacological studies and clinical applications].
Topics: Antineoplastic Agents, Phytogenic; Biotransformation; Camptothecin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Enzyme Inhibitors; Evidence-Based Medicine; Female; Humans; Irinotecan; Male; Neoplasms | 2000 |
Clinical use of topoisomerase I inhibitors in anticancer treatment.
Topics: Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Child; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Irinotecan; Mice; Neoplasms; Topoisomerase I Inhibitors; Topotecan | 2000 |
Novel oral chemotherapy agents.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Dacarbazine; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Neoplasms; Tegafur; Temozolomide; Uracil | 2000 |
The evolving role of irinotecan: a broad-spectrum chemotherapeutic agent. Introduction.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Enzyme Inhibitors; Humans; Irinotecan; Neoplasms; Topoisomerase I Inhibitors | 2000 |
Docetaxel followed by gemcitabine and irinotecan in solid tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Paclitaxel; Survival Rate; Taxoids | 2001 |
[Platinum compounds in cancer therapy--past, present, and future].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Forecasting; Humans; Irinotecan; Medical Oncology; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Platinum | 2001 |
Irinotecan and radiation in combined-modality therapy for solid tumors.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Enzyme Inhibitors; Female; Gastrointestinal Neoplasms; Head and Neck Neoplasms; Humans; Irinotecan; Lung Neoplasms; Male; Neoplasms; Radiotherapy, Adjuvant; Topoisomerase I Inhibitors; Uterine Cervical Neoplasms | 2001 |
The development of camptothecin analogs in childhood cancers.
Topics: Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Child; Child, Preschool; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Enzyme Inhibitors; Humans; Infant; Irinotecan; Neoplasms; Topoisomerase I Inhibitors; Topotecan | 2001 |
Irinotecan for pediatric solid tumors: the Memorial Sloan-Kettering experience.
Topics: Adolescent; Adult; Antineoplastic Agents, Phytogenic; Bone Marrow Diseases; Bone Neoplasms; Camptothecin; Child; Child, Preschool; Diarrhea; Drug Evaluation; Enzyme Inhibitors; Female; Humans; Irinotecan; Lymphoma, Non-Hodgkin; Male; Neoplasm Proteins; Neoplasms; Neuroectodermal Tumors, Primitive; New York City; Osteosarcoma; Retrospective Studies; Rhabdomyosarcoma; Sarcoma, Ewing; Topoisomerase I Inhibitors; Treatment Outcome | 2002 |
Clinical trials with the topoisomerase I inhibitors.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as Topic; Forecasting; Humans; Irinotecan; Neoplasms; Topoisomerase I Inhibitors; Topotecan | 1992 |
Novel chemotherapeutic agents in early clinical development.
Topics: Adenine; Alkaloids; Anthraquinones; Antineoplastic Agents; Biphenyl Compounds; Camptothecin; Humans; Imides; Irinotecan; Isoquinolines; Naphthalimides; Neoplasms; Organophosphonates; Paclitaxel; Pyrazoles; Quinazolines; Sulfonylurea Compounds; Terpenes; Trimetrexate | 1990 |
170 trial(s) available for irinotecan and Neoplasms
| Article | Year |
|---|---|
Delayed elimination of SN-38 in cancer patients with severe renal failure.
Topics: Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Female; Genotype; Glucuronides; Glucuronosyltransferase; Humans; Irinotecan; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Prospective Studies; Renal Dialysis; Renal Insufficiency | 2011 |
A phase I evaluation of the effect of curcumin on dose-limiting toxicity and pharmacokinetics of irinotecan in participants with solid tumors.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Curcumin; Humans; Irinotecan; Maximum Tolerated Dose; Neoplasms | 2022 |
Pharmacogenomics guided dosing for fluoropyrimidine and irinotecan chemotherapies for patients with cancer (PACIFIC-PGx): study protocol of a multicentre clinical trial.
Topics: Heterocyclic Compounds; Humans; Immunologic Factors; Irinotecan; Multicenter Studies as Topic; Neoplasms; Pharmacogenetics | 2022 |
Preclinical and Clinical Trial Results Using Talazoparib and Low-Dose Chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Irinotecan; Neoplasms; Temozolomide | 2023 |
A phase I trial of metformin in combination with vincristine, irinotecan, and temozolomide in children with relapsed or refractory solid and central nervous system tumors: A report from the national pediatric cancer foundation.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Central Nervous System Neoplasms; Child; Child, Preschool; Dacarbazine; Humans; Irinotecan; Maximum Tolerated Dose; Metformin; Neoplasm Recurrence, Local; Neoplasms; Sarcoma, Ewing; Temozolomide; Vincristine | 2023 |
A Phase I Study of a Combination of Liposomal Irinotecan and Veliparib in Solid Tumors.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Humans; Irinotecan; Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Topoisomerase I Inhibitors | 2023 |
A phase I trial of talazoparib and irinotecan with and without temozolomide in children and young adults with recurrent or refractory solid malignancies.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Female; Humans; Irinotecan; Male; Neoplasms; Phthalazines; Poly(ADP-ribose) Polymerase Inhibitors; Temozolomide; Young Adult | 2020 |
Phase 1 trial of olaratumab monotherapy and in combination with chemotherapy in pediatric patients with relapsed/refractory solid and central nervous system tumors.
Topics: Adolescent; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Child; Child, Preschool; Doxorubicin; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Ifosfamide; Irinotecan; Male; Maximum Tolerated Dose; Neoplasm Recurrence, Local; Neoplasms; Prognosis; Salvage Therapy; Tissue Distribution; Vincristine | 2021 |
Phase 1 study of alisertib (MLN8237) and weekly irinotecan in adults with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azepines; Cohort Studies; Drug Administration Schedule; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Young Adult | 2021 |
Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antigens, Neoplasm; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Adhesion Molecules; Female; Glucuronosyltransferase; Half-Life; Humans; Immunoconjugates; Immunoglobulin G; Irinotecan; Male; Middle Aged; Neoplasms; Neutropenia; Response Evaluation Criteria in Solid Tumors; Time Factors | 2017 |
A phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer (PembroPlus).
Topics: Adenocarcinoma; Adult; Aged; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Diarrhea; Docetaxel; Doxorubicin; Drug Eruptions; Fatigue; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasms; Ovarian Neoplasms; Paclitaxel; Pancreatic Neoplasms; Polyethylene Glycols; Sarcoma; Small Cell Lung Carcinoma; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine; Vomiting | 2017 |
A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Camptothecin; Diphenylamine; Female; Humans; Irinotecan; Male; Morpholines; Neoplasms; Phosphoinositide-3 Kinase Inhibitors; TOR Serine-Threonine Kinases; Triazines | 2017 |
Effects of Shengjiangxiexin decoction on irinotecan-induced toxicity in patients with UGT1A1*28 and UGT1A1*6 polymorphisms.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Camptothecin; Diarrhea; Drugs, Chinese Herbal; Female; Fluorouracil; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Nausea; Neoplasms; Neutropenia; Polymorphism, Genetic; Treatment Outcome; Vomiting; Young Adult | 2017 |
Pharmacometabolomics Reveals Irinotecan Mechanism of Action in Cancer Patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Cell Line; Humans; Irinotecan; Metabolomics; Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Reactive Oxygen Species; Topoisomerase I Inhibitors | 2019 |
Phase I dose-escalation study of EZN-2208 (PEG-SN38), a novel conjugate of poly(ethylene) glycol and SN38, administered weekly in patients with advanced cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Camptothecin; Data Interpretation, Statistical; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neoplasms; Polyethylene Glycols; Prodrugs; Treatment Outcome | 2013 |
A randomised, placebo-controlled, double-blind study of aprepitant in nondrinking women younger than 70 years receiving moderately emetogenic chemotherapy.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Camptothecin; Carboplatin; Dexamethasone; Double-Blind Method; Drug Therapy, Combination; Endometrial Neoplasms; Female; Granisetron; Humans; Irinotecan; Logistic Models; Middle Aged; Morpholines; Neoplasms; Ovarian Neoplasms; Temperance; Treatment Outcome; Vomiting | 2013 |
A phase I study of vincristine, irinotecan, temozolomide and bevacizumab (vitb) in pediatric patients with relapsed solid tumors.
Topics: Adolescent; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Camptothecin; Child; Child, Preschool; Dacarbazine; Dose-Response Relationship, Drug; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Neoplasms; Recurrence; Temozolomide; Vincristine; Young Adult | 2013 |
Population pharmacokinetics of PEGylated liposomal CPT-11 (IHL-305) in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Female; Humans; Infusions, Intravenous; Irinotecan; Liposomes; Male; Middle Aged; Models, Biological; Neoplasms; Polyethylene Glycols | 2013 |
Phase I study of bevacizumab plus irinotecan in pediatric patients with recurrent/refractory solid tumors.
Topics: Adolescent; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Central Nervous System Neoplasms; Child; Child, Preschool; Drug Administration Schedule; Drug Resistance, Neoplasm; Ependymoma; Female; Glioma; Humans; Irinotecan; Male; Maximum Tolerated Dose; Medulloblastoma; Neoplasm Recurrence, Local; Neoplasms; Rhabdomyosarcoma; Treatment Outcome; Young Adult | 2013 |
UGT1A1 genotype-guided phase I study of irinotecan, oxaliplatin, and capecitabine.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Female; Fluorouracil; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Organoplatinum Compounds; Oxaliplatin | 2013 |
A phase I dose escalation and pharmacodynamic study of SU5416 (semaxanib) combined with weekly cisplatin and irinotecan in patients with advanced solid tumors.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy-Induced Febrile Neutropenia; Cisplatin; Dose-Response Relationship, Drug; Female; Humans; Indoles; Irinotecan; Male; Middle Aged; Nausea; Neoplasms; Pyrroles; Thrombocytopenia; Treatment Outcome | 2013 |
Phase 1 trial of temsirolimus in combination with irinotecan and temozolomide in children, adolescents and young adults with relapsed or refractory solid tumors: a Children's Oncology Group Study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Child; Child, Preschool; Dacarbazine; Female; Follow-Up Studies; Humans; Infant; Irinotecan; Male; Maximum Tolerated Dose; Neoplasm Recurrence, Local; Neoplasms; Prognosis; Remission Induction; Sirolimus; Temozolomide; Young Adult | 2014 |
Dose-finding and pharmacokinetic study to optimize the dosing of irinotecan according to the UGT1A1 genotype of patients with cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Camptothecin; Dose-Response Relationship, Drug; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Neoplasms | 2014 |
Phase I dose escalation and pharmacokinetic study of oral gefitinib and irinotecan in children with refractory solid tumors.
Topics: Administration, Oral; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Biological Availability; Camptothecin; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Interactions; Female; Gefitinib; Humans; Irinotecan; Male; Maximum Tolerated Dose; Neoplasms; Quinazolines; Treatment Outcome; Young Adult | 2014 |
Phase I study of nanoliposomal irinotecan (PEP02) in advanced solid tumor patients.
Topics: Adult; Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Dose-Response Relationship, Drug; Female; Genotype; Glucuronosyltransferase; Half-Life; Humans; Infusions, Intravenous; Irinotecan; Liposomes; Male; Maximum Tolerated Dose; Middle Aged; Nanoparticles; Neoplasms; Pharmacogenetics; Treatment Outcome | 2015 |
Open-label, randomized, comparative, phase III study on effects of reducing steroid use in combination with Palonosetron.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dexamethasone; Female; Humans; Irinotecan; Isoquinolines; Male; Middle Aged; Nausea; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Palonosetron; Quality of Life; Quinuclidines; Serotonin Antagonists; Treatment Outcome | 2015 |
Increased Plasma Levels of Chemoresistance-Inducing Fatty Acid 16:4(n-3) After Consumption of Fish and Fish Oil.
Topics: Academic Medical Centers; Animals; Antineoplastic Agents; Biomarkers; Camptothecin; Cell Line, Tumor; Cisplatin; Dietary Supplements; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fatty Acids; Fish Oils; Fishes; Food-Drug Interactions; Health Care Surveys; Humans; Irinotecan; Mice, Inbred BALB C; Neoplasms; Netherlands; Organoplatinum Compounds; Oxaliplatin; Seafood; Surveys and Questionnaires; Tumor Burden; Up-Regulation | 2015 |
Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with irinotecan: results of an open-label, phase 1 study.
Topics: Adenocarcinoma; Adult; Aged; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Colonic Neoplasms; Diarrhea; Disease Progression; Dose-Response Relationship, Drug; Febrile Neutropenia; Female; Hematologic Diseases; Humans; Irinotecan; Male; Middle Aged; Neoplasm Proteins; Neoplasms; Proto-Oncogene Proteins c-bcl-2; Salvage Therapy; Sulfonamides; Treatment Outcome | 2015 |
Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Camptothecin; Cell Cycle Proteins; DNA Repair; Female; Histones; Humans; Irinotecan; Male; Middle Aged; Neoplasms; Nuclear Proteins; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases | 2016 |
A phase I dose escalation study of NK012, an SN-38 incorporating macromolecular polymeric micelle.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Dose-Response Relationship, Drug; Drug Carriers; Female; Glucuronosyltransferase; Homozygote; Humans; Infusions, Intravenous; Irinotecan; Male; Maximum Tolerated Dose; Micelles; Middle Aged; Neoplasms; Polymers | 2016 |
Phase I study of capecitabine in combination with cisplatin and irinotecan in patients with advanced solid malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cisplatin; Deoxycytidine; DNA Adducts; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms | 2009 |
Phase I and pharmacokinetic study of mitomycin C and celecoxib as potential modulators of tumor resistance to irinotecan in patients with solid malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Celecoxib; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Male; Middle Aged; Mitomycin; Neoplasms; Pyrazoles; Sulfonamides; Treatment Outcome; Young Adult | 2009 |
A phase I trial of irinotecan alternating with epirubicin in patients with advanced malignancies.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease-Free Survival; Epirubicin; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Salvage Therapy; Survival Rate; Treatment Outcome | 2008 |
A phase 1 dose-escalation study of irinotecan in combination with 17-allylamino-17-demethoxygeldanamycin in patients with solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzoquinones; Camptothecin; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; HSP90 Heat-Shock Proteins; Humans; Irinotecan; Lactams, Macrocyclic; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Treatment Outcome | 2008 |
Phase 1 and pharmacokinetic study of concurrent carboplatin and irinotecan in subjects aged 1 to 21 years with refractory solid tumors.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Child; Child, Preschool; Female; Humans; Infant; Irinotecan; Male; Maximum Tolerated Dose; Neoplasms | 2009 |
Safety, pharmacokinetics, and efficacy of CPX-1 liposome injection in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Camptothecin; Cohort Studies; Dose-Response Relationship, Drug; Female; Floxuridine; Humans; Irinotecan; Liposomes; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Treatment Outcome | 2009 |
Phase 1 study of oxaliplatin and irinotecan in pediatric patients with refractory solid tumors: a children's oncology group study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Child; Child, Preschool; Drug Administration Schedule; Female; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Male; Neoplasms; Organoplatinum Compounds; Oxaliplatin | 2009 |
A phase I/II trial of fixed-dose docetaxel plus irinotecan and escalating doses of estramustine phosphate for second-line or greater treatment of selected advanced solid tumors.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Estramustine; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasms; Taxoids; Treatment Outcome | 2009 |
Pharmacokinetic analysis of irinotecan plus bevacizumab in patients with advanced solid tumors.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Bevacizumab; Camptothecin; Drug Interactions; Female; Fluorouracil; Gastrointestinal Tract; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Leucovorin; Leukopenia; Male; Middle Aged; Neoplasms; Pharmacogenetics; Polymorphism, Genetic; Prodrugs | 2009 |
Tyrosine kinase inhibitor enhances the bioavailability of oral irinotecan in pediatric patients with refractory solid tumors.
Topics: Administration, Oral; Adolescent; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Biological Availability; Camptothecin; Child; Child, Preschool; Drug Synergism; Female; Gefitinib; Humans; Infant; Infusions, Intravenous; Irinotecan; Male; Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Toxicity Tests; Young Adult | 2009 |
Phase I and pharmacokinetic study of cetuximab and irinotecan in children with refractory solid tumors: a study of the pediatric oncology experimental therapeutic investigators' consortium.
Topics: Adolescent; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Child; Child, Preschool; Cohort Studies; Dose-Response Relationship, Drug; Female; Humans; Infant; Irinotecan; Male; Maximum Tolerated Dose; Neoplasms | 2009 |
Additive effects of drug transporter genetic polymorphisms on irinotecan pharmacokinetics/pharmacodynamics in Japanese cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asian People; Camptothecin; Cisplatin; Genotype; Glucuronosyltransferase; Haplotypes; Humans; Irinotecan; Multidrug Resistance-Associated Protein 2; Neoplasms; Neutropenia; Organic Anion Transporters; Polymorphism, Single Nucleotide | 2010 |
A phase I study of pegylated liposomal doxorubicin and irinotecan in patients with solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Polyethylene Glycols; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Treatment Outcome; Young Adult | 2009 |
Phase I dose escalation study of gemcitabine plus irinotecan in advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Case-Control Studies; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms; Prognosis; Survival Rate | 2009 |
Phase I trial of two schedules of vincristine, oral irinotecan, and temozolomide (VOIT) for children with relapsed or refractory solid tumors: a Children's Oncology Group phase I consortium study.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Child; Child, Preschool; Dacarbazine; Female; Humans; Infant; Irinotecan; Male; Neoplasm Recurrence, Local; Neoplasms; Temozolomide; Vincristine; Young Adult | 2010 |
The maximum tolerated dose and biologic effects of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) in combination with irinotecan for patients with refractory solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Camptothecin; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Drug Synergism; Female; Glucuronosyltransferase; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Polymorphism, Genetic; Pyridines; Thiosemicarbazones; Treatment Outcome | 2010 |
Phase I evaluation of telatinib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in combination with irinotecan and capecitabine in patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Pyridazines; Pyridines; Receptors, Vascular Endothelial Growth Factor; Treatment Outcome; Young Adult | 2010 |
Extended phase I evaluation of vincristine, irinotecan, temozolomide, and antibiotic in children with refractory solid tumors.
Topics: Adolescent; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Child; Child, Preschool; Dacarbazine; Female; Humans; Infant; Irinotecan; Male; Maximum Tolerated Dose; Neoplasms; Temozolomide; Vincristine; Young Adult | 2010 |
Pharmacokinetic and pharmacodynamic investigation of irinotecan hydrochloride in pediatric patients with recurrent or progressive solid tumors.
Topics: Adolescent; Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Child; Child, Preschool; Female; Humans; Irinotecan; Leukocyte Count; Male; Models, Biological; Neoplasm Recurrence, Local; Neoplasms; Neutrophils; Nonlinear Dynamics; Regression Analysis | 2010 |
Phase I trial of weekly irinotecan and paclitaxel combined with carboplatin in patients with advanced cancer: a Hellenic Cooperative Oncology Group Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Drug Administration Schedule; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Staging; Neoplasms; Paclitaxel; Treatment Outcome; Young Adult | 2010 |
A Phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Staurosporine; Young Adult | 2011 |
A phase I, dose-finding study of sunitinib in combination with irinotecan in patients with advanced solid tumours.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administration Schedule; Female; Humans; Indoles; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pyrroles; Sunitinib; Treatment Outcome | 2010 |
Phase I study of oral irinotecan as a single-agent and given sequentially with capecitabine.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Treatment Outcome | 2012 |
Phase I study of NK012, a novel SN-38-incorporating micellar nanoparticle, in adult patients with solid tumors.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Dose-Response Relationship, Drug; Female; Humans; Irinotecan; Male; Middle Aged; Nanoparticles; Neoplasms | 2010 |
A phase I clinical trial of FOLFIRI in combination with the pan-cyclin-dependent kinase (CDK) inhibitor flavopiridol.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Flavonoids; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasms; Piperidines; Protein Kinase Inhibitors; Treatment Outcome | 2010 |
Efficacy and safety of endostar combined with chemotherapy in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Deoxycytidine; Docetaxel; Endostatins; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Recombinant Proteins; Survival Rate; Taxoids; Treatment Outcome | 2010 |
Effect of omeprazole on the pharmacokinetics and toxicities of irinotecan in cancer patients: a prospective cross-over drug-drug interaction study.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Cross-Over Studies; Drug Interactions; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasms; Omeprazole; Prospective Studies; Proton Pump Inhibitors; Tumor Cells, Cultured | 2011 |
Dose escalation of intravenous irinotecan using oral cefpodoxime: a phase I study in pediatric patients with refractory solid tumors.
Topics: Adolescent; Antibiotic Prophylaxis; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cefpodoxime; Ceftizoxime; Child; Child, Preschool; Diarrhea; Female; Humans; Infusions, Intravenous; Irinotecan; Male; Maximum Tolerated Dose; Neoplasms; Topoisomerase I Inhibitors; Young Adult | 2012 |
Pharmacokinetics of SN2310, an injectable emulsion that incorporates a new derivative of SN-38 in patients with advanced solid tumors.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Chemistry, Pharmaceutical; Emulsions; Female; Half-Life; Humans; Infusions, Intravenous; Irinotecan; Male; Maximum Tolerated Dose; Metabolic Clearance Rate; Middle Aged; Neoplasms; Neutropenia; Succinates; Technology, Pharmaceutical; Vitamin E | 2011 |
The effect of thalidomide on the pharmacokinetics of irinotecan and metabolites in advanced solid tumor patients.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Cross-Over Studies; Drug Interactions; Humans; Irinotecan; Neoplasms; Thalidomide | 2011 |
Feasibility of biweekly combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in patients with metastatic solid tumors: results of a two-step phase I trial: XELIRI and XELIRINOX.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chromatography, High Pressure Liquid; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Feasibility Studies; Female; Fluorouracil; Glucuronosyltransferase; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Neoplasm Metastasis; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Prospective Studies | 2012 |
Phase I dose-escalation study of intravenous aflibercept administered in combination with irinotecan, 5-fluorouracil and leucovorin in patients with advanced solid tumours.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasms; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Young Adult | 2013 |
Phase I and pharmacokinetic study of IHL-305 (PEGylated liposomal irinotecan) in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Dose-Response Relationship, Drug; Female; Glucuronosyltransferase; Humans; Irinotecan; Liposomes; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Polyethylene Glycols; Treatment Outcome | 2012 |
Intravenous aflibercept administered in combination with irinotecan, 5-fluorouracil and leucovorin in patients with advanced solid tumours: results from the expansion cohort of a phase I study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cohort Studies; Dose-Response Relationship, Drug; Double-Blind Method; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Magnetic Resonance Imaging; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Prognosis; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Tissue Distribution | 2013 |
Irinotecan and gemcitabine in patients with solid tumors: phase I trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Diarrhea; Gemcitabine; Hematologic Diseases; Humans; Irinotecan; Maximum Tolerated Dose; Nausea; Neoplasms; Neoplasms, Unknown Primary; Pancreatic Neoplasms; Vomiting | 2002 |
Phase I trial of irinotecan and epirubicin in advanced cancer. Preliminary report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Camptothecin; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Epirubicin; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Neoplasm Staging; Neoplasms; Patient Selection; Prognosis; Survival Rate; Treatment Outcome | 2002 |
Mitomycin as a modulator of irinotecan anticancer activity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Camptothecin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Mitomycin; Neoplasm Staging; Neoplasms; Patient Selection; Prognosis; Survival Analysis; Treatment Outcome | 2002 |
Phase I study of weekly irinotecan combined with weekly cisplatin in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasms; Treatment Outcome | 2002 |
Phase I and pharmacokinetic study of irinotecan in combination with raltitrexed.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Drug Administration Schedule; Fatigue; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasms; Neutropenia; Quinazolines; Thiophenes | 2002 |
A phase I study of sequential irinotecan and 5-fluorouracil/leucovorin.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Female; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasms; Neutropenia | 2002 |
Phase I clinical and pharmacologic study of weekly cisplatin and irinotecan combined with amifostine for refractory solid tumors.
Topics: Adolescent; Adult; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Child; Child, Preschool; Cisplatin; Cohort Studies; DNA Adducts; Drug Administration Schedule; Female; Humans; Irinotecan; Male; Metabolic Clearance Rate; Neoplasms; Safety | 2003 |
An open phase I study assessing the feasibility of the triple combination: oxaliplatin plus irinotecan plus leucovorin/ 5-fluorouracil every 2 weeks in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Organoplatinum Compounds; Oxaliplatin | 2003 |
Pilot trial of intravenous infusion of a replication-selective adenovirus (ONYX-015) in combination with chemotherapy or IL-2 treatment in refractory cancer patients.
Topics: Adenoviridae; Adenovirus E1B Proteins; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Cytokines; Female; Fluorouracil; Genetic Therapy; Humans; Immunotherapy; Infusions, Intravenous; Interleukin-2; Irinotecan; Male; Middle Aged; Neoplasms; Pilot Projects; Tumor Suppressor Protein p53; Viral Vaccines; Virus Replication | 2003 |
Phase I evaluation of sequential topoisomerase targeting with irinotecan/cisplatin followed by etoposide in patients with advanced malignancy.
Topics: Adult; Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Cisplatin; Cohort Studies; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA-Binding Proteins; Etoposide; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 2003 |
Phase I. Trial of irinotecan plus carboplatin in two dose schedules.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Randomized Controlled Trials as Topic; Treatment Outcome | 2003 |
Phase I. Trial of irinotecan and temozolomide in patients with solid tumors.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dacarbazine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Temozolomide; Treatment Outcome | 2003 |
Combined inhibition of topoisomerases: a phase I. Study of irinotecan and epirubicin.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Drug Evaluation; Drug Therapy, Combination; Enzyme Inhibitors; Epirubicin; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Topoisomerase Inhibitors | 2003 |
Population-based maximum tolerated dose of irinotecan and carboplatin.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Carboplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Treatment Outcome | 2003 |
Phase I study of cisplatin, irinotecan, and epirubicin administered every 3 weeks in patients with advanced solid tumours.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Epirubicin; Female; Humans; Infusions, Intravenous; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Treatment Outcome | 2003 |
Phase I and pharmacokinetic study of two different schedules of oxaliplatin, irinotecan, Fluorouracil, and leucovorin in patients with solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Peripheral Nervous System Diseases | 2003 |
A phase I study of irinotecan as a 3-week schedule in children with refractory or recurrent solid tumors.
Topics: Adolescent; Antineoplastic Agents, Phytogenic; Camptothecin; Child, Preschool; Drug Administration Schedule; Humans; Infant; Infusions, Intravenous; Irinotecan; Maximum Tolerated Dose; Neoplasms; Neutropenia | 2003 |
A phase I and pharmacokinetic study of irinotecan in patients with hepatic or renal dysfunction or with prior pelvic radiation: CALGB 9863.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Female; Humans; Irinotecan; Kidney Diseases; Liver Diseases; Male; Middle Aged; Neoplasms; Pelvis; Radiotherapy | 2003 |
Drug-drug interaction pharmacokinetic study with the Raf kinase inhibitor (RKI) BAY 43-9006 administered in combination with irinotecan (CPT-11) in patients with solid tumors.
Topics: Administration, Oral; Antineoplastic Agents, Phytogenic; Benzenesulfonates; Camptothecin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Humans; Irinotecan; Neoplasms; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-raf; Pyridines; Sorafenib | 2003 |
A novel combination of cisplatin, irinotecan, and capecitabine in patients with advanced cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drugs, Investigational; Female; Fluorouracil; Gastrointestinal Diseases; Humans; Irinotecan; Male; Middle Aged; Neoplasms | 2004 |
Phase I and pharmacokinetic study of the farnesyltransferase inhibitor R115777 in combination with irinotecan in patients with advanced cancer.
Topics: Administration, Oral; Aged; Alkyl and Aryl Transferases; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Diarrhea; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Inhibitors; Farnesyltranstransferase; Female; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neoplasms; Quinolones | 2004 |
Phase I trial of temozolomide and protracted irinotecan in pediatric patients with refractory solid tumors.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Base Pair Mismatch; Camptothecin; Cell Line, Tumor; Child; Child, Preschool; Dacarbazine; DNA Repair; Female; Humans; Immunohistochemistry; Infant; Irinotecan; Male; Maximum Tolerated Dose; Neoplasms; O(6)-Methylguanine-DNA Methyltransferase; Phenotype; Temozolomide; Time Factors | 2004 |
Phase I trial of UFT/leucovorin and irinotecan in patients with advanced cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dose-Response Relationship, Drug; Female; Genotype; Hematologic Diseases; Humans; Irinotecan; Leucovorin; Male; Methylenetetrahydrofolate Dehydrogenase (NADP); Middle Aged; Neoplasms; Polymorphism, Genetic; Tablets; Tegafur; Treatment Outcome; Uracil | 2004 |
Comparative pharmacokinetics of weekly and every-three-weeks docetaxel.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Irinotecan; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Taxoids | 2004 |
Phase I and pharmacokinetic study of irinotecan in combination with R115777, a farnesyl protein transferase inhibitor.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Humans; Infusions, Intravenous; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Quinolones; Treatment Outcome | 2004 |
Prevention of irinotecan-induced diarrhoea by oral carbonaceous adsorbent (Kremezin) in cancer patients.
Topics: Adsorption; Adult; Aged; Antidiarrheals; Antineoplastic Agents, Phytogenic; Camptothecin; Carbon; Defecation; Diarrhea; Female; Humans; Irinotecan; Male; Microspheres; Middle Aged; Neoplasms; Oxides; Time Factors; Treatment Outcome | 2004 |
A phase I trial of olanzapine (Zyprexa) for the prevention of delayed emesis in cancer patients: a Hoosier Oncology Group study.
Topics: Adult; Aged; Anorexia; Antiemetics; Antineoplastic Agents; Benzodiazepines; Camptothecin; Cohort Studies; Cyclophosphamide; Dose-Response Relationship, Drug; Doxorubicin; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Mood Disorders; Nausea; Neoplasms; Olanzapine; Organoplatinum Compounds; Time Factors; Treatment Outcome; Vomiting | 2004 |
A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Cyclosporine; Dose-Response Relationship, Drug; Drug Interactions; Drug Resistance, Neoplasm; Drug Therapy, Combination; Endpoint Determination; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Half-Life; Humans; Hypnotics and Sedatives; Immunosuppressive Agents; Irinotecan; Lymphoma; Male; Middle Aged; Neoplasms; Phenobarbital | 2004 |
Phase I study of an oral formulation of irinotecan administered daily for 14 days every 3 weeks in patients with advanced solid tumours.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Drug Administration Schedule; Enzyme Inhibitors; Female; Gastrointestinal Tract; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Topoisomerase I Inhibitors | 2005 |
Phase I and pharmacokinetic study of oral irinotecan given once daily for 5 days every 3 weeks in combination with capecitabine in patients with solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasms | 2005 |
Phase I pharmacokinetic, food effect, and pharmacogenetic study of oral irinotecan given as semisolid matrix capsules in patients with solid tumors.
Topics: Administration, Oral; Adult; Aged; Anemia; Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Capsules; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Diarrhea; Dietary Fats; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Leukopenia; Male; Middle Aged; Nausea; Neoplasms; Neutropenia; Polymorphism, Genetic; Promoter Regions, Genetic; Thrombocytopenia; Time Factors; Treatment Outcome; Vomiting | 2005 |
A phase I study of irinotecan administered on a weekly schedule in pediatric patients.
Topics: Adolescent; Adult; Antineoplastic Agents, Phytogenic; Camptothecin; Child; Child, Preschool; Drug Administration Schedule; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Neoplasms | 2006 |
Phase I clinical and pharmacokinetic trial of docetaxel and irinotecan administered on a weekly schedule.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Docetaxel; Drug Administration Schedule; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Taxoids | 2005 |
A phase I, dose-finding study of irinotecan (CPT-11) short i.v. infusion combined with fixed dose of 5-fluorouracil (5-FU) protracted i.v. infusion in adult patients with advanced solid tumours.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Female; Fluorouracil; Half-Life; Humans; Infusions, Intravenous; Irinotecan; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Neutropenia | 2005 |
A phase I clinical trial of the sequential combination of irinotecan followed by flavopiridol.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bilirubin; Camptothecin; Cell Cycle Proteins; Cyclin-Dependent Kinase Inhibitor p21; Drug Administration Schedule; Drug Interactions; Female; Flavonoids; Humans; Intracellular Signaling Peptides and Proteins; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Piperidines; Treatment Outcome; Tumor Suppressor Protein p53 | 2005 |
A phase I pharmacologic and pharmacogenetic trial of sequential 24-hour infusion of irinotecan followed by leucovorin and a 48-hour infusion of fluorouracil in adult patients with solid tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Genotype; Glucuronosyltransferase; Humans; Infusion Pumps; Irinotecan; Leucovorin; Male; Neoplasms; Neutropenia; Pharmacogenetics; Promoter Regions, Genetic; Thymidylate Synthase; Treatment Outcome | 2005 |
A phase I trial of celecoxib in combination with docetaxel and irinotecan in patients with advanced cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Celecoxib; Cyclooxygenase Inhibitors; Diarrhea; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Irinotecan; Male; Middle Aged; Nausea; Neoplasms; Pyrazoles; Sulfonamides; Taxoids; Treatment Outcome | 2005 |
Phase I study of the combination of topotecan and irinotecan in children with refractory solid tumors.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Child; Child, Preschool; Drug Administration Schedule; Humans; Irinotecan; Neoplasms; Topotecan; Treatment Outcome | 2006 |
Pharmacokinetic modelling of 5-FU production from capecitabine--a population study in 40 adult patients with metastatic cancer.
Topics: Adult; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Capecitabine; Chromatography, High Pressure Liquid; Deoxycytidine; Dose-Response Relationship, Drug; Floxuridine; Fluorouracil; Humans; Irinotecan; Middle Aged; Models, Biological; Molecular Structure; Neoplasm Metastasis; Neoplasms; Prodrugs; Sesquiterpenes | 2005 |
A phase I and pharmacokinetic study of a powder-filled capsule formulation of oral irinotecan (CPT-11) given daily for 5 days every 3 weeks in patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Chromatography, High Pressure Liquid; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasms; Powders; Sensitivity and Specificity | 2006 |
Cefixime allows greater dose escalation of oral irinotecan: a phase I study in pediatric patients with refractory solid tumors.
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Agents, Phytogenic; Camptothecin; Cefixime; Child; Child, Preschool; Chromatography, High Pressure Liquid; Diarrhea; Feces; Female; Glucuronidase; Humans; Irinotecan; Lactones; Male; Neoplasms; Severity of Illness Index | 2006 |
A phase I and pharmacokinetic study of fixed-dose selenomethionine and irinotecan in solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Diarrhea; Dose-Response Relationship, Drug; Female; Humans; Injections, Intravenous; Irinotecan; Male; Middle Aged; Nausea; Neoplasms; Selenomethionine; Treatment Outcome | 2006 |
A phase I dose-finding clinical pharmacokinetic study of an oral formulation of irinotecan (CPT-11) administered for 5 days every 3 weeks in patients with advanced solid tumours.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasms; Topoisomerase I Inhibitors | 2006 |
Irinotecan for children with relapsed solid tumors.
Topics: Camptothecin; Child; Child, Preschool; Female; Humans; Infant; Irinotecan; Male; Neoplasms; Neuroblastoma; Recurrence; Remission Induction; Rhabdomyosarcoma; Tumor Burden; Wilms Tumor | 2006 |
Dose-finding phase I clinical and pharmacokinetic study of orally administered irinotecan in patients with advanced solid tumors.
Topics: Administration, Oral; Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Dose-Response Relationship, Drug; Female; Gastrointestinal Tract; Half-Life; Humans; Irinotecan; Male; Neoplasm Metastasis; Neoplasms | 2006 |
Phase 1 and pharmacokinetic study of intravenous irinotecan in refractory solid tumor patients with hepatic dysfunction.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; Bilirubin; Camptothecin; Diarrhea; Female; Humans; Infusions, Intravenous; Irinotecan; Liver Diseases; Liver Function Tests; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Neutropenia; Patient Selection | 2006 |
Influence of low-energy laser in the prevention of oral mucositis in children with cancer receiving chemotherapy.
Topics: Adolescent; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Child; Child, Preschool; Cohort Studies; Etoposide; Female; Humans; Ifosfamide; Irinotecan; Low-Level Light Therapy; Male; Methotrexate; Mouth Mucosa; Neoplasms; Nutritional Status; Oral Hygiene; Severity of Illness Index; Stomatitis; Treatment Outcome | 2007 |
Pharmacogenetics of SLCO1B1 gene and the impact of *1b and *15 haplotypes on irinotecan disposition in Asian cancer patients.
Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Asia; Camptothecin; Female; Genotype; Half-Life; Haplotypes; Humans; Inactivation, Metabolic; Irinotecan; Leukocyte Count; Liver-Specific Organic Anion Transporter 1; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Organic Anion Transporters | 2006 |
A Phase I study of bortezomib plus irinotecan in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Camptothecin; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasms; Proteasome Inhibitors; Pyrazines | 2006 |
Results from an in vitro and a clinical/pharmacological phase I study with the combination irinotecan and sorafenib.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Camptothecin; Cohort Studies; Dose-Response Relationship, Drug; Female; Humans; Irinotecan; Male; Microsomes, Liver; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome | 2007 |
A phase I study of oral LY293111 given daily in combination with irinotecan in patients with solid tumours.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzoates; Camptothecin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neoplasms; Ontario; Time Factors; Treatment Outcome | 2007 |
Pharmacokinetic and safety study of weekly irinotecan and oral capecitabine in patients with advanced solid cancers.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Capecitabine; Carboxylesterase; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neoplasms; Neutropenia; Treatment Outcome | 2007 |
A phase I and pharmacokinetic study of pemetrexed plus irinotecan in patients with advanced solid malignancies.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cohort Studies; Dietary Supplements; Drug Interactions; Female; Glutamates; Guanine; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pemetrexed; Vitamins | 2007 |
Phase I study of carboplatin in combination with gemcitabine and irinotecan in patients with solid tumors: preliminary evidence of activity in small cell and neuroendocrine carcinomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Neuroendocrine; Carcinoma, Small Cell; Deoxycytidine; Feasibility Studies; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms | 2007 |
A phase I study of bi-weekly administration of 24-h gemcitabine followed by 24-h irinotecan in patients with solid tumors.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Carcinoma, Small Cell; Cholangiocarcinoma; Deoxycytidine; Diarrhea; Dose-Response Relationship, Drug; Drug Interactions; Female; Gastrointestinal Hemorrhage; Gemcitabine; Half-Life; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasms | 2007 |
Phase I and pharmacokinetic study of UCN-01 in combination with irinotecan in patients with solid tumors.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Enzyme Inhibitors; Female; Follow-Up Studies; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Staurosporine; Topoisomerase I Inhibitors | 2008 |
Haplotypes and a novel defective allele of CES2 found in a Japanese population.
Topics: Alleles; Animals; Antineoplastic Agents, Phytogenic; Asian People; Camptothecin; Carboxylesterase; Chlorocebus aethiops; COS Cells; Haplotypes; Humans; Hypersensitivity; Irinotecan; Linkage Disequilibrium; Neoplasms; Polymorphism, Single Nucleotide; Prodrugs; RNA, Messenger; Sequence Analysis, DNA | 2007 |
A phase I and pharmacokinetic study of lapatinib in combination with infusional 5-fluorouracil, leucovorin and irinotecan.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Fluorouracil; Humans; Irinotecan; Lapatinib; Leucovorin; Male; Middle Aged; Neoplasms; Quinazolines; Tandem Mass Spectrometry | 2007 |
Phase II trial of irinotecan in children with refractory solid tumors: a Children's Oncology Group Study.
Topics: Adolescent; Adult; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Child; Child, Preschool; Female; Glucuronosyltransferase; Hepatoblastoma; Humans; Infant; Irinotecan; Male; Medulloblastoma; Neoplasms; Treatment Outcome | 2007 |
A Phase I and pharmacokinetic study of selenomethionine in combination with a fixed dose of irinotecan in solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasms; Selenomethionine; Treatment Outcome | 2008 |
Activated charcoal to prevent irinotecan-induced diarrhea in children.
Topics: Adolescent; Antineoplastic Agents; Camptothecin; Charcoal; Child; Child, Preschool; Diarrhea; Female; Humans; Infant; Irinotecan; Male; Neoplasms; Treatment Outcome | 2008 |
Safety of repeated administrations of ixabepilone given as a 3-hour infusion every other week in combination with irinotecan in patients with advanced malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Camptothecin; Diarrhea; Dose-Response Relationship, Drug; Epothilones; Female; Hematologic Diseases; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Nausea; Neoplasms; Paresthesia; Vomiting | 2008 |
Phase I clinical and pharmacokinetic study of oxaliplatin, irinotecan and capecitabine.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Organoplatinum Compounds; Oxaliplatin | 2009 |
Camptothecin analogues: studies from the Johns Hopkins Oncology Center.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Administration Schedule; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Irinotecan; Kidney; Leukemia; Liver; Metabolic Clearance Rate; Neoplasms; Platelet Count; Topoisomerase I Inhibitors; Topotecan | 1994 |
Limited sampling models for simultaneous estimation of the pharmacokinetics of irinotecan and its active metabolite SN-38.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Female; Half-Life; Humans; Infusions, Intravenous; Irinotecan; Linear Models; Male; Middle Aged; Models, Biological; Neoplasms; Sampling Studies | 1995 |
Phase I study of CPT-11 and etoposide in patients with refractory solid tumors.
Topics: Adult; Aged; Agranulocytosis; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administration Schedule; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Male; Middle Aged; Neoplasms; Treatment Outcome | 1993 |
A pharmacokinetic and pharmacodynamic analysis of CPT-11 and its active metabolite SN-38.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Female; Humans; Irinotecan; Japan; Kinetics; Leukopenia; Male; Middle Aged; Neoplasms; Prospective Studies | 1995 |
Pharmacological correlation between total drug concentration and lactones of CPT-11 and SN-38 in patients treated with CPT-11.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Chromatography, High Pressure Liquid; Female; Humans; Irinotecan; Kinetics; Lactones; Male; Middle Aged; Neoplasms; Prospective Studies | 1995 |
Phase I and pharmacokinetic study of irinotecan (CPT-11) administered daily for three consecutive days every three weeks in patients with advanced solid tumors.
Topics: Adult; Aged; Alopecia; Camptothecin; Chromatography, High Pressure Liquid; Diarrhea; Drug Administration Schedule; Female; Half-Life; Humans; Irinotecan; Leukopenia; Male; Middle Aged; Neoplasms; Prodrugs; Salvage Therapy; Treatment Outcome | 1995 |
Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials.
Topics: Adult; Aged; Bone Marrow Diseases; Camptothecin; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Female; Gastrointestinal Diseases; Half-Life; Humans; Irinotecan; Male; Middle Aged; Neoplasms; Prodrugs; Treatment Outcome | 1995 |
Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients.
Topics: Adult; Aged; Agranulocytosis; Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Drug Administration Schedule; Female; Gastrointestinal Diseases; Half-Life; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Nausea; Neoplasms; Treatment Outcome; Vomiting | 1995 |
Phase I and pharmacokinetic study of the camptothecin derivative irinotecan, administered on a weekly schedule in cancer patients.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Drug Administration Schedule; Female; Humans; Irinotecan; Leukopenia; Male; Middle Aged; Neoplasms; Neutropenia | 1994 |
Preclinical and phase I trials of topoisomerase I inhibitors.
Topics: Antineoplastic Agents; Camptothecin; Cell Line; Female; Humans; Indoles; Irinotecan; Male; Neoplasms; Pyridines; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured; Tumor Stem Cell Assay | 1994 |
Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Female; Humans; Irinotecan; Loperamide; Male; Middle Aged; Neoplasms | 1994 |
Phase I and pharmacokinetic trial of weekly CPT-11.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Chromatography, High Pressure Liquid; Drug Administration Schedule; Female; Humans; Irinotecan; Least-Squares Analysis; Male; Middle Aged; Neoplasms | 1993 |
Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks.
Topics: Adult; Aged; Anorexia; Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Drug Administration Schedule; Feasibility Studies; Humans; Infusions, Intravenous; Irinotecan; Middle Aged; Muscle Cramp; Neoplasms; Neutropenia; Thrombocytopenia; Vomiting | 1994 |
[Taxotere (docetaxel) and CPT 11 (irinotecan): phase I trials].
Topics: Antidiarrheals; Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Tolerance; Female; Humans; Irinotecan; Loperamide; Male; Neoplasms; Neutropenia; Paclitaxel; Remission Induction; Taxoids; Topoisomerase I Inhibitors | 1996 |
Limited-sampling models for irinotecan pharmacokinetics-pharmacodynamics: prediction of biliary index and intestinal toxicity.
Topics: Antineoplastic Agents, Phytogenic; Biliary Tract; Camptothecin; Diarrhea; Female; Humans; Irinotecan; Male; Middle Aged; Models, Biological; Neoplasms | 1996 |
Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors.
Topics: Adult; Aged; Antidotes; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasms | 1996 |
Rationale for the dosage and schedule of CPT-11 (irinotecan) selected for phase II studies, as determined by European phase I studies.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Europe; Female; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neoplasms; Survival Rate; Treatment Outcome | 1996 |
High dose-intensity of irinotecan administered every 3 weeks in advanced cancer patients: a feasibility study.
Topics: Adult; Aged; Agranulocytosis; Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Feasibility Studies; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasms; Thrombocytopenia | 1997 |
Pharmacokinetic interrelationships of irinotecan (CPT-11) and its three major plasma metabolites in patients enrolled in phase I/II trials.
Topics: Antineoplastic Agents, Phytogenic; Biotransformation; Camptothecin; France; Glucuronates; Humans; Irinotecan; Metabolic Clearance Rate; Models, Biological; Neoplasms | 1997 |
Phase I clinical and pharmacologic study of weekly cisplatin combined with weekly irinotecan in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Administration Schedule; Drug Synergism; Female; Glucuronates; Humans; Irinotecan; Male; Middle Aged; Neoplasms; Treatment Outcome | 1998 |
Phase I and pharmacokinetic trial of oral irinotecan administered daily for 5 days every 3 weeks in patients with solid tumors.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Camptothecin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasms | 1999 |
Sparse-data set analysis for irinotecan and SN-38 pharmacokinetics in cancer patients co-treated with cisplatin.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Cisplatin; Female; Humans; Irinotecan; Linear Models; Male; Middle Aged; Models, Biological; Neoplasms; Predictive Value of Tests; Reproducibility of Results | 1999 |
Direct translation of a protracted irinotecan schedule from a xenograft model to a phase I trial in children.
Topics: Adolescent; Adult; Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Child; Child, Preschool; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Evaluation; Female; Humans; Irinotecan; Male; Mice; Neoplasms; Neuroblastoma; Subrenal Capsule Assay; Treatment Outcome | 1999 |
Phase I and pharmacokinetic study of irinotecan administered as a low-dose, continuous intravenous infusion over 14 days in patients with malignant solid tumors.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Digestive System; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Evaluation; Female; Glucuronates; Glucuronides; Hematopoiesis; Humans; Infusions, Intravenous; Irinotecan; Leukocyte Count; Male; Middle Aged; Neoplasms; Treatment Outcome | 1999 |
Phase I study of irinotecan combined with carboplatin in previously untreated solid cancers.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Carboplatin; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasms; Prospective Studies | 1999 |
Phase I and pharmacologic study of irinotecan administered as a 96-hour infusion weekly to adult cancer patients.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Drug Administration Schedule; Female; Follow-Up Studies; Hematologic Diseases; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Nausea; Neoplasms; Vomiting | 2000 |
Phase I and pharmacokinetic study of irinotecan and docetaxel in patients with advanced solid tumors: preliminary evidence of clinical activity.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Docetaxel; Humans; Infusions, Intravenous; Irinotecan; Maximum Tolerated Dose; Middle Aged; Neoplasms; Paclitaxel; Taxoids; Treatment Outcome | 2000 |
Ifosfamide and irinotecan in solid tumors: a phase I dose-finding trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Humans; Ifosfamide; Irinotecan; Male; Middle Aged; Neoplasms; Salvage Therapy | 2000 |
Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following I.V. infusion of [(14)C]CPT-11 in cancer patients.
Topics: Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; Bile; Biotransformation; Camptothecin; Chromatography, High Pressure Liquid; Feces; Female; Humans; Infusions, Intravenous; Irinotecan; Male; Mass Spectrometry; Middle Aged; Neoplasms | 2000 |
Pharmacokinetics of irinotecan and its metabolites SN-38 and APC in children with recurrent solid tumors after protracted low-dose irinotecan.
Topics: Adolescent; Adult; Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Child; Child, Preschool; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Irinotecan; Neoplasm Recurrence, Local; Neoplasms; Neoplasms, Complex and Mixed; Neoplasms, Connective and Soft Tissue; Neoplasms, Glandular and Epithelial; Neutropenia; Time Factors | 2000 |
Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans.
Topics: Adolescent; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line; Child, Preschool; Chromatography, High Pressure Liquid; Chromatography, Liquid; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Female; Humans; Irinotecan; Male; Mass Spectrometry; Microsomes, Liver; Mixed Function Oxygenases; Neoplasms; Topoisomerase I Inhibitors | 2000 |
Dose escalation and pharmacokinetic study of irinotecan in combination with paclitaxel in patients with advanced cancer.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasms; Paclitaxel | 2000 |
Phase I and pharmacokinetic study of docetaxel and irinotecan in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Docetaxel; Drug Administration Schedule; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasms; Paclitaxel; Taxoids | 2000 |
Irinotecan and UFT/leucovorin in patients with advanced cancers.
Topics: Administration, Oral; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasms; Tegafur; Uracil | 2000 |
A phase I study of irinotecan in pediatric patients: a pediatric oncology group study.
Topics: Adolescent; Adult; Antineoplastic Agents, Phytogenic; Camptothecin; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Female; Hematologic Tests; Humans; Infant; Infusions, Intravenous; Irinotecan; Male; Neoplasms; Topoisomerase I Inhibitors; Toxicity Tests; Treatment Outcome | 2001 |
Modulation of irinotecan-induced diarrhea by cotreatment with neomycin in cancer patients.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Cross-Over Studies; Diarrhea; Humans; Irinotecan; Middle Aged; Neomycin; Neoplasms | 2001 |
Phase I trial of gemcitabine and CPT-11 given weekly for four weeks every six weeks.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Diarrhea; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neoplasms; Neutropenia; Thrombocytopenia | 2001 |
Phase I clinical trial of weekly combined topotecan and irinotecan.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administration Schedule; Enzyme Inhibitors; Female; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Male; Middle Aged; Neoplasms; Topoisomerase I Inhibitors; Topotecan | 2001 |
Limited sampling models for CPT-11, SN-38, and SN-38 glucuronide.
Topics: Antineoplastic Agents, Phytogenic; Area Under Curve; Biological Availability; Camptothecin; Female; Glucuronates; Humans; Infusions, Intravenous; Irinotecan; Male; Models, Statistical; Neoplasms; Sampling Studies | 2001 |
Phase I clinical and pharmacogenetic trial of irinotecan and raltitrexed administered every 21 days to patients with cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; Dose-Response Relationship, Drug; Fatigue; Female; Genotype; Homocysteine; Humans; Irinotecan; Male; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Neoplasms; Neutropenia; Oxidoreductases Acting on CH-NH Group Donors; Quinazolines; Thiophenes | 2001 |
Phase I dose-finding and pharmacokinetic trial of irinotecan (CPT-11) administered every two weeks.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms | 2001 |
Novel chemotherapeutic agents in early clinical development.
Topics: Adenine; Alkaloids; Anthraquinones; Antineoplastic Agents; Biphenyl Compounds; Camptothecin; Humans; Imides; Irinotecan; Isoquinolines; Naphthalimides; Neoplasms; Organophosphonates; Paclitaxel; Pyrazoles; Quinazolines; Sulfonylurea Compounds; Terpenes; Trimetrexate | 1990 |
[Phase I clinical study of CPT-11. Research group of CPT-11].
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Drug Evaluation; Female; Gastrointestinal Neoplasms; Humans; Irinotecan; Japan; Lung Neoplasms; Male; Middle Aged; Multicenter Studies as Topic; Neoplasms | 1990 |
226 other study(ies) available for irinotecan and Neoplasms
| Article | Year |
|---|---|
Syntheses and biological evaluation of topoisomerase I-targeting agents related to 11-[2-(N,N-dimethylamino)ethyl]-2,3-dimethoxy-8,9-methylenedioxy-11H-isoquino[4,3-c]cinnolin-12-one (ARC-31).
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Enzyme Inhibitors; Female; Humans; Magnetic Resonance Spectroscopy; Mass Spectrometry; Mice; Mice, Nude; Neoplasms; Quinolones; Topoisomerase I Inhibitors; Xenograft Model Antitumor Assays | 2008 |
Synthesis and antiproliferative evaluation of 6-aryl-11-iminoindeno[1,2-c]quinoline derivatives.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; G1 Phase; Humans; Neoplasms; Quinolines | 2011 |
Discovery, synthesis, and biological evaluation of orally active pyrrolidone derivatives as novel inhibitors of p53-MDM2 protein-protein interaction.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Cycle Proteins; Cell Proliferation; Humans; Imidazoles; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Models, Molecular; Neoplasms; Nuclear Proteins; Protein Binding; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-mdm2; Pyrrolidinones; Structure-Activity Relationship; Tumor Suppressor Protein p53 | 2012 |
Novel 3-Azaindolyl-4-arylmaleimides exhibiting potent antiangiogenic efficacy, protein kinase inhibition, and antiproliferative activity.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Cell Cycle; Cell Proliferation; Cells, Cultured; Chick Embryo; fms-Like Tyrosine Kinase 3; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Growth Inhibitors; Human Umbilical Vein Endothelial Cells; Humans; Maleimides; Molecular Structure; Neoplasms; Neovascularization, Pathologic; Protein Kinase Inhibitors; Structure-Activity Relationship; Vascular Endothelial Growth Factor Receptor-2; Vascular Endothelial Growth Factor Receptor-3 | 2012 |
Design, synthesis, biological evaluation and molecular modeling studies of 1-aryl-6-(3,4,5-trimethoxyphenyl)-3(Z)-hexen-1,5-diynes as a new class of potent antitumor agents.
Topics: Alkynes; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Crystallography, X-Ray; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; HeLa Cells; Humans; Mice; Mice, Nude; Models, Molecular; Molecular Structure; Neoplasms; Structure-Activity Relationship | 2013 |
Synthesis and antitumor activity of novel substituted uracil-1'(N)-acetic acid ester derivatives of 20(S)-camptothecins.
Topics: Acetates; Animals; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cell Survival; DNA Topoisomerases, Type I; Humans; Mice, Nude; Neoplasms; Topoisomerase I Inhibitors; Uracil | 2017 |
Design, synthesis and potent cytotoxic activity of novel 7-(N-[(substituted-sulfonyl)piperazinyl]-methyl)-camptothecin derivatives.
Topics: Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cell Survival; Drug Design; Drug Screening Assays, Antitumor; Humans; Methylation; Neoplasms; Piperazine; Piperazines; Sulfones | 2017 |
Design, synthesis and evaluation of 4-substituted anthra[2,1-c][1,2,5]thiadiazole-6,11-dione derivatives as novel non-camptothecin topoisomerase I inhibitors.
Topics: Anthraquinones; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; DNA Topoisomerases, Type I; Drug Design; Humans; Molecular Docking Simulation; Neoplasms; Thiadiazoles; Topoisomerase I Inhibitors | 2017 |
Discovery of novel ataxia telangiectasia mutated (ATM) kinase modulators: Computational simulation, biological evaluation and cancer combinational chemotherapy study.
Topics: Ataxia Telangiectasia; Ataxia Telangiectasia Mutated Proteins; Cell Cycle Proteins; Cell Line, Tumor; DNA-Binding Proteins; Humans; Neoplasms; Phosphorylation; Protein Serine-Threonine Kinases | 2022 |
SN38-based albumin-binding prodrug for efficient targeted cancer chemotherapy.
Topics: Albumins; Animals; Camptothecin; Cell Line, Tumor; Drug Delivery Systems; Irinotecan; Mice; Neoplasms; Prodrugs | 2021 |
Integration of DNA sequencing with population pharmacokinetics to improve the prediction of irinotecan exposure in cancer patients.
Topics: Administration, Intravenous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; ErbB Receptors; Female; Glucuronosyltransferase; High-Throughput Nucleotide Sequencing; Humans; Irinotecan; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Neoplasms; Pharmacogenomic Variants; Polymorphism, Single Nucleotide; Sequence Analysis, DNA | 2022 |
Spatially resolved quantification of drug metabolism and efficacy in 3D paper-based tumor mimics.
Topics: Chromatography, Liquid; Humans; Irinotecan; Mass Spectrometry; Neoplasms; Pharmaceutical Preparations; Tumor Microenvironment | 2021 |
DPYD polymorphisms c.496A>G, c.2194G>A and c.85T>C and risk of severe adverse drug reactions in patients treated with fluoropyrimidine-based protocols.
Topics: Adult; Antimetabolites; Bayes Theorem; Dihydrouracil Dehydrogenase (NADP); Drug-Related Side Effects and Adverse Reactions; Fluorouracil; Genotype; Humans; Irinotecan; Neoplasms; Polymorphism, Single Nucleotide | 2022 |
A Phenylfurocoumarin Derivative Reverses ABCG2-Mediated Multidrug Resistance In Vitro and In Vivo.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Biological Transport; Cell Proliferation; Chlorophyll; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Flow Cytometry; Furocoumarins; HCT116 Cells; Heterografts; High-Throughput Screening Assays; Humans; Irinotecan; Mice; Neoplasm Proteins; Neoplasms | 2021 |
Single cell mass spectrometry analysis of drug-resistant cancer cells: Metabolomics studies of synergetic effect of combinational treatment.
Topics: Anti-Infective Agents; Irinotecan; Mass Spectrometry; Metabolomics; Metformin; Neoplasms | 2022 |
Model-Based Prediction of Irinotecan-Induced Grade 4 Neutropenia in Advanced Cancer Patients: Influence of Demographic and Clinical Factors.
Topics: Bilirubin; Demography; Humans; Irinotecan; Neoplasms; Neutropenia | 2022 |
Two-Photon Photodynamic Therapy Targeting Cancers with Low Carboxylesterase 2 Activity Guided by Ratiometric Fluorescence.
Topics: Fluorescence; Humans; Irinotecan; Neoplasms; Photochemotherapy; Photosensitizing Agents; Prodrugs; Singlet Oxygen | 2022 |
Evaluation of UGT1A1 and CYP3A Genotyping and Single-Point Irinotecan and Metabolite Concentrations as Predictors of the Occurrence of Adverse Events in Cancer Treatment.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Cytochrome P-450 CYP3A; Diarrhea; Genotype; Humans; Irinotecan; Neoplasms | 2023 |
pH/redox-responsive core cross-linked based prodrug micelle for enhancing micellar stability and controlling delivery of chemo drugs: An effective combination drug delivery platform for cancer therapy.
Topics: Animals; Antineoplastic Agents; Cell Survival; Doxorubicin; HeLa Cells; Humans; Hydrogen-Ion Concentration; Irinotecan; Micelles; Neoplasms; Oxidation-Reduction; Prodrugs; Zebrafish | 2022 |
Therapy-Induced Senescent/Polyploid Cancer Cells Undergo Atypical Divisions Associated with Altered Expression of Meiosis, Spermatogenesis and EMT Genes.
Topics: Cellular Senescence; Epithelial-Mesenchymal Transition; Humans; Irinotecan; Ki-67 Antigen; Male; Meiosis; Neoplasms; Polyploidy; Spermatogenesis | 2022 |
Liposome Formulation for Tumor-Targeted Drug Delivery Using Radiation Therapy.
Topics: Chloral Hydrate; Cholesterol; Fluorescent Dyes; Halogens; Humans; Irinotecan; Lipid Bilayers; Liposomes; Neoplasms; Phosphatidylethanolamines; Polyethylene Glycols; Protons; Tissue Distribution | 2022 |
Durable disease control with apatinib, irinotecan and temozolomide in a case of metastatic primitive myxoid mesenchymal tumour of infancy.
Topics: Humans; Infant; Irinotecan; Neoplasms; Pyridines; Temozolomide | 2023 |
Critical roles of linker length in determining the chemical and self-assembly stability of SN38 homodimeric nanoprodrugs.
Topics: Humans; Irinotecan; Nanostructures; Neoplasms; Prodrugs; Solubility | 2023 |
Opioid-induced microbial dysbiosis disrupts irinotecan (CPT-11) metabolism and increases gastrointestinal toxicity in a murine model.
Topics: Analgesics, Opioid; Animals; Antineoplastic Agents, Phytogenic; Bacteria; Camptothecin; Disease Models, Animal; Dysbiosis; Glucuronidase; Humans; Irinotecan; Male; Mice; Mice, Inbred C57BL; Morphine Derivatives; Neoplasms; RNA, Ribosomal, 16S | 2023 |
Metal-organic framework for biomimetic nitric oxide generation and anticancer drug delivery.
Topics: Animals; Antineoplastic Agents; Biomimetics; Irinotecan; Metal-Organic Frameworks; Mice; Mice, Nude; Neoplasms; Nitric Oxide; Nitric Oxide Donors | 2023 |
Increased Expression of Hepatic Stearoyl-CoA Desaturase (SCD)-1 and Depletion of Eicosapentaenoic Acid (EPA) Content following Cytotoxic Cancer Therapy Are Reversed by Dietary Fish Oil.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Docosahexaenoic Acids; Eicosapentaenoic Acid; Fatty Acids; Fatty Liver; Female; Fish Oils; Fluorouracil; Interleukin-4; Irinotecan; Leptin; Liver; Neoplasms; Rats; Stearoyl-CoA Desaturase; Triglycerides | 2023 |
Rabbit derived VL single-domains as promising scaffolds to generate antibody-drug conjugates.
Topics: Animals; Antibodies, Monoclonal; Antigens; Antineoplastic Agents; Dogs; Humans; Immunoconjugates; Irinotecan; Mice; Neoplasms; Rabbits | 2023 |
Chemotherapy-induced ileitis associated or not with colitis in digestive oncology patients: An AGEO multicentre study.
Topics: Antineoplastic Agents; Colitis; Diarrhea; Humans; Ileitis; Irinotecan; Neoplasms | 2023 |
Artesunate ameliorates irinotecan-induced intestinal injury by suppressing cellular senescence and significantly enhances anti-tumor activity.
Topics: Animals; Artesunate; Camptothecin; Cellular Senescence; Humans; Intestinal Diseases; Irinotecan; Mice; Neoplasms; TOR Serine-Threonine Kinases | 2023 |
A ROS-response hyaluronic acid-coated/chitosan polymer prodrug for enhanced tumour targeting efficacy of SN38.
Topics: Animals; Camptothecin; Cell Line, Tumor; Chitosan; Hyaluronic Acid; Irinotecan; Mice; Neoplasms; Polymers; Prodrugs; Reactive Oxygen Species; Tumor Microenvironment | 2023 |
Evolution of Resistance to Irinotecan in Cancer Cells Involves Generation of Topoisomerase-Guided Mutations in Non-Coding Genome That Reduce the Chances of DNA Breaks.
Topics: Camptothecin; DNA; DNA Breaks, Double-Stranded; DNA Topoisomerases, Type I; Irinotecan; Mutation; Neoplasms | 2023 |
Quantification of Irinotecan in Single Spheroids Using Internal Standards by MALDI Mass Spectrometry Imaging.
Topics: Diagnostic Imaging; Humans; Irinotecan; Neoplasms; Reference Standards; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tumor Microenvironment | 2023 |
Discovery and Evaluation of 3-Quinoxalin Urea Derivatives as Potent, Selective, and Orally Available ATM Inhibitors Combined with Chemotherapy for the Treatment of Cancer via Goal-Oriented Molecule Generation and Virtual Screening.
Topics: Ataxia Telangiectasia Mutated Proteins; Early Detection of Cancer; Goals; Humans; Irinotecan; Neoplasms; Quinoxalines | 2023 |
Topics: Camptothecin; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Neoplasms; Patient Safety | 2023 |
Mesothelin-targeted CAR-T therapy combined with irinotecan for the treatment of solid cancer.
Topics: Animals; Cell Line, Tumor; Disease Models, Animal; GPI-Linked Proteins; Humans; Immunotherapy, Adoptive; Irinotecan; Mesothelin; Mice; Neoplasms; Receptors, Chimeric Antigen | 2023 |
Promoting antitumor efficacy by suppressing hypoxia via nano self-assembly of two irinotecan-based dual drug conjugates having a HIF-1α inhibitor.
Topics: A549 Cells; Animals; Antineoplastic Agents; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Indazoles; Irinotecan; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms; Receptors, Vascular Endothelial Growth Factor; Tumor Hypoxia | 2019 |
Tyrosine modified irinotecan-loaded liposomes capable of simultaneously targeting LAT1 and ATB
Topics: Amino Acid Transport Systems; Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Delivery Systems; Humans; Irinotecan; Large Neutral Amino Acid-Transporter 1; Liposomes; Male; MCF-7 Cells; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms; Tyrosine | 2019 |
Personalized Drug Efficacy Monitoring Chip.
Topics: Apoptosis; DNA Topoisomerases, Type I; Drug Monitoring; Drug Resistance, Neoplasm; Electric Impedance; Gene Expression Regulation, Neoplastic; HCT116 Cells; Humans; Irinotecan; Lab-On-A-Chip Devices; Models, Biological; Neoplasms; Precision Medicine; Topoisomerase I Inhibitors | 2019 |
Diversity of the Senescence Phenotype of Cancer Cells Treated with Chemotherapeutic Agents.
Topics: Antineoplastic Agents; Cell Proliferation; Cellular Senescence; Cyclin-Dependent Kinase Inhibitor p21; Doxorubicin; Fluorouracil; Humans; Irinotecan; Methotrexate; Neoplasms; Oxaliplatin; Paclitaxel; Phenotype; Tumor Cells, Cultured | 2019 |
Breaking the selectivity-uptake trade-off of photoimmunoconjugates with nanoliposomal irinotecan for synergistic multi-tier cancer targeting.
Topics: Cell Line, Tumor; Combined Modality Therapy; Drug Liberation; Drug Stability; Humans; Immunoconjugates; Irinotecan; Liposomes; Nanoparticles; Neoplasms; Phototherapy | 2020 |
Prospective use of the single-mouse experimental design for the evaluation of PLX038A.
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Cell Line, Tumor; Disease Models, Animal; DNA Damage; Female; Irinotecan; Mice; Mice, SCID; Neoplasms; Prospective Studies; Research Design; Tumor Burden; Xenograft Model Antitumor Assays | 2020 |
Double-crosslinked nanocomposite hydrogels for temporal control of drug dosing in combination therapy.
Topics: A549 Cells; Alginates; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Carriers; Drug Synergism; Humans; Hydrogels; Irinotecan; Male; Mice, Inbred BALB C; Nanocomposites; Nanoparticles; Neoplasms; Peptides; Xenograft Model Antitumor Assays | 2020 |
Targeted inhibition of gut bacterial β-glucuronidase activity enhances anticancer drug efficacy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Bacteria; Disease Models, Animal; Dysbiosis; Enzyme Inhibitors; Female; Gastrointestinal Microbiome; Glucuronidase; Humans; Irinotecan; Mice; Mice, Nude; Neoplasms | 2020 |
Single-ligand dual-targeting irinotecan liposomes: Control of targeting ligand display by pH-responsive PEG-shedding strategy to enhance tumor-specific therapy and attenuate toxicity.
Topics: Cell Line, Tumor; Drug Delivery Systems; Humans; Hydrogen-Ion Concentration; Irinotecan; Ligands; Liposomes; Neoplasms | 2020 |
Adverse event load, onset, and maximum grade: A novel method of reporting adverse events in cancer clinical trials.
Topics: Adverse Drug Reaction Reporting Systems; Antineoplastic Agents; Clinical Trials as Topic; Female; Humans; Irinotecan; Male; Neoplasms; Oxaliplatin | 2021 |
Design, Synthesis, and In Vitro/In Vivo Anti-Cancer Activities of Novel (20
Topics: A549 Cells; Animals; Antineoplastic Agents; Apoptosis; Benzodioxoles; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Hep G2 Cells; HL-60 Cells; Humans; Indolizines; Irinotecan; K562 Cells; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms; Transcription, Genetic | 2020 |
In situ activation of STING pathway with polymeric SN38 for cancer chemoimmunotherapy.
Topics: Antineoplastic Agents; Humans; Immunotherapy; Irinotecan; Neoplasms; Polymers | 2021 |
Anti-PD-L1 mediating tumor-targeted codelivery of liposomal irinotecan/JQ1 for chemo-immunotherapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Azepines; B7-H1 Antigen; Cell Line, Tumor; Female; Immune Checkpoint Inhibitors; Irinotecan; Mice; Mice, Inbred BALB C; Neoplasms; Programmed Cell Death 1 Receptor; T-Lymphocytes, Regulatory; Triazoles; Tumor Microenvironment | 2021 |
Self-Monitoring and Self-Delivery of Self-Assembled Fluorescent Nanoparticles in Cancer Therapy.
Topics: Animals; Apoptosis; Cell Cycle; Cell Death; Cell Line, Tumor; Curcumin; Drug Carriers; Drug Delivery Systems; Drug Liberation; Endocytosis; Fluorescence; Humans; Imaging, Three-Dimensional; Irinotecan; Nanoparticles; Neoplasms; Particle Size; Zebrafish | 2021 |
Minimal contribution of the hepatic uptake transporter OATP1B1 to the inter-individual variability in SN-38 pharmacokinetics in cancer patients without severe renal failure.
Topics: Aged; Area Under Curve; Chromatography, Liquid; Dose-Response Relationship, Drug; Female; Glomerular Filtration Rate; Humans; Irinotecan; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Neoplasms; Prospective Studies; Renal Insufficiency; Severity of Illness Index; Tandem Mass Spectrometry; Topoisomerase I Inhibitors | 2021 |
Self-Activating Therapeutic Nanoparticle: A Targeted Tumor Therapy Using Reactive Oxygen Species Self-Generation and Switch-on Drug Release.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Liberation; Female; Humans; Irinotecan; Isothiocyanates; Male; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Neoplasms; Oligopeptides; Photosensitizing Agents; Precision Medicine; Prodrugs; Reactive Oxygen Species; Silanes; Silicon; Xenograft Model Antitumor Assays | 2021 |
Integrated pan-cancer of AURKA expression and drug sensitivity analysis reveals increased expression of AURKA is responsible for drug resistance.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aurora Kinase A; Azepines; Benzodioxoles; Biomarkers, Tumor; Camptothecin; Cell Line, Tumor; Chromones; Dactinomycin; Datasets as Topic; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Morpholines; Neoplasms; Prognosis; Pyridines; Triazoles | 2021 |
Orthotopic patient-derived xenografts of paediatric solid tumours.
Topics: Animals; Bortezomib; Camptothecin; Cell Cycle Proteins; Child; Clone Cells; Drug Therapy, Combination; Epigenesis, Genetic; Female; Heterografts; High-Throughput Screening Assays; Humans; Hydroxamic Acids; Indoles; Irinotecan; Mice; Neoplasms; Nuclear Proteins; Panobinostat; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Pyrimidinones; Rhabdomyosarcoma; Vincristine; Xenograft Model Antitumor Assays | 2017 |
UGT1A1 Gene Polymorphism Predicts Irinotecan-Induced Severe Neutropenia and Diarrhea in Chinese Cancer Patients.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Neoplasms; Neutropenia; Polymorphism, Genetic | 2017 |
Executioner caspases and CAD are essential for mutagenesis induced by TRAIL or vincristine.
Topics: Apoptosis; Aspartate Carbamoyltransferase; Camptothecin; Carbamoyl-Phosphate Synthase (Glutamine-Hydrolyzing); Caspases; Cell Line, Tumor; Cell Survival; Cisplatin; Dacarbazine; Dihydroorotase; DNA Damage; Doxorubicin; Enzyme Activation; Humans; Irinotecan; Mutagenesis; Mutation; Neoplasms; Signal Transduction; Temozolomide; TNF-Related Apoptosis-Inducing Ligand; Vincristine | 2017 |
Antitumor potential of a novel camptothecin derivative, ZBH-ZM-06.
Topics: Acetylcholinesterase; Antineoplastic Agents; Camptothecin; Caspase 3; Cell Cycle; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Gene Expression Regulation, Neoplastic; GPI-Linked Proteins; Humans; Irinotecan; Neoplasms; Poly(ADP-ribose) Polymerases; Prodrugs | 2018 |
Integrated population pharmacokinetics of etirinotecan pegol and its four metabolites in cancer patients with solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Camptothecin; Clinical Trials as Topic; Female; Glucuronosyltransferase; Heterocyclic Compounds, 4 or More Rings; Humans; Irinotecan; Male; Middle Aged; Models, Biological; Neoplasms; Polyethylene Glycols | 2018 |
Assessment of exposure risk of irinotecan and its active metabolite, SN-38, through perspiration during chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Female; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Neoplasms; Sweat; Topoisomerase I Inhibitors | 2019 |
Reality of the emetogenic level of irinotecan.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antiemetics; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Cyclophosphamide; Emetics; Female; Humans; Induction Chemotherapy; Irinotecan; Male; Middle Aged; Nausea; Neoplasms; Outpatients; Quality of Life; Retrospective Studies; Severity of Illness Index; Vomiting | 2018 |
Predictive factors for the development of irinotecan-related cholinergic syndrome using ordered logistic regression analysis.
Topics: Abdominal Pain; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Blood Pressure; Camptothecin; Diarrhea; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Logistic Models; Male; Middle Aged; Neoplasms; Predictive Value of Tests; Quality of Life; Retrospective Studies; Salivation; Syndrome; Young Adult | 2018 |
Improvement of oral efficacy of Irinotecan through biodegradable polymeric nanoparticles through in vitro and in vivo investigations.
Topics: Administration, Oral; Animals; Antineoplastic Agents, Phytogenic; Biological Availability; Brain; Caco-2 Cells; Camptothecin; Chitosan; Drug Carriers; Humans; Intestinal Absorption; Irinotecan; Lactic Acid; Male; MCF-7 Cells; Nanoparticles; Neoplasms; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Rats; Rats, Wistar | 2018 |
[Factors Affecting Development of Cholinergic Symptoms after Irinotecan Administration].
Topics: Abdominal Pain; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Cholinergic Agents; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasms; Retrospective Studies; Sweat | 2018 |
Azo-based small molecular hypoxia responsive theranostic for tumor-specific imaging and therapy.
Topics: Animals; Antineoplastic Agents; Azo Compounds; Caenorhabditis elegans; Cell Line, Tumor; Cell Survival; Female; Humans; Irinotecan; Mice, Inbred BALB C; Mice, Nude; Microsomes, Liver; Neoplasms; Rats; Theranostic Nanomedicine; Tumor Hypoxia | 2018 |
Design, synthesis and pharmacological evaluation of a novel PEG-cRGD-conjugated irinotecan derivative as potential antitumor agent.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cell Proliferation; Chickens; Female; Humans; Integrin alphaVbeta3; Irinotecan; Male; Mice, Inbred BALB C; Mice, Nude; Neoplasms; Peptides, Cyclic; Polyethylene Glycols; Rats, Sprague-Dawley | 2018 |
Coadministration of cytotoxic chemotherapeutic agents with irinotecan is a risk factor for irinotecan-induced cholinergic syndrome in Japanese patients with cancer.
Topics: Abdominal Pain; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cholinergic Agents; Diarrhea; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Irinotecan; Japan; Male; Middle Aged; Neoplasms; Prognosis; Quality of Life; Retrospective Studies; Risk Factors; Syndrome | 2019 |
Preexisting Interstitial Lung Disease and Lung Injury Associated with Irinotecan in Patients with Neoplasms.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Camptothecin; Female; Follow-Up Studies; Humans; Irinotecan; Lung Diseases, Interstitial; Lung Injury; Male; Middle Aged; Neoplasms; Prognosis; Retrospective Studies; Risk Factors | 2018 |
Liposomal codelivery of an SN38 prodrug and a survivin siRNA for tumor therapy.
Topics: Animals; Apoptosis; Biological Transport; Camptothecin; Cell Line, Tumor; Cell Survival; Drug Delivery Systems; Endocytosis; Female; Gene Silencing; Gene Transfer Techniques; HeLa Cells; Humans; Inhibitor of Apoptosis Proteins; Irinotecan; Liposomes; Mice, Nude; Neoplasms; Particle Size; Prodrugs; RNA, Small Interfering; Survivin; Tissue Distribution; Transferrin | 2018 |
Prophylactic effect of scopolamine butylbromide, a competitive antagonist of muscarinic acetylcholine receptor, on irinotecan-related cholinergic syndrome.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Protocols; Butylscopolammonium Bromide; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Incidence; Irinotecan; Japan; Male; Middle Aged; Muscarinic Antagonists; Neoplasms; Parasympathetic Nervous System; Risk Factors; Syndrome | 2019 |
Novel SN38 derivative-based liposome as anticancer prodrug: an in vitro and in vivo study.
Topics: 1-Octanol; Animals; Antineoplastic Agents; Cell Death; Cell Line, Tumor; Drug Delivery Systems; Humans; Irinotecan; Liposomes; Mice; Neoplasms; Particle Size; Prodrugs; Solubility; Static Electricity; Tissue Distribution; Water | 2019 |
Effective co-encapsulation of doxorubicin and irinotecan for synergistic therapy using liposomes prepared with triethylammonium sucrose octasulfate as drug trapping agent.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Doxorubicin; Drug Liberation; Drug Synergism; Erythrocytes; Female; Humans; Irinotecan; Liposomes; Methylamines; Mice, Inbred BALB C; Neoplasms; Rabbits; Rats, Sprague-Dawley; Sucrose; Tissue Distribution; Tumor Burden | 2019 |
Enzyme and Transporter Kinetics for CPT-11 (Irinotecan) and SN-38: An Insight on Tumor Tissue Compartment Pharmacokinetics Using PBPK.
Topics: Adult; Biological Availability; Carrier Proteins; Catalysis; Computer Simulation; Enzymes; Female; Humans; Inactivation, Metabolic; Irinotecan; Kinetics; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Protein Binding; Tissue Distribution; Whole Body Imaging | 2019 |
BR2 and CyLoP1 enhance in-vivo SN38 delivery using pegylated PAMAM dendrimers.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Cell Survival; Dendrimers; Drug Carriers; Drug Liberation; Erythrocytes; Female; Hemolysis; Humans; Irinotecan; Mice, Inbred BALB C; Nanoparticles; Neoplasms; Oligopeptides; Polyethylene Glycols; Tissue Distribution | 2019 |
Genetics and adverse events with irinotecan treatment: what do we know?
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug-Related Side Effects and Adverse Reactions; Genetics; Genotype; Humans; Irinotecan; Neoplasms; Topoisomerase I Inhibitors | 2019 |
IKKα Kinase Regulates the DNA Damage Response and Drives Chemo-resistance in Cancer.
Topics: Animals; DNA Damage; DNA Repair; Drug Resistance, Neoplasm; Fluorouracil; HCT116 Cells; Humans; I-kappa B Kinase; Irinotecan; MAP Kinase Signaling System; MCF-7 Cells; Mice; Mice, Nude; Neoplasm Metastasis; Neoplasm Proteins; Neoplasms; Telomere; Xenograft Model Antitumor Assays | 2019 |
Combinational drug-loaded lipid nanocapsules for the treatment of cancer.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Combinations; Erythrocytes; Female; Hemolysis; Humans; Irinotecan; Lipids; Mice, Inbred BALB C; Nanocapsules; Neoplasms; Phenylurea Compounds; Pyridines | 2019 |
Milatuzumab-SN-38 conjugates for the treatment of CD74+ cancers.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, Differentiation, B-Lymphocyte; Antigens, Neoplasm; Camptothecin; Cell Adhesion Molecules; Doxorubicin; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Histocompatibility Antigens Class II; Humans; Irinotecan; Neoplasms; Xenograft Model Antitumor Assays | 2013 |
Risk factors for severe adverse effects and treatment-related deaths in Japanese patients treated with irinotecan-based chemotherapy: a postmarketing survey.
Topics: Aged; Analysis of Variance; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Asian People; Breast Neoplasms; Camptothecin; Colorectal Neoplasms; Death; Diarrhea; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Irinotecan; Japan; Leukopenia; Logistic Models; Lung Neoplasms; Lymphoma; Male; Middle Aged; Neoplasms; Ovarian Neoplasms; Product Surveillance, Postmarketing; Risk Assessment; Risk Factors; Sex Factors; Skin Neoplasms; Stomach Neoplasms; Thrombocytopenia | 2013 |
ABCG2 inhibitor YHO-13351 sensitizes cancer stem/initiating-like side population cells to irinotecan.
Topics: Acrylonitrile; Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Blotting, Western; Camptothecin; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; Flow Cytometry; Fluorescent Antibody Technique; Humans; Irinotecan; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Proteins; Neoplasms; Neoplastic Stem Cells; Side-Population Cells; Tumor Cells, Cultured; Tumor Stem Cell Assay; Xenograft Model Antitumor Assays | 2013 |
Antiemetic prophylaxis and frequency of chemotherapy-induced nausea and vomiting in palliative first-line treatment of colorectal cancer patients: the Northern Bavarian IVOPAK I Project.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dexamethasone; Female; Fluorouracil; Germany; Humans; Irinotecan; Male; Middle Aged; Nausea; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Practice Guidelines as Topic; Prospective Studies; Vomiting; Young Adult | 2013 |
Tumor redox heterogeneity-responsive prodrug nanocapsules for cancer chemotherapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Irinotecan; Mice; Molecular Structure; Nanocapsules; Neoplasms; Oxidation-Reduction; Prodrugs; Structure-Activity Relationship | 2013 |
A high-throughput yeast assay identifies synergistic drug combinations.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Cell Survival; Drug Evaluation, Preclinical; Drug Synergism; Humans; Irinotecan; Mitomycin; Neoplasms; Two-Hybrid System Techniques | 2013 |
Cost comparison and economic implications of commonly used originator and generic chemotherapy drugs in India.
Topics: Camptothecin; Cost Savings; Cost-Benefit Analysis; Deoxycytidine; Docetaxel; Drugs, Generic; Gemcitabine; Humans; India; Irinotecan; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Poverty; Taxoids | 2013 |
Identification of preferred chemotherapeutics for combining with a CHK1 inhibitor.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carbolines; Cell Cycle Checkpoints; Checkpoint Kinase 1; Dacarbazine; Deoxycytidine; DNA Damage; Gemcitabine; HCT116 Cells; High-Throughput Nucleotide Sequencing; HT29 Cells; Humans; Irinotecan; Mice; Mice, Nude; Neoplasms; Neoplasms, Experimental; Protein Kinase Inhibitors; Protein Kinases; Pyridines; Pyrroles; Temozolomide; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2013 |
Rational combination therapy of vintafolide (EC145) with commonly used chemotherapeutic drugs.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cell Line, Tumor; Cell Proliferation; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Folic Acid; HeLa Cells; Humans; Irinotecan; Mice, Inbred BALB C; Mice, Inbred DBA; Mice, Nude; Neoplasms; Neoplasms, Experimental; Paclitaxel; Taxoids; Topotecan; Treatment Outcome; Vinca Alkaloids; Xenograft Model Antitumor Assays | 2014 |
Biofunctionalized polymer-lipid supported mesoporous silica nanoparticles for release of chemotherapeutics in multidrug resistant cancer cells.
Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Camptothecin; Cell Line, Tumor; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Hydrogen-Ion Concentration; Intracellular Space; Irinotecan; Lipids; Mice; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Neoplasm Proteins; Neoplasms; Particle Size; Polymers; Porosity; Silicon Dioxide; Static Electricity; Time Factors; X-Ray Diffraction; Xenograft Model Antitumor Assays | 2014 |
The circadian rest-activity rhythm, a potential safety pharmacology endpoint of cancer chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Circadian Rhythm; Fatigue; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Monitoring, Physiologic; Motor Activity; Neoplasm Metastasis; Neoplasm Staging; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Prognosis; Prospective Studies; Rest; Weight Loss | 2014 |
Se-methylselenocysteine offers selective protection against toxicity and potentiates the antitumour activity of anticancer drugs in preclinical animal models.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Cyclophosphamide; Cytoprotection; Female; Humans; Irinotecan; Mice; Mice, Nude; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Rats; Rats, Inbred F344; Selenocysteine; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2014 |
Old drug new use--amoxapine and its metabolites as potent bacterial β-glucuronidase inhibitors for alleviating cancer drug toxicity.
Topics: Amoxapine; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Disease Models, Animal; Dose-Response Relationship, Drug; Enzyme Activation; Female; Glycoproteins; Irinotecan; Mice; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Neoplasms; Protective Agents; Protein Binding; Xenograft Model Antitumor Assays | 2014 |
Clinical observations on associations between the UGT1A1 genotype and severe toxicity of irinotecan.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Bilirubin; Camptothecin; Diarrhea; Female; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Neoplasms; Neutropenia; Young Adult | 2014 |
Human serum albumin conjugates of 7-ethyl-10-hydroxycamptothecin (SN38) for cancer treatment.
Topics: Animals; Blood Cell Count; Camptothecin; Cell Death; Cell Survival; Drug Stability; Electrophoresis, Polyacrylamide Gel; HT29 Cells; Humans; Inhibitory Concentration 50; Irinotecan; Mice, Inbred BALB C; Microscopy, Electron, Scanning; Neoplasms; Particle Size; Serum Albumin; Static Electricity; Tissue Distribution | 2014 |
Determination of irinotecan and its metabolite SN-38 in rabbit plasma and tumors using a validated method of tandem mass spectrometry coupled with liquid chromatography.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptotheca; Camptothecin; Chromatography, High Pressure Liquid; Irinotecan; Limit of Detection; Neoplasms; Rabbits; Reproducibility of Results; Tandem Mass Spectrometry | 2014 |
Irinotecan pharmacogenetics: a finished puzzle?
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Glucuronosyltransferase; Humans; Irinotecan; Male; Neoplasms | 2014 |
Allelic expression of phase II metabolizing enzymes and relationship to irinotecan toxicity.
Topics: Alleles; Antineoplastic Agents, Phytogenic; Camptothecin; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Glucuronosyltransferase; Humans; Irinotecan; Neoplasms; Oncology Nursing; Polymorphism, Single Nucleotide | 2014 |
Cytotoxicity and therapeutic effect of irinotecan combined with selenium nanoparticles.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Cell Line, Tumor; Female; Humans; Irinotecan; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Neoplasms; Rats; Selenium | 2014 |
Application of a combination of a knowledge-based algorithm and 2-stage screening to hypothesis-free genomic data on irinotecan-treated patients for identification of a candidate single nucleotide polymorphism related to an adverse effect.
Topics: Adult; Algorithms; Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Female; Genome-Wide Association Study; Genome, Human; Genomics; Humans; Irinotecan; KCNQ Potassium Channels; Knowledge Bases; Male; Neoplasms; Polymorphism, Single Nucleotide; ROC Curve | 2014 |
Pre-treatment serum total bilirubin level as an indicator of optimal CPT-11 dosage.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Bilirubin; Biomarkers; Camptothecin; Female; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Neoplasms; Polymorphism, Genetic; Predictive Value of Tests; Retrospective Studies | 2015 |
Polypeptide-based Micelles for Delivery of Irinotecan: Physicochemical and In vivo Characterization.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Cell Survival; Chemistry, Pharmaceutical; Dose-Response Relationship, Drug; Drug Carriers; Humans; Irinotecan; Mice, Inbred BALB C; Mice, Nude; Micelles; Nanoparticles; Neoplasms; Polyethylene Glycols; Solubility; Technology, Pharmaceutical; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Female; Humans; Irinotecan; Liposomes; Male; Middle Aged; Neoplasms; Polyethylene Glycols | 2015 |
[DNA topoisomerase I--targeting drugs].
Topics: Camptothecin; Humans; Irinotecan; Molecular Targeted Therapy; Neoplasms; Topoisomerase I Inhibitors; Topotecan | 2015 |
Irinotecan induces cell cycle arrest, but not apoptosis or necrosis, in Caco-2 and CW2 colorectal cancer cell lines.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Caco-2 Cells; Camptothecin; Cell Cycle Checkpoints; Cell Line, Tumor; Humans; Irinotecan; Male; Mice, Nude; Necrosis; Neoplasms; Tumor Burden | 2015 |
Clinical validity of new genetic biomarkers of irinotecan neutropenia: an independent replication study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Camptothecin; Cohort Studies; Female; Genetic Markers; Genotype; Humans; Irinotecan; Male; Middle Aged; Multidrug Resistance-Associated Protein 2; Neoplasms; Neutropenia | 2016 |
Iterative and prolonged remission in metastatic breast cancer using pegylated irinotecan: a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Female; Humans; Irinotecan; Middle Aged; Neoplasms; Remission Induction; Topoisomerase I Inhibitors | 2015 |
Identification of Circadian Determinants of Cancer Chronotherapy through In Vitro Chronopharmacology and Mathematical Modeling.
Topics: Animals; Antineoplastic Agents; Apoptosis; Camptothecin; Cell Line, Tumor; Circadian Clocks; DNA Topoisomerases, Type I; Drug Chronotherapy; Gene Expression Regulation, Neoplastic; Humans; In Vitro Techniques; Irinotecan; Mice; Models, Theoretical; Neoplasms | 2015 |
Topoisomerase-I PS506 as a Dual Function Cancer Biomarker.
Topics: Amino Acid Sequence; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Colonic Neoplasms; DNA Topoisomerases, Type I; Female; Gene Expression; Humans; Irinotecan; Lung; Lung Neoplasms; Molecular Sequence Data; Neoplasms; Ovarian Neoplasms; Phosphorylation; Serine; Topotecan | 2015 |
HSP90 Inhibitor-SN-38 Conjugate Strategy for Targeted Delivery of Topoisomerase I Inhibitor to Tumors.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Camptothecin; Cell Line, Tumor; Female; HSP90 Heat-Shock Proteins; Humans; Irinotecan; Mice, Inbred ICR; Mice, SCID; Microscopy, Fluorescence; Molecular Targeted Therapy; Neoplasms; Resorcinols; Topoisomerase I Inhibitors; Treatment Outcome; Triazoles; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
Increased Plasma Concentrations of Unbound SN-38, the Active Metabolite of Irinotecan, in Cancer Patients with Severe Renal Failure.
Topics: Acute Kidney Injury; Antineoplastic Agents, Phytogenic; Camptothecin; Humans; Irinotecan; Kidney; Models, Biological; Neoplasms; Protein Binding | 2016 |
Regorafenib: Antitumor Activity upon Mono and Combination Therapy in Preclinical Pediatric Malignancy Models.
Topics: Adolescent; Adult; Aged; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Cell Line, Tumor; Cell Proliferation; Child; Drug Screening Assays, Antitumor; Female; Humans; In Situ Hybridization, Fluorescence; Irinotecan; Male; MAP Kinase Signaling System; Mice; Neoplasm Transplantation; Neoplasms; Neovascularization, Pathologic; Phenylurea Compounds; Pyridines | 2015 |
Wnt/β-catenin pathway regulates MGMT gene expression in cancer and inhibition of Wnt signalling prevents chemoresistance.
Topics: Animals; Antineoplastic Agents; Benzeneacetamides; beta Catenin; Brain Neoplasms; Camptothecin; Celecoxib; Cisplatin; Colorectal Neoplasms; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Doxorubicin; Drug Resistance, Neoplasm; Flow Cytometry; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Glioma; Glucose-6-Phosphate Isomerase; Heterocyclic Compounds, 3-Ring; Humans; Immunoblotting; Immunohistochemistry; Irinotecan; Medulloblastoma; Mice; Neoplasm Transplantation; Neoplasms; Neuroblastoma; Pyrans; Pyrazines; Pyridines; Real-Time Polymerase Chain Reaction; Sulfones; Temozolomide; Triazoles; Tumor Suppressor Proteins; Vincristine; Wnt Proteins; Wnt Signaling Pathway | 2015 |
Multi-responsive photothermal-chemotherapy with drug-loaded melanin-like nanoparticles for synergetic tumor ablation.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Death; Doxorubicin; Drug Liberation; Drug Stability; Endocytosis; HeLa Cells; Humans; Hyperthermia, Induced; Indoles; Inhibitory Concentration 50; Irinotecan; Male; MCF-7 Cells; Melanins; Mice; Mice, Inbred BALB C; Nanoparticles; Neoplasms; NIH 3T3 Cells; Phototherapy; Polyethylene Glycols; Polymers | 2016 |
Molecular Genetics External Quality Assessment Pilot Scheme for Irinotecan-Related UGT1A1 Genotyping in China.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line; China; Genotype; Genotyping Techniques; Glucuronosyltransferase; Humans; Irinotecan; Neoplasms; Pharmacogenetics; Polymorphism, Genetic; Topoisomerase I Inhibitors | 2016 |
Effects of UGT1A1*6, UGT1A1*28, and ABCB1-3435C>T polymorphisms on irinotecan induced toxicity in Chinese cancer patients.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B; Camptothecin; Diarrhea; Female; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Neoplasms; Neutropenia; Polymorphism, Genetic | 2016 |
Synthesis, characterization, and evaluation of mPEG-SN38 and mPEG-PLA-SN38 micelles for cancer therapy.
Topics: Animals; Antineoplastic Agents; Apoptosis; Camptothecin; Cell Line, Tumor; Drug Liberation; Endocytosis; Fluorescein-5-isothiocyanate; Humans; Irinotecan; Mice, Inbred BALB C; Mice, Nude; Micelles; Neoplasms; Polyesters; Polyethylene Glycols; Tissue Distribution; Treatment Outcome | 2016 |
Synthesis and Investigation of Tetrahydro-β-carboline Derivatives as Inhibitors of the Breast Cancer Resistance Protein (ABCG2).
Topics: Adenosine Triphosphatases; Animals; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily G, Member 2; Camptothecin; Carbolines; Cell Line; Dogs; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Neoplasm Proteins; Neoplasms | 2016 |
Vitamin D Enhances the Efficacy of Irinotecan through miR-627-Mediated Inhibition of Intratumoral Drug Metabolism.
Topics: Animals; Camptothecin; Cell Line, Tumor; Cytochrome P-450 CYP3A; Disease Models, Animal; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Male; Mice; MicroRNAs; Neoplasms; Pharmacogenetics; RNA Interference; Vitamin D; Xenograft Model Antitumor Assays | 2016 |
Lack of pharmacokinetic drug-drug interaction between ramucirumab and irinotecan in patients with advanced solid tumors.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Area Under Curve; Asian People; Camptothecin; Drug Interactions; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasms; Ramucirumab | 2016 |
Clinical Outcomes of Patients with Rare and Heavily Pretreated Solid Tumors Treated according to the Results of Tumor Molecular Profiling.
Topics: Biomarkers, Tumor; Camptothecin; Cisplatin; Disease-Free Survival; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Male; Neoplasm Proteins; Neoplasms; Pathology, Molecular | 2016 |
Sequential designs for individualized dosing in phase I cancer clinical trials.
Topics: Algorithms; Antineoplastic Agents; Area Under Curve; Camptothecin; Clinical Trials, Phase I as Topic; Computer Simulation; Dose-Response Relationship, Drug; Humans; Irinotecan; Neoplasms; Phenotype | 2017 |
[Role of UGT1A1*28 and UGT1A1*6 for irinotecan-induced adverse drug reaction].
Topics: Camptothecin; Glucuronosyltransferase; Humans; Irinotecan; Multigene Family; Neoplasms; Polymorphism, Genetic | 2008 |
Genetic testing for UGT1A1*28 and *6 in Japanese patients who receive irinotecan chemotherapy.
Topics: Antineoplastic Agents, Phytogenic; Asian People; Camptothecin; Female; Genetic Predisposition to Disease; Glucuronosyltransferase; Humans; Irinotecan; Male; Neoplasms; Polymorphism, Genetic | 2008 |
[A case of recurrent gastroesophageal junction adenocarcinoma successfully treated with radiation plus chemotherapy (5-FU+CDDP, S-1, Paclitaxel, CPT-11) for long-term survival with good QOL].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Combined Modality Therapy; Drug Combinations; Esophageal Neoplasms; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasms; Oxonic Acid; Paclitaxel; Quality of Life; Stomach Neoplasms; Tegafur; Time Factors; Tomography, X-Ray Computed | 2008 |
UGT1A1*6 polymorphism is most predictive of severe neutropenia induced by irinotecan in Japanese cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Camptothecin; Female; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Neoplasms; Neutropenia; Organic Anion Transporters; Polymorphism, Genetic | 2009 |
Pharmacodynamic genes do not influence risk of neutropenia in cancer patients treated with moderately high-dose irinotecan.
Topics: Adult; Aged; Aged, 80 and over; Camptothecin; Cohort Studies; Dose-Response Relationship, Drug; Female; Haplotypes; Humans; Irinotecan; Male; Middle Aged; Neoplasms; Neutropenia; Polymorphism, Genetic; Risk Factors | 2009 |
DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antibodies, Monoclonal; Antineoplastic Agents, Phytogenic; Apoptosis Regulatory Proteins; Calcium-Binding Proteins; Camptothecin; Cell Line, Tumor; Cell Proliferation; Chaperonin 60; Drug Synergism; Humans; Inhibitor of Apoptosis Proteins; Intercellular Signaling Peptides and Proteins; Intracellular Signaling Peptides and Proteins; Irinotecan; Membrane Proteins; Mice; Neoplasms; Neoplastic Stem Cells; Neovascularization, Pathologic; Receptors, Notch; Secondary Prevention; Xenograft Model Antitumor Assays | 2009 |
Single nucleotide polymorphism in ABCG2 is associated with irinotecan-induced severe myelosuppression.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Bone Marrow Cells; Camptothecin; Case-Control Studies; Female; Humans; Immune Tolerance; Irinotecan; Male; Middle Aged; Models, Biological; Neoplasm Proteins; Neoplasms; Polymorphism, Single Nucleotide; Retrospective Studies | 2009 |
In vivo antitumor efficacy of interleukin-21 in combination with chemotherapeutics.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Cell Proliferation; Doxorubicin; Female; Fluorouracil; Interleukins; Irinotecan; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Neoplasms; Organoplatinum Compounds; Oxaliplatin; T-Lymphocytes | 2009 |
Mismatch repair system decreases cell survival by stabilizing the tetraploid G1 arrest in response to SN-38.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Camptothecin; Cell Survival; Checkpoint Kinase 1; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase 4; DNA Damage; DNA Mismatch Repair; G1 Phase; Humans; Irinotecan; MutL Protein Homolog 1; Neoplasms; Nuclear Proteins; Phosphorylation; Ploidies; Protein Kinases; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Tumor Cells, Cultured; Tumor Stem Cell Assay; Tumor Suppressor Protein p53 | 2010 |
Individualizing dosing of irinotecan.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Dose-Response Relationship, Drug; Drug Dosage Calculations; Humans; Irinotecan; Metabolic Clearance Rate; Models, Biological; Neoplasms; Precision Medicine; Randomized Controlled Trials as Topic | 2010 |
Indispensability of UGT1A1*6 genotyping in Japanese cancer patients treated with irinotecan.
Topics: Antineoplastic Agents, Phytogenic; Asian People; Camptothecin; Genetic Predisposition to Disease; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Japan; Neoplasms; Neutropenia; Phenotype; Polymorphism, Genetic; Risk Assessment; Risk Factors; Severity of Illness Index | 2010 |
Association of carboxylesterase 1A genotypes with irinotecan pharmacokinetics in Japanese cancer patients.
Topics: Antineoplastic Agents, Phytogenic; Area Under Curve; Asian People; Camptothecin; Carboxylesterase; Carboxylic Ester Hydrolases; Enzyme Inhibitors; Gene Frequency; Genotype; Humans; Irinotecan; Japan; Multivariate Analysis; Neoplasms; Polymorphism, Single Nucleotide | 2010 |
Discovery of drug mode of action and drug repositioning from transcriptional responses.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Algorithms; Antineoplastic Agents; Autophagy; Blotting, Western; Camptothecin; Cell Line, Tumor; Doxorubicin; Drug Discovery; Drug Screening Assays, Antitumor; Flavonoids; Fuzzy Logic; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; HeLa Cells; Humans; Irinotecan; Neoplasms; Oligonucleotide Array Sequence Analysis; Phosphorylation; Piperidines; Pyrazoles; Pyrroles; RNA Polymerase II | 2010 |
Are herbal medicines ripe for the cancer clinic?
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Complementary Therapies; Gastrointestinal Tract; Herbal Medicine; Humans; Irinotecan; Mice; Neoplasms | 2010 |
[mRNA quantification. The next challenge in routine diagnostics].
Topics: Algorithms; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Drug Delivery Systems; Fluorouracil; Humans; Irinotecan; Lung Neoplasms; Molecular Diagnostic Techniques; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Predictive Value of Tests; Prognosis; RNA, Messenger; Survival Rate; Thymidylate Synthase | 2010 |
Effects of mannose-binding lectin polymorphisms on irinotecan-induced febrile neutropenia.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Female; Fever; Genetic Predisposition to Disease; Genotype; Haplotypes; Humans; Irinotecan; Male; Mannose-Binding Lectin; Middle Aged; Neoplasms; Neutropenia; Polymorphism, Genetic; Promoter Regions, Genetic | 2010 |
Enhancement of CPT-11 antitumor activity by adenovirus-mediated expression of β-glucuronidase in tumors.
Topics: Adenoviridae; Antineoplastic Agents, Phytogenic; Bystander Effect; Camptothecin; Combined Modality Therapy; Genetic Therapy; Genetic Vectors; Glucuronates; Glucuronidase; Humans; Irinotecan; Neoplasms; Prodrugs; Tumor Cells, Cultured | 2011 |
Barking up the wrong genome--we are not alone.
Topics: Animals; Antineoplastic Agents, Phytogenic; Bacteria; Camptothecin; Diarrhea; Enzyme Inhibitors; Glucuronidase; Glucuronosyltransferase; Humans; Irinotecan; Mice; Neoplasms; Pharmacogenetics; Polymorphism, Genetic; Prodrugs; Topoisomerase I Inhibitors | 2011 |
APEX microarray panel for genotyping polymorphisms in cancer chemotherapy and estimation frequencies in a Slovak population.
Topics: Antineoplastic Agents; Biomarkers, Pharmacological; Camptothecin; Drug Resistance, Neoplasm; Fluorouracil; Gene Frequency; Genetic Association Studies; Humans; Irinotecan; Linkage Disequilibrium; Methotrexate; Neoplasms; Oligonucleotide Array Sequence Analysis; Polymorphism, Single Nucleotide; Slovakia | 2011 |
Clarification of clinical features of interstitial lung disease induced by irinotecan based on postmarketing surveillance data and spontaneous reports.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Drug Hypersensitivity; Female; Humans; Irinotecan; Lung Diseases, Interstitial; Male; Middle Aged; Neoplasms; Pneumonia; Product Surveillance, Postmarketing; Pulmonary Alveoli; Steroids; Tomography, X-Ray Computed | 2011 |
Novel acrylonitrile derivatives, YHO-13177 and YHO-13351, reverse BCRP/ABCG2-mediated drug resistance in vitro and in vivo.
Topics: Acrylonitrile; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Camptothecin; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Female; HCT116 Cells; Humans; Irinotecan; K562 Cells; Male; Mice; Mice, Inbred BALB C; Mice, Inbred ICR; Mice, Nude; Neoplasm Proteins; Neoplasms; Xenograft Model Antitumor Assays | 2011 |
Early clinical development of ARQ 197, a selective, non-ATP-competitive inhibitor targeting MET tyrosine kinase for the treatment of advanced cancers.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Dose-Response Relationship, Drug; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Hepatocyte Growth Factor; Humans; Irinotecan; Mice; Neoplasms; Proto-Oncogene Proteins c-met; Pyrrolidinones; Quinazolines; Quinolines; Randomized Controlled Trials as Topic; Receptors, Growth Factor | 2011 |
Cancer-stroma targeting therapy by cytotoxic immunoconjugate bound to the collagen 4 network in the tumor tissue.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Camptothecin; Collagen; Endothelium, Vascular; Female; Immunoconjugates; Irinotecan; Mice; Mice, Inbred BALB C; Neoplasms; Polyethylene Glycols; Stromal Cells; Topoisomerase I Inhibitors; Xenograft Model Antitumor Assays | 2011 |
[Protective effects of d-chlorpheniramine maleate pre-treatment against acute side effects of Irinotecan(CPT- 11)].
Topics: Acute Disease; Antineoplastic Agents, Phytogenic; Camptothecin; Chlorpheniramine; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasms | 2011 |
Post-marketing surveillance (PMS) of all patients treated with irinotecan in Japan: clinical experience and ADR profile of 13,935 patients.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Colorectal Neoplasms; Diarrhea; Drug Administration Schedule; Female; Genital Neoplasms, Female; Glucuronosyltransferase; Humans; Incidence; Infusions, Intravenous; Irinotecan; Japan; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neoplasms; Patient Selection; Polymorphism, Genetic; Product Surveillance, Postmarketing; Risk Assessment; Risk Factors; Surveys and Questionnaires; Thrombocytopenia | 2011 |
Lipid-based nanoformulation of irinotecan: dual mechanism of action allows for combination chemo/angiogenic therapy.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Camptothecin; Chemistry, Pharmaceutical; Humans; Irinotecan; Lipids; Liposomes; Models, Biological; Models, Chemical; Neoplasms | 2011 |
Targeted drug delivery to tumor vasculature by a carbohydrate mimetic peptide.
Topics: Amino Acid Sequence; Animals; Annexin A1; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carbohydrates; Cell Line, Tumor; Drug Delivery Systems; HCT116 Cells; Humans; Hydrazines; Injections, Intravenous; Irinotecan; Luminescent Measurements; Mice; Mice, Inbred C57BL; Mice, Nude; Molecular Mimicry; Molecular Sequence Data; Neoplasms; Neovascularization, Pathologic; Peptides; Protein Binding; Xenograft Model Antitumor Assays | 2011 |
[Examination of factors affecting adverse reactions and dosage reduction in UGT1A1 genotyped patients: a retrospective survey of irinotecan].
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Female; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Neoplasms; Neutropenia; Polymorphism, Genetic; Retrospective Studies | 2012 |
Concomitant polypharmacy is associated with irinotecan-related adverse drug reactions in patients with cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; Female; Fluorouracil; Glucuronosyltransferase; Humans; Irinotecan; Leucovorin; Logistic Models; Male; Middle Aged; Neoplasms; Neutropenia; Polypharmacy; Retrospective Studies | 2013 |
Infused chemotherapy use in the elderly after patent expiration.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Camptothecin; Cost Savings; Cross-Sectional Studies; Female; Health Services for the Aged; Humans; Irinotecan; Male; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Patents as Topic; Practice Patterns, Physicians'; Time Factors; United States | 2012 |
Irinotecan (CPT-11) chemotherapy alters intestinal microbiota in tumour bearing rats.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cecum; Cell Transformation, Neoplastic; Dose-Response Relationship, Drug; Feces; Female; Intestines; Irinotecan; Metagenome; Neoplasms; Rats | 2012 |
Preclinical combination therapy of thiarabine plus various clinical anticancer agents.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Camptothecin; Cell Line, Tumor; Cisplatin; Cyclophosphamide; Female; HT29 Cells; Humans; Irinotecan; Male; Mice; Mice, Nude; Mice, SCID; Neoplasms; Paclitaxel; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
Preclinical antitumor activity of a nanoparticulate SN38.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Proliferation; Female; HCT116 Cells; Humans; Irinotecan; Mice; Mitomycin; Nanoparticles; Neoplasms; Survival Analysis; Xenograft Model Antitumor Assays | 2013 |
Polymorphisms of the UDP-glucuronosyl transferase 1A genes are associated with adverse events in cancer patients receiving irinotecan-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Camptothecin; Colonic Neoplasms; Diarrhea; Drug-Related Side Effects and Adverse Reactions; Female; Genetic Predisposition to Disease; Glucuronosyltransferase; Humans; Irinotecan; Isoenzymes; Lung Neoplasms; Male; Middle Aged; Neoplasms; Neutropenia; Pharmacogenetics; Polymorphism, Genetic; Stomach Neoplasms | 2013 |
[Irinotecan plus temozolomide in refractory or relapsed pediatric solid tumors].
Topics: Adolescent; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Child; Child, Preschool; Dacarbazine; Female; Humans; Infant; Irinotecan; Male; Neoplasm Recurrence, Local; Neoplasms; Retrospective Studies; Temozolomide | 2013 |
Clinical pharmacokinetics of irinotecan and its metabolites: a population analysis.
Topics: Adult; Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Chi-Square Distribution; Female; Half-Life; Humans; Infusions, Intravenous; Irinotecan; Male; Neoplasms; Tissue Distribution | 2002 |
Human carboxylesterase 2 is commonly expressed in tumor tissue and is correlated with activation of irinotecan.
Topics: Blotting, Western; Camptothecin; Carboxylesterase; Carboxylic Ester Hydrolases; Cytosol; Dose-Response Relationship, Drug; Electrophoresis, Polyacrylamide Gel; Humans; Immunohistochemistry; Irinotecan; Kinetics; Liver; Microsomes, Liver; Neoplasms; Protein Isoforms; Tumor Cells, Cultured | 2002 |
St. John's Wort: more implications for cancer patients.
Topics: Antidepressive Agents; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Enzyme Induction; Enzyme Inhibitors; Humans; Hypericum; Irinotecan; Mixed Function Oxygenases; Neoplasms | 2002 |
Pharmacokinetics of irinotecan and its metabolites.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Humans; Hydrogen-Ion Concentration; Infusions, Intravenous; Irinotecan; Isotonic Solutions; Light; Neoplasms; Research Design; Sodium Chloride | 2002 |
Functional characterization of human UDP-glucuronosyltransferase 1A9 variant, D256N, found in Japanese cancer patients.
Topics: Amino Acid Substitution; Animals; Antineoplastic Agents; Asparagine; Aspartic Acid; Camptothecin; COS Cells; Exons; Genetic Variation; Glucuronates; Glucuronic Acid; Glucuronosyltransferase; Humans; Irinotecan; Japan; Mutation; Neoplasms; Polymorphism, Single Nucleotide; Transfection; UDP-Glucuronosyltransferase 1A9 | 2003 |
[A symphony for the camptothecins].
Topics: Antineoplastic Agents; Camptothecin; Enzyme Inhibitors; Irinotecan; Music; Neoplasms; Organosilicon Compounds; Structure-Activity Relationship; Topoisomerase I Inhibitors; Topotecan | 2003 |
Pharmacogenomics: road to anticancer therapeutics nirvana?
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as Topic; DNA Repair; Drug Design; Humans; Irinotecan; Neoplasms; Pharmacogenetics; Thymidylate Synthase | 2003 |
Ex vivo analysis of topotecan: advancing the application of laboratory-based clinical therapeutics.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Synergism; Female; Humans; In Vitro Techniques; Irinotecan; Lethal Dose 50; Lung Neoplasms; Male; Neoplasms; Prostatic Neoplasms; Topotecan; Tumor Cells, Cultured | 2003 |
Enzyme-prodrug systems: carboxylesterase/CPT-11.
Topics: Amino Acid Sequence; Animals; Antineoplastic Agents, Phytogenic; Biotransformation; Camptothecin; Carboxylesterase; Carboxylic Ester Hydrolases; Genes, Transgenic, Suicide; Genetic Therapy; Humans; Irinotecan; Liver; Molecular Sequence Data; Neoplasms; Prodrugs; Rabbits; Sequence Alignment; Sequence Homology, Amino Acid | 2004 |
Modeling antitumor activity by using a non-linear mixed-effects model.
Topics: Algorithms; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Computer Simulation; Dacarbazine; Data Interpretation, Statistical; Humans; Irinotecan; Mice; Neoplasms; Nonlinear Dynamics; Rhabdomyosarcoma; Temozolomide; Treatment Outcome; Xenograft Model Antitumor Assays | 2004 |
Selective modulation of the therapeutic efficacy of anticancer drugs by selenium containing compounds against human tumor xenografts.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Camptothecin; Carcinoma, Squamous Cell; Cell Line, Tumor; Colonic Neoplasms; Cysteine; Dose-Response Relationship, Drug; Drug Synergism; Female; Humans; Irinotecan; Maximum Tolerated Dose; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms; Organoselenium Compounds; Radiation-Sensitizing Agents; Selenium; Selenocysteine; Selenomethionine; Time Factors | 2004 |
UGT1A1 haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecan-administered Japanese patients with cancer.
Topics: Aged; Bilirubin; Camptothecin; Female; Genetic Linkage; Glucuronides; Glucuronosyltransferase; Haplotypes; Humans; Irinotecan; Japan; Male; Middle Aged; Neoplasms; Polymorphism, Single Nucleotide | 2004 |
[Management of chemotherapy induced diarrhea].
Topics: Antidiarrheals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; Drug Therapy; Drug-Related Side Effects and Adverse Reactions; Fluorouracil; Humans; Irinotecan; Loperamide; Neoplasms; Octreotide; Patient Care Management; Practice Guidelines as Topic | 2004 |
Flat-fixed dosing of irinotecan: influence on pharmacokinetic and pharmacodynamic variability.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; Body Surface Area; Camptothecin; Dose-Response Relationship, Drug; Female; Glucuronates; Humans; Irinotecan; Male; Metabolic Clearance Rate; Middle Aged; Models, Statistical; Neoplasms | 2004 |
Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Female; Gene Frequency; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Mutation; Neoplasms; Polymorphism, Genetic; UDP-Glucuronosyltransferase 1A9 | 2004 |
ABCG2 pharmacogenetics: ethnic differences in allele frequency and assessment of influence on irinotecan disposition.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Black People; Camptothecin; Drug Resistance, Multiple; Female; Gene Frequency; Genotype; Humans; Irinotecan; Male; Middle Aged; Neoplasm Proteins; Neoplasms; Pharmacogenetics; Polymorphism, Genetic; White People | 2004 |
In vivo efficacy of HSV-TK transcriptionally targeted to the tumour vasculature is augmented by combination with cytotoxic chemotherapy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Aorta; Camptothecin; Cell Line, Tumor; Cisplatin; Drug Therapy, Combination; Endothelial Cells; Genes, Reporter; Genetic Therapy; Genetic Vectors; Humans; Irinotecan; Neoplasms; Retroviridae; Simplexvirus; Survival Rate; Swine; Thymidine Kinase; Transcription, Genetic; Treatment Outcome | 2005 |
[Molecular biology methods in cancer medicine: options beyond steel instrument, ray and chemotherapy].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Bevacizumab; Breast Neoplasms; Camptothecin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Disease Progression; Female; Humans; Immunotherapy; Irinotecan; Male; Mutation; Neoplasms; Prostatic Neoplasms; Research; Simplexvirus; Trastuzumab; Vascular Endothelial Growth Factor A | 2004 |
Cancer cell adaptation to chemotherapy.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biopsy; Camptothecin; Cell Line, Tumor; Cisplatin; Down-Regulation; Doxorubicin; Drug Resistance, Neoplasm; Drug Therapy; Epirubicin; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Irinotecan; Neoplasms; Paclitaxel; Recurrence; Reverse Transcriptase Polymerase Chain Reaction; Time Factors; Topotecan; Treatment Outcome; Up-Regulation | 2005 |
Clinical trial designs for prospective validation of biomarkers.
Topics: Biomarkers, Tumor; Camptothecin; Clinical Trials as Topic; Genotype; Humans; Inactivation, Metabolic; Irinotecan; Neoplasms; Outcome Assessment, Health Care; Predictive Value of Tests; Reproducibility of Results; Research Design | 2005 |
Effect of milk thistle (Silybum marianum) on the pharmacokinetics of irinotecan.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Carcinoma; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Synergism; Female; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Neoplasms; Plant Extracts; Silybum marianum; Time Factors | 2005 |
[Management of chemotherapy-induced mucositis and diarrhea].
Topics: Allopurinol; Antineoplastic Agents; Camptothecin; Diarrhea; Free Radical Scavengers; Histamine H2 Antagonists; Humans; Irinotecan; Neoplasms; Proton Pump Inhibitors; Quality of Life; Stomatitis | 2006 |
UGT1A1 genotyping in patients undergoing treatment with irinotecan.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Neoplasms; Polymorphism, Genetic; Predictive Value of Tests; Prospective Studies; Retrospective Studies | 2005 |
Expression of drug pathway proteins is independent of tumour type.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Breast Neoplasms; Camptothecin; Colonic Neoplasms; Cytochrome P-450 Enzyme System; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Humans; Immunohistochemistry; Irinotecan; Lung Neoplasms; Lymphoma; Male; Melanoma; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Neoplasms; Ovarian Neoplasms; Prostatic Neoplasms; Tissue Array Analysis | 2006 |
Novel single nucleotide polymorphism of UGT1A7 gene in Japanese.
Topics: Alleles; Amino Acid Substitution; Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; DNA; Exons; Female; Gene Frequency; Glucuronosyltransferase; Humans; Irinotecan; Japan; Male; Molecular Sequence Data; Neoplasms; Polymorphism, Single Nucleotide; Reverse Transcriptase Polymerase Chain Reaction | 2006 |
Novel single nucleotide polymorphism of UGT1A9 gene in Japanese.
Topics: Alleles; Antineoplastic Agents, Phytogenic; Camptothecin; DNA, Neoplasm; Exons; Gene Frequency; Glucuronosyltransferase; Humans; Introns; Irinotecan; Japan; Molecular Sequence Data; Mutation; Neoplasms; Polymorphism, Single Nucleotide; Reverse Transcriptase Polymerase Chain Reaction; UDP-Glucuronosyltransferase 1A9 | 2006 |
Irinogenetics: what is the right star?
Topics: Alleles; Antineoplastic Agents, Phytogenic; Asian People; Camptothecin; Carcinoma, Non-Small-Cell Lung; DNA Topoisomerases, Type I; Drug-Related Side Effects and Adverse Reactions; Glucuronosyltransferase; Humans; Irinotecan; Lung Neoplasms; Neoplasms; Pharmacogenetics; Polymorphism, Genetic; Topoisomerase I Inhibitors | 2006 |
Thalidomide and celecoxib as potential modulators of irinotecan's activity in cancer patients.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Celecoxib; Chemotherapy, Adjuvant; Chromatography, High Pressure Liquid; Cyclooxygenase 2 Inhibitors; Dose-Response Relationship, Drug; Female; Fibroblast Growth Factor 2; Follow-Up Studies; Humans; Irinotecan; Male; Middle Aged; Neoplasms; NF-kappa B; Pyrazoles; Sulfonamides; Thalidomide; Tumor Necrosis Factor-alpha | 2007 |
Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Cisplatin; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Drug Synergism; Floxuridine; Humans; Irinotecan; Liposomes; Mice; Neoplasms; Xenograft Model Antitumor Assays | 2006 |
Pharmacogenetic impact of polymorphisms in the coding region of the UGT1A1 gene on SN-38 glucuronidation in Japanese patients with cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Clinical Trials as Topic; Female; Genotype; Glucuronides; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Neoplasms; Pharmacogenetics; Polymerase Chain Reaction; Polymorphism, Genetic; Promoter Regions, Genetic; Prospective Studies; Risk Factors; Topoisomerase I Inhibitors | 2006 |
[What happened during these 12 years since CPT-11 was launched in Japan ?].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Clinical Trials Data Monitoring Committees; Drug Approval; Fluorouracil; Humans; Irinotecan; Japan; Leucovorin; Neoplasms; Organoplatinum Compounds; Oxaliplatin | 2006 |
Efficacy of increasing the therapeutic index of irinotecan, plasma and tissue selenium concentrations is methylselenocysteine dose dependent.
Topics: Administration, Oral; Animals; Bone Marrow; Camptothecin; Cysteine; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Female; Humans; Irinotecan; Kidney; Kinetics; Liver; Mice; Mice, Nude; Neoplasms; Organoselenium Compounds; Plasma; Selenium; Selenocysteine | 2007 |
Hypoxia-targeted over-expression of carboxylesterase as a means of increasing tumour sensitivity to irinotecan (CPT-11).
Topics: Adenoviridae; Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Carboxylesterase; Cell Hypoxia; Cell Line; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Genetic Vectors; Humans; Irinotecan; Neoplasms; Rabbits; Transplantation, Heterologous | 2007 |
Medicinal cannabis does not influence the clinical pharmacokinetics of irinotecan and docetaxel.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Cannabinoids; Cytochrome P-450 CYP3A; Docetaxel; Drug Interactions; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasms; Statistics, Nonparametric; Taxoids | 2007 |
Genetic linkage of UGT1A7 and UGT1A9 polymorphisms to UGT1A1*6 is associated with reduced activity for SN-38 in Japanese patients with cancer.
Topics: Adult; Aged; Aged, 80 and over; Asian People; Camptothecin; Female; Glucuronosyltransferase; Haplotypes; Humans; Irinotecan; Japan; Linkage Disequilibrium; Male; Middle Aged; Neoplasms; Polymorphism, Genetic; UDP-Glucuronosyltransferase 1A9 | 2007 |
Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Asian People; Camptothecin; Exons; Female; Glucuronosyltransferase; Haplotypes; Humans; Irinotecan; Japan; Male; Middle Aged; Multivariate Analysis; Neoplasms; Pharmacogenetics; Polymorphism, Genetic; Prodrugs | 2007 |
UGT1A1 promoter genotype correlates with SN-38 pharmacokinetics, but not severe toxicity in patients receiving low-dose irinotecan.
Topics: Adolescent; Adult; Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Chi-Square Distribution; Child; Child, Preschool; Clinical Trials as Topic; DNA, Neoplasm; Female; Genotype; Glucuronosyltransferase; Humans; Infusions, Intravenous; Irinotecan; Male; Neoplasm Recurrence, Local; Neoplasms; Promoter Regions, Genetic; Risk Factors | 2007 |
Influence of UGT1A9 intronic I399C>T polymorphism on SN-38 glucuronidation in Asian cancer patients.
Topics: Adult; Aged; Asian People; Camptothecin; Female; Glucuronides; Glucuronosyltransferase; Haplotypes; Humans; Introns; Irinotecan; Liver; Male; Middle Aged; Neoplasms; Polymorphism, Genetic; UDP-Glucuronosyltransferase 1A9 | 2008 |
Increased preclinical efficacy of irinotecan and floxuridine coencapsulated inside liposomes is associated with tumor delivery of synergistic drug ratios.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Survival; Dose-Response Relationship, Drug; Drug Antagonism; Drug Combinations; Drug Compounding; Drug Evaluation, Preclinical; Drug Synergism; Female; Floxuridine; Humans; Injections, Intravenous; Irinotecan; Liposomes; Mice; Neoplasms; Pharmaceutical Vehicles; Survival Rate; Tissue Distribution; Tumor Burden; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2007 |
Impact of CYP3A4 haplotypes on irinotecan pharmacokinetics in Japanese cancer patients.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Cytochrome P-450 CYP3A; Female; Haplotypes; Humans; Irinotecan; Japan; Male; Metabolic Clearance Rate; Middle Aged; Multivariate Analysis; Neoplasms; Polymorphism, Genetic; Prodrugs; Sex Factors | 2008 |
AACR-NCI-EORTC--19th symposium. Molecular Targets and Cancer Therapeutics--Part 1.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Cycle Proteins; Clinical Trials as Topic; Humans; Irinotecan; Janus Kinase 2; Neoplasms; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase C; Protein Serine-Threonine Kinases | 2007 |
Importance of UDP-glucuronosyltransferase 1A1*6 for irinotecan toxicities in Japanese cancer patients.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Asian People; Bilirubin; Camptothecin; Female; Genotype; Glucuronosyltransferase; Humans; Incidence; Irinotecan; Japan; Male; Middle Aged; Neoplasms; Polymorphism, Genetic; Retrospective Studies | 2008 |
Pharmacokinetics of irinotecan and its metabolites in pediatric cancer patients: a report from the children's oncology group.
Topics: Adolescent; Adult; Antineoplastic Agents; Area Under Curve; Bilirubin; Camptothecin; Child; Child, Preschool; Clinical Trials, Phase II as Topic; Computer Simulation; Cytochrome P-450 CYP3A; Female; Glucuronates; Glucuronosyltransferase; Humans; Infant; Infusions, Intravenous; Irinotecan; Male; Metabolic Clearance Rate; Models, Biological; Multicenter Studies as Topic; Neoplasms | 2008 |
Defective p53 signaling in p53 wild-type tumors attenuates p21waf1 induction and cyclin B repression rendering them sensitive to Chk1 inhibitors that abrogate DNA damage-induced S and G2 arrest.
Topics: Camptothecin; Cell Cycle; Cell Proliferation; Checkpoint Kinase 1; Cyclin B; Cyclin-Dependent Kinase Inhibitor p21; DNA Damage; G2 Phase; Gene Expression Regulation, Neoplastic; HCT116 Cells; Humans; Irinotecan; Neoplasms; Protein Kinase Inhibitors; Protein Kinases; S Phase; Signal Transduction; Staurosporine; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2008 |
[CPT-11 (Irinotecan)].
Topics: Antineoplastic Agents; Camptothecin; Humans; Irinotecan; Neoplasms; Polymorphism, Genetic | 2008 |
Novel delivery of SN38 markedly inhibits tumor growth in xenografts, including a camptothecin-11-refractory model.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Camptothecin; Carcinoma; Cell Proliferation; Colorectal Neoplasms; Disease Models, Animal; Drug Delivery Systems; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Mice; Mice, Nude; Models, Biological; Neoplasms; Pancreatic Neoplasms; Polyethylene Glycols; Treatment Outcome; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2008 |
Pharmacogenetic pathway analysis of irinotecan.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as Topic; Enterohepatic Circulation; Female; Glucuronosyltransferase; Humans; Irinotecan; Male; Metabolic Clearance Rate; Middle Aged; Models, Biological; Multidrug Resistance-Associated Protein 2; Neoplasms; Pharmacogenetics; Polymorphism, Genetic; Prodrugs | 2008 |
Efficient sampling strategies for forecasting pharmacokinetic parameters of irinotecan (CPT-11): implication for area under the concentration-time curve monitoring.
Topics: Adult; Antineoplastic Agents, Phytogenic; Bayes Theorem; Camptothecin; Drug Monitoring; Humans; Irinotecan; Neoplasms | 1995 |
Topoisomerase I inhibition: a new target or new missiles?
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials, Phase I as Topic; Drug Design; Drug Synergism; Humans; Irinotecan; Neoplasm Proteins; Neoplasms; Topoisomerase I Inhibitors; Topotecan | 1995 |
Enhanced expression of the DNA topoisomerase II gene in response to heat shock stress in human epidermoid cancer KB cells.
Topics: Camptothecin; DNA Topoisomerases, Type II; Etoposide; Gene Expression; Hot Temperature; Humans; Irinotecan; KB Cells; Neoplasms; RNA, Messenger; Teniposide | 1993 |
Cytogenetic effects of CPT-11 and its active metabolite, SN-38 on human lymphocytes.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Chromosome Aberrations; Dose-Response Relationship, Drug; Humans; Irinotecan; Lymphocytes; Mutagens; Neoplasms; Sister Chromatid Exchange; Time Factors | 1993 |
Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients.
Topics: Antineoplastic Agents; Area Under Curve; Camptothecin; Female; Humans; Irinotecan; Male; Neoplasms; Phenotype; Racial Groups; Severity of Illness Index; Sex Characteristics; Topoisomerase I Inhibitors | 1997 |
Combined inhibition of topoisomerases I and II--is this a worthwhile/feasible strategy?
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Enzyme Inhibitors; Humans; Irinotecan; Neoplasms; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan | 1997 |
In vivo human carboxylesterase cDNA gene transfer to activate the prodrug CPT-11 for local treatment of solid tumors.
Topics: Adenoviridae; Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Carboxylesterase; Carboxylic Ester Hydrolases; Gene Transfer Techniques; Genetic Therapy; Genetic Vectors; Humans; Irinotecan; Mice; Mice, Nude; Neoplasms; Prodrugs; Tumor Cells, Cultured | 1998 |
[New cancer therapies: balancing risk and benefit].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Humans; Irinotecan; Neoplasms; Risk | 1998 |
A risk-benefit assessment of irinotecan in solid tumours.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Cisplatin; Colorectal Neoplasms; Diarrhea; Drug Therapy, Combination; Etoposide; Fluorouracil; Humans; Irinotecan; Lung Neoplasms; Neoplasms; Risk Assessment | 1998 |
Potent and broad antitumor effects of DX-8951f, a water-soluble camptothecin derivative, against various human tumors xenografted in nude mice.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Colonic Neoplasms; Humans; Irinotecan; Kidney Neoplasms; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms; Stomach Neoplasms; Subrenal Capsule Assay; Tumor Cells, Cultured | 1998 |
Continual reassessment methods in phase I trials of the combination of two drugs in oncology.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Camptothecin; Clinical Trials, Phase I as Topic; Computer Simulation; Diarrhea; Docetaxel; Dose-Response Relationship, Drug; Humans; Irinotecan; Likelihood Functions; Neoplasms; Neutropenia; Paclitaxel; Retrospective Studies; Taxoids | 1999 |
Sensitive determination of irinotecan (CPT-11) and its active metabolite SN-38 in human serum using liquid chromatography-electrospray mass spectrometry.
Topics: Acetonitriles; Adult; Antineoplastic Agents, Phytogenic; Camptothecin; Chemical Precipitation; Chromatography, High Pressure Liquid; Humans; Irinotecan; Male; Mass Spectrometry; Neoplasms; Reproducibility of Results; Sensitivity and Specificity | 1999 |
[Current problems of early phase clinical trials for new anticancer agents in Japan].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as Topic; Humans; Irinotecan; Japan; Medical Oncology; Neoplasms; Workforce | 2000 |
New highly lipophilic camptothecin BNP1350 is an effective drug in experimental human cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Colonic Neoplasms; Doxorubicin; Drug Resistance, Multiple; Enzyme Inhibitors; Female; Humans; Irinotecan; Lung Neoplasms; Melanoma; Mice; Mice, Nude; Neoplasms; Ovarian Neoplasms; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2000 |
Differential activity of topotecan, irinotecan and SN-38 in fresh human tumour cells but not in cell lines.
Topics: Antineoplastic Agents; Camptothecin; Dose-Response Relationship, Drug; Enzyme Inhibitors; Fluorometry; Humans; Irinotecan; Neoplasms; Topotecan; Tumor Cells, Cultured | 2000 |
Glucagon-like peptide (GLP)-2 reduces chemotherapy-associated mortality and enhances cell survival in cells expressing a transfected GLP-2 receptor.
Topics: Animals; Antineoplastic Agents; Apoptosis; Bacterial Infections; Camptothecin; Cell Line; Cell Survival; Female; Fluorouracil; Glucagon-Like Peptide 2; Glucagon-Like Peptide-1 Receptor; Glucagon-Like Peptides; Humans; Intestines; Irinotecan; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Neoplasms; Neoplasms, Experimental; Peptides; Rats; Receptors, Glucagon; Survival Rate; Time Factors; Transfection; Tumor Cells, Cultured | 2001 |
Factors affecting the pharmacokinetics of CPT-11: the body mass index, age and sex are independent predictors of pharmacokinetic parameters of CPT-11.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; Body Mass Index; Camptothecin; Enzyme Inhibitors; Female; Humans; Irinotecan; Logistic Models; Male; Middle Aged; Neoplasms; Sex Factors | 2001 |
Potentiation of antitumor activity of irinotecan by chemically modified oligonucleotides.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cyclic AMP-Dependent Protein Kinases; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Enzyme Inhibitors; Female; Humans; Irinotecan; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms; Nuclear Proteins; Oligonucleotides, Antisense; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-mdm2; Topoisomerase I Inhibitors; Treatment Outcome | 2001 |
Highlights of the Eighth European Cancer Conference.
Topics: Amifostine; Antineoplastic Agents; Breast Neoplasms; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Docetaxel; Head and Neck Neoplasms; Humans; Irinotecan; Neoplasms; Paclitaxel; Radiation Injuries; Radiation-Protective Agents; Taxoids; Vinblastine; Vinorelbine | 1995 |
Characterization of a thymidylate synthase (TS)-inducible cell line: a model system for studying sensitivity to TS- and non-TS-targeted chemotherapies.
Topics: Blotting, Northern; Blotting, Western; Camptothecin; CDC2-CDC28 Kinases; Cell Cycle; Cell Division; Cisplatin; Cyclin A; Cyclin E; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinases; Dose-Response Relationship, Drug; Fluorouracil; Folic Acid Antagonists; Gene Expression Regulation, Enzymologic; Humans; Irinotecan; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Protein Serine-Threonine Kinases; Quinazolines; RNA, Messenger; Tetracycline; Thiophenes; Thymidylate Synthase; Tumor Cells, Cultured | 2001 |
O(6)-methylguanine-DNA methyltransferase (MGMT) as a determinant of resistance to camptothecin derivatives.
Topics: Antineoplastic Agents, Phytogenic; Blotting, Western; Camptothecin; Drug Evaluation; Drug Resistance, Neoplasm; Enzyme Inhibitors; Glutathione; Humans; Irinotecan; Neoplasms; O(6)-Methylguanine-DNA Methyltransferase; Plasmids; RNA, Messenger; Topoisomerase I Inhibitors; Transfection; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2002 |
Future treatment options with capecitabine in solid tumours.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Fluorouracil; Forecasting; Humans; Irinotecan; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Taxoids | 2002 |
[Globalization of anti-cancer therapies].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carboplatin; Cisplatin; Colorectal Neoplasms; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Neoplasms; Ovarian Neoplasms; Paclitaxel; Prostatic Neoplasms; Stomach Neoplasms | 2002 |
Combined chemotherapy trials require combined pharmacogenetic approaches.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Enzyme Inhibitors; Humans; Irinotecan; Methylenetetrahydrofolate Reductase (NADPH2); Neoplasms; Oxidoreductases Acting on CH-NH Group Donors; Polymorphism, Genetic; Quinazolines; Thiophenes | 2002 |
Third Wave, Daiichi to develop personalized cancer treatment.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as Topic; Humans; Irinotecan; Neoplasms; Polymorphism, Single Nucleotide | 2002 |
Enhanced tumor killing by Apo2L/TRAIL and CPT-11 co-treatment is associated with p21 cleavage and differential regulation of Apo2L/TRAIL ligand and its receptors.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Apoptosis Regulatory Proteins; Camptothecin; Carcinoma; Caspases; Cell Cycle; Cells, Cultured; Colonic Neoplasms; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Drug Synergism; Humans; Irinotecan; Kinetics; Membrane Glycoproteins; Neoplasms; Receptors, Tumor Necrosis Factor; RNA, Neoplasm; TNF-Related Apoptosis-Inducing Ligand; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 2002 |
Genetic polymorphisms of the UDP-glucuronosyltransferase 1A7 gene and irinotecan toxicity in Japanese cancer patients.
Topics: Adult; Aged; Alleles; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Female; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Japan; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasms; Polymorphism, Genetic; Polymorphism, Restriction Fragment Length | 2002 |